Development of Pneumolysin as a vaccine candidate by Mughal, Muhammad Kashif
  
 
 
 
 
 
 
Mughal, Muhammad Kashif (2014) Development of Pneumolysin as a 
vaccine candidate. PhD thesis. 
 
 
http://theses.gla.ac.uk/5151/  
 
 
 
 
Copyright and moral rights for this work are retained by the author 
A copy can be downloaded for personal non-commercial research or study, without prior 
permission or charge 
This work cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author 
When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
Enlighten:Theses 
http://theses.gla.ac.uk/ 
theses@gla.ac.uk 
Development of Pneumolysin as a vaccine 
candidate 
 
A thesis submitted to the University of Glasgow for the degree of  
Doctor of Philosophy 
 
By 
 
 
Muhammad Kashif Mughal 
 
Bachelor of Medicine and Bachelor of Surgery (M.B.,B.S) 
 
 
 
Submitted January 2014 
 
 
 
Institute of Infection, Immunity and Inflammation 
College of Medical, Veterinary and Life Sciences 
University of Glasgow 
120 University Place 
Glasgow G12 8TA 
©Muhammad Kashif Mughal 
 
 
 
 
 
2 
Acknowledgement 
 
First and the foremost, I would like to thank the Almighty ALLAH who gave me 
the courage and strength to finish this PhD. 
I would like to thank Professor Tim.J.Mitchell for providing me the opportunity 
to work in his laboratory and giving me excellent suggestions and feedback 
throughout my project. Thanks to my assessors Dr Roger Parton and Dr Dan 
Walker for giving me valuable feedback on my work. Massive thanks to all the 
present and previous members of TJM group especially Dr Andrea Mitchell, Dr 
Ashleigh Holmes, Dr Jiang Tao Ma, Dr Jenny Herbert, Dr Carol McInally, Dr Kirtsy 
Ross and Catherine Dalziel. Also worth mentioning is the company of Dr Sultan 
Al-Sharif, Dr Yahya Noori, Ms Denise Candlish, Margaret Frame and June Irvine 
who gave me confidence, support, help and shared jokes when all these were 
desperately needed. 
I would also like to thank all my friends here in Glasgow for their company and 
without whom it would have been difficult to survive in the extreme weather 
and miles away from my country and my extended family; Khurram Ashraf, Dr 
Kashif Shafique, Syed Mairaj Hassan, Dr Muhammad Jaffar Khan, Dr Omer Malik, 
Dr Asif Ali, Dr Zia-ul-Haq, Dr Sabir Almadni, Dr Abdus Salam, Hani Harbi, Nawaf 
Alreshidi and others.  
I am grateful to my parents (Mum and dad) for continuously praying and 
supporting me for my success and teaching all the important lessons of life and 
even sacrificing their own desires to see me and my siblings shine and prosper. 
3 
Thanks to my brothers Dr Akber, Atif and my sisters Mrs Farah Nadeem and Dr 
Saba Asif and all my friends and relatives back home for their never ending 
support, love and prayers. 
Finally, I would like to extend my gratitude to my lovely wife, Dr Afirah Naz for 
her huge sacrifice made by staying back home in first year of my PhD, only after 
3 months of our marriage and for all her patience, help and support after coming 
here in the U.K. After all the late shifts in the lab, she used to greet me with a 
lovely smile and delicious food. 
4 
Author’s Declaration 
 
This thesis is the original work of the author unless stated otherwise. 
 
Muhammad Kashif Mughal 
January 2014 
5 
Abstract 
 
More than 90 serotypes of Streptococcus pneumoniae are responsible for causing 
a number of invasive and non-invasive diseases in humans. To combat this 
pathogen there are two types of vaccines available namely pneumococcal 
polysaccharide vaccine (PPV) and pneumococcal conjugate vaccine (PCV). 
Although these vaccines have reduced the incidence and prevalence of 
pneumococcal diseases yet these vaccines are unable to curb the disease and 
have some potential drawbacks. The problems associated with PPV is inability to 
mount appropriate immune response in young children (<2 years) of age and with 
PCV, disadvantages are serotype replacement and affordability. These 
disadvantages have shifted the focus of attention on developing vaccines that 
can provide serotype independent protection and is cost effective and can be 
used in developing and under-developing countries as well. 
Pneumolysin (PLY) is one of the members of cholesterol dependent cytolysin 
(CDC) family and is one of the key virulence factors of the bacterium. PLY has a 
wide variety of functions but the two most important functions are the ability to 
lyse the host cell by forming pores and activating the complement pathway. 
Studies have shown recombinant PLY to be a good vaccine candidate; however 
PLY is toxic and cannot be used as a vaccine. A number of toxoid versions have 
been made targeting residues responsible for toxin’s lytic activity and tested in-
vivo models. ∆6 PLY is a toxoid made by deleting two amino acid residues and 
seems to be a potential candidate to be included in next generation 
pneumococcal vaccines. ∆6 PLY is immunogenic and act as an adjuvant as well, 
6 
however ∆6 PLY causes the aggregation of red blood cells and therefore cannot 
be used in the vaccine. 
The present study is carried out to identify the residue/s responsible for causing 
this agglutination behaviour. A number of molecular biology techniques were 
used in this study for making mutants in different backgrounds and were tested 
for their lytic and agglutination activity. The study identified the single residue 
in domain 4 causing aggregation of the red blood cells. The agglutination 
negative mutant was then tested at different concentrations through a series of 
experiments including hemagglutination assays, fluorescence microscopy and 
fluorescence activated cell sorter (FACS). 
The study also highlighted some important regions of the toxins responsible for 
maintaining structure of the toxin. This new toxoid seems to have the potential 
to be used in future pneumococcal vaccines alone, in combination with other 
pneumococcal proteins and/or polysaccharides. 
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1 Introduction 
Streptococcus pneumoniae, also known as pneumococcus, is a gram positive 
facultative anaerobic organism involved in an array of human diseases ranging 
from non-invasive otitis media and sinusitis to invasive life threatening bacterial 
pneumonia, meningitis and sepsis (O'Brien et al., 2009). The bacterium is able to 
cause such diseases in all age groups, but infants, elderly and the 
immunocompromised are more vulnerable (Tai, 2006). 
The bacterium grows in chains or pairs, hence the name diplococcus, and was 
simultaneously isolated by two scientists named Pasteur and Steinberg in 1881 
(Sternberg, 1881, Pasteur, 1881). Pneumococcus is classified according to the 
immunochemistry of the polysaccharide capsule that surrounds them by the 
Quellung reaction (swelling reaction) which was discovered by Neufeld in 1902 
(Neufeld, 1902). The reaction is visualised as capsular swelling/bacterial 
agglutination with anti sera raised against the homologous capsular 
polysaccharide. More than 90 different capsular types (serotypes) of the 
organism have been identified (Henrichsen, 1995, Park et al., 2007). The 
distribution of these different serotypes vary geographically and the different 
subtypes within a serotype can cross react with each other (Austrian, 1981, Calix 
& Nahm, 2010). This cross reactivity led to the reclassification of different 
serotypes from chronological order of discovery to the Danish nomenclature; 
which places them in different serogroups (Dochez & Gillespie, 1913). Quellung 
reaction is quite a useful tool in pneumococcal characterisation and is still used 
in laboratories but has certain limitations. The anti sera are expensive and 
mistyping of certain sera occurs due to cross reactivity. Moreover, there are 
some strains which do not express capsules (un-encapsulated) or have down 
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regulated their capsular expression genes so cannot be typed (non-serotypables) 
(Pai et al., 2006, Smart, 1986). 
The advancement in the molecular biology tools has led to more accurate and 
specific typing. One of these is Multi locus Sequencing Technique (MLST) which is 
simpler, reliable and based on the sequencing of different isolates for the seven 
housekeeping genes which are glucose kinase (gki), shikimate dehydrogenase 
(aroE), glucose-6-phosphate dehydrogenase (gdh), signal peptidase I (spi), 
transketolase (recP), D-alanine-D-alanine ligase (ddl) and xanthine 
phosphoribosyltransferase (xpt). The sequencing results of each allele is 
matched on the MLST website (http://spneumoniae.mlst.net/) and based on the 
results is assigned a number. This number is compared with other isolates 
already present on the database and based on the allelic variation of genes, 
isolates are assigned specific sequence type (ST) (Enright & Spratt, 1998). A 
number of STs can exist within a serotype and also some STs can be found in 
more than one serotypes thus exhibiting capsular switching. Capsular switching 
enables pneumococcus to escape from vaccines targeted against capsular 
polysaccharide (Coffey et al., 1998, Jacobs et al., 2009, Jefferies et al., 2004, 
Pai et al., 2006). MLST is a useful online tool and is helpful in maintaining the 
same standard in majority of laboratories across the globe. It enables 
researchers and clinicians to monitor spread of any virulent isolate in a specific 
geographical area or emergence of any antibiotic resistant strains and thus 
provide useful information about the epidemiology and genetic variation of the 
organism (Enright & Spratt, 1999, McGee et al., 2001). 
The microarray analysis of clinical isolates has pointed out certain limitation of 
MLST by exhibiting genetic variations in isolates that were found to be identical 
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by serotyping and MLST (Silva et al., 2006, Dagerhamn et al., 2008). However, 
the cost of microarrays is too expensive to be used routinely for identification in 
diagnostic labs. The next generation genome sequencing is by far the most 
accurate method of identification of the clinical isolates but the high cost and 
affordability, especially in the developing and under developed countries 
remains the major issue with these new techniques. There is a dire need of 
quicker, reliable and cheaper technique for identification and diagnosis of 
pneumococcal infections in the developing and under developed countries where 
the disease burden is highest with limited resources. 
1.1 Disease burden 
S.pneumoniae is among the leading bacterial pathogens causing respiratory tract 
infections cumulating 14.5 million pneumococcal cases worldwide with 11% 
mortality (excluding pneumococcal deaths in HIV positive) in children below 5 
years of age (O'Brien et al., 2009). Children under two years of age are more 
susceptible because of insufficient development of immune system and passive 
immunity acquired in the form of maternal antibodies (IgG) from placenta, 
which diminishes approximately after 3 months. After 3 months the immune 
system of healthy babies starts producing their own antibodies.  Overall, Asia 
and Africa account for 66% of pneumococcal cases worldwide; and the top four 
out of five countries with highest number of cases are present in Asia (India 27%, 
China 12%, Nigeria 5%, Pakistan 5% and Bangladesh 4%) (O'Brien et al., 2009). 
According to World Health Organization (WHO) statistics over 2 million deaths in 
children occur due to pneumonia each year and it accounts for more deaths in 
children than measles, malaria and AIDS combined. One out of every five 
children worldwide dies before reaching the fifth birthday due to this deadly 
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disease (figure 1) 
http://whqlibdoc.who.int/publications/2006/9280640489_eng.pdf.    
 
  
Figure 1-1 Pie chart showing cause-specific mortality worldwide in children less than 5 
years old 
Figure adapted from http://whqlibdoc.who.int/publications/2006/9280640489_eng.pdf 
 
Figure 1.1 showing that pneumonia leads the list of causes of mortality 
worldwide in children less than 5 years of age. The old age group people are also 
susceptible to pneumococcal disease mainly due to decrease in immunity as 
antibody body titres goes down with increasing age (Simell et al., 2008). Other 
risk factors predisposing pneumococcal infections include alcoholism, heart and 
lung diseases and patients receiving immunosuppressive therapies (Koivula et 
al., 1994). 
In the USA alone nearly 50,000 people died due to pneumonia in the year 2009 
and 1.1 million people required hospitalization 
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(http://www.cdc.gov/Features/Pneumonia/). These figures reflect the 
magnitude of this disease in a developed country and the numbers are far higher 
in developing and under developed countries where access to health facilities 
are limited, the diagnostic facilities poor, the data recording is not accurate, 
the resources spent on health of people are sparse and, and less than 20% of 
children receive the recommended antibiotic treatment 
(http://whqlibdoc.who.int/publications/2006/9280640489_eng.pdf). 
The mortality associated with pneumococcal bacteremia is very high. A study 
done in a developing African country (Kenya) showed a high incidence rate of 
disease 597 per 100 000 children under five years of age with a mortality rate of 
16% (Brent et al., 2006). The disease can be treated with antibiotics but less 
than 1/3 of the children in the world receive proper antibiotic treatment 
http://www.who.int/mediacentre/factsheets/fs331/en/index.html. 
1.2 Pneumococcal carriage dynamics 
Pneumococcus resides in the upper respiratory tract (nasophayrnx) as a harmless 
coloniser along with the other bacterial species like Moraxella cattarrhalis, 
Haemophilus influenza, Niesseria meningitides, Staphylococcus and other 
streptococcus species. Every individual experiences colonisation with one of 
these organisms at least once in a life time. This colonisation is the first step in 
route of the development towards invasive disease if the organism manages to 
break the immunological barriers (Bogaert et al., 2004). Since colonisation is an 
important step the organism has evolved certain mechanisms to combat its 
survival. Pneumococcus produces hydrogen peroxide (H2O2), neuraminidase and 
bacteriocin which can inhibit the growth of other microorganisms ( e.g. 
H.influenzae, N.meningitides) in the nasophayrnx which minimises the chances 
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of these organisms of causing invasive diseases (Pericone et al., 2000, 
Shakhnovich et al., 2002, Dawid et al., 2009). 
Colonisation by pneumococcus starts at a very early age and in the developing 
world 95% of healthy children (under 3 years of age) and 40% of adults are 
carriers of up to four serotypes (Obaro & Adegbola, 2002, Gray et al., 1980). The 
colonisation declines with increasing age as the immune system matures and 
pneumococcal carriage drops to less than 5% in adults. (IgG production starts 
three months after birth and reaches adult levels at 2-7 years thus resulting in 
this decrease in colonization) (Flamaing et al., 2010). Other risk factors can also 
increase the chances of pneumococcal carriage and hence disease which 
includes overcrowding, smoking, alcoholism, asthma, ethnicity and the use of 
antibiotics (Kurtti et al., 1998, Bogaert et al., 2004, Greenberg et al., 2006, 
Hoge et al., 1994). 
1.3 Pneumococcal diseases 
1.3.1 Pneumonia 
S.pneumoniae is also called pneumococcus because of the ability to cause 
pneumonia. It is one of the most important causative agents of community 
acquired pneumonia. Pneumonia is defined as inflammatory response of the lung 
tissues as a consequence of an infection resulting in the consolidation and 
exudation of alveolar spaces and thereby hindering the gaseous perfusion 
between the blood stream and alveoli. 
In the year 2000, pneumonia accounted for more than 95% of all the 
pneumococcal cases  and had  a global incidence of 13.8 million cases in children 
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under the age of 5, out of which 0.74 million lost their lives due to this disease 
(O'Brien et al., 2009). In Pakistan alone, one in four deaths in children under 5 
years of age is due to this disease (Owais et al., 2010). 
A number of other factors are also responsible for predisposing individuals to 
pneumonia which includes old age, cigarette smoking, chronic obstructive 
pulmonary disease (COPD), alcohol abuse, liver disease, congestive heart failure, 
HIV infection and previous history of pneumonia (Musher et al., 2000). 
Pneumonia may lead to bacteremia which is a state where bacteria are found in 
the normal sterile blood stream, which can lead to sepsis and death (Laterre et 
al., 2005). 
1.3.2  Meningitis 
Pneumococcus can cause meningitis, a disease characterised by the 
inflammation of the fluid filled thin membranous covering surrounding the brain 
and the spinal cord. The disease is normally preceded by an infection at a site 
other than Central Nervous System (CNS). It has been shown that 30% of patients 
with pneumococcal meningitis had focus of infection in the ear followed by 18% 
and 8% in the lungs and sinus (Ostergaard et al., 2005). However, it has been 
shown in a murine model that organism can invade and infect the CNS directly 
through olfactory neurons (van Ginkel et al., 2003). 
In the year 2000, there were more than a hundred thousand pneumococcal  
meningitis cases worldwide with a mortality rate of nearly 60% (O'Brien et al., 
2009). The symptoms of the disease are neck stiffening, severe headaches, 
fever, seizures and coma which may lead to death. The case fatality of 
meningitis is 21% even in industrialised nations and up to 30% of the surviving 
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cases face the devastating long-term sequelae of hearing loss and mental 
impairment (Schuchat et al., 1997, Koedel et al., 2002). 
The mechanism through which pneumococcus crosses the blood brain barrier 
(BBB) and gains entry into the CNS requires further investigation. The toxin 
Pneumolysin (PLY) plays a role in damaging cerebral endothelial cells and 
allowing the bacterium to cross the BBB and gaining access to the cerebral 
compartment (Zysk et al., 2001). The role of neuraminidase (NanA), a 
pneumococcal cell surface protein as an important mediator of the pathogen 
entry into the CNS has also been reported (Uchiyama et al., 2009). 
1.3.3 Acute otitis media 
Acute otitis media (AOM) is a relatively benign but a very common middle ear 
infection in children. In the United States, it is the one of the leading causes for 
physicians visit and ranks first among all the infectious disease for which 
antibiotics are prescribed. The disease has a huge economic burden and in the 
US alone, it costs more than 5 billion dollars (Klein, 2000). The magnitude of the 
disease can be determined by the fact that more than 80% of children have more 
than or equal to one episode and 46% have greater than or equal to 3 episodes of 
the disease during their first 3 years of life (Teele et al., 1989). Although this 
disease is rarely fatal, but it can cause morbid conditions including hearing loss 
and developmental delays (Klein, 2000). 
1.3.4 Other diseases 
Pneumococcus is also responsible for some relatively less common infections 
which are described in the subsequent paragraphs. 
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Pneumococcus can cause conjunctivitis which is the redness and the 
inflammation of the thin membrane that covers the front of the eye 
(conjunctiva). The disease is usually caused by the unencapsulated (non-typable) 
strains in disease outbreaks although sporadic cases of conjunctivitis have also 
been found (Ertugrul et al., 1997, Barker et al., 1999). The current vaccines 
target pneumococcal capsule and therefore have no effect on this non-typable 
strains. 
Pneumococcus can also cause endocarditis (inflammation of the inner most layer 
of tissue the lining heart chamber) and cerebral abscesses (collection of pus in 
brain). Although these diseases are very uncommon but are associated with a 
significant morbidity and mortality (Eastham et al., 2004, Bruyn et al., 1990, 
Carpenter et al., 2007). 
1.4 Pneumococcal virulence factors (VF) 
The bacterium includes the following most important virulence factors (VF) 
namely, the capsule, pneumolysin, cell surface proteins and various enzymes. 
Virulence factors of bacterium aids in establishing disease in the host of 
particular species and increases its potential to cause disease. In pneumococcus, 
VF are responsible for colonisation of the organism and/or causing disease and 
aids pneumococcus in evading the host defences. A number of other putative 
virulence factors have been identified by full genome sequencing and signature 
tagged mutagenesis (Frolet et al., 2010, Hava & Camilli, 2002, Hiller et al., 
2007, Lau et al., 2001, Polissi et al., 1998, Tettelin et al., 2001). The function of 
a number of these putative VF remain unknown but research is ongoing in this 
field and studies are being conducted and published to ascertain their functions 
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(Frolet et al., 2010). The well studied VF and a summary of their functions are 
summarized in the table 1.1.  
1.4.1 Capsule 
The capsule is one of the foremost important virulence factors of the bacterium 
as it evades the host immune response by its anti-phagocytic property.(Hyams et 
al., 2010, Melin et al., 2010) Capsular Polysaccharide (CPS) importance can be 
ascertained by the fact that all clinical isolates that cause invasive disease are 
encapsulated and loss of capsule through genetic mutation resulted in decreased 
virulence in animal models of infection (Watson & Musher, 1990). Un-
encapsulated strains rarely cause invasive disease and are isolated from cases of 
sporadic and epidemic pneumococcal conjunctivitis which is a non invasive 
disease causing inflammation of conjunctiva (Barker et al., 1999, Martin et al., 
2003). 
The thickness of capsule determines the colony morphology. In the nasophayrnx, 
the transparent colonies (having thin layer of capsule) enables cell surface 
proteins and pili to adhere to the nasal mucosa and hence associated with 
colonisation (Weiser, 1998). The opaque colonies are usually recovered from 
blood in the invasive disease and have a thick capsule enabling the organism to 
escape from antibody and/or complement mediated phagocytosis (Serrano et 
al., 2006, Hyams et al., 2010). However, these colony morphologies were found 
to be reversible and aided in transition of bacterium from carriage to invasive 
disease (Hammerschmidt et al., 2005). 
Pneumococcus has the ability to switch its capsular serotype through horizontal 
gene transfer and hence escape the vaccines which are directed against the 
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specific serotypes (Coffey et al., 1998). This has resulted in the evolution of 
specific pneumococcal isolates of particular STs within different serotypes 
(Coffey et al., 1999, Pai et al., 2006). This serotype replacement has shifted the 
attention of scientists on other virulence factors for designing vaccines other 
than the CPS. 
1.4.2 Pili 
It was initially thought that capsule is the first point of contact with the host 
cells before pilus was discovered and was shown to extend beyond the 
polysaccharide capsule and responsible for mediating the attachment of the 
bacterium to the mucosal surfaces. There are two pilus islet in the 
pneumococcus which encodes for the pilus, PI-1 and PI-2 (Hava & Camilli, 2002, 
Bagnoli et al., 2008). 
A study done by Barocchi et al., 2006 showed introduction of PI-1 to a pilus 
negative encapsulated strain increased the attachment of the bacterium to the 
lung epithelial cells and provided competitive advantage in-vivo when infected 
simultaneously with the pilus negative strain. Furthermore, pilus expressing 
isolates were more virulent in a murine model of pneumonia and bacteremia 
than the non piliated deletion mutants (Barocchi et al., 2006). 
1.4.3 Cell wall 
The cell wall of pneumococcus is made up of peptidoglycan backbone covalently 
linked with the teichoic acid and lipoteichoic acid which is attached to the 
plasma membrane. Phosphorylcholine (Pho), a component of both teichoic and 
lipoteichoic acid provides the site of attachment for the choline binding proteins 
(Mosser & Tomasz, 1970, Yother & White, 1994). The cell wall components can 
Chapter 1  30 
induce the production of inflammatory mediators and challenges with the cell 
wall components in animal models can reproduce symptoms of pneumonia, otitis 
media and meningitis (Giebink et al., 1988, Hoffmann et al., 2007, 
Riesenfeldorn et al., 1989, Tuomanen et al., 1987). 
1.4.4 Pneumococcal cell surface proteins 
Pneumococcal cell surface proteins are divided into three groups based on their 
attachment with cell wall. These three families of proteins along with the other 
important virulence factors are shown in the figure 1.2. The surface cell surface 
proteins are classified as choline- binding proteins (nearly 16 members), 
Lipoproteins (around 50 members), and LPXTG anchored proteins (up to18 
members) (Perez-Dorado et al., 2012). 
 
Figure 1-2 Diagrammatic representation of main pneumococcal virulence factors 
The three families of cell surface proteins are choline binding proteins, lipoproteins and 
LPXTG-anchored proteins PavA, pneumococcal adhesion and virulence A; PsaA, 
pneumococcal surface antigen A; PspA, pneumococcal surface protein A; PspC, 
pneumococcal surface protein C. Figure taken from (Mitchell, 2003). 
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1.4.4.1 Choline binding proteins 
CBPs possess carboxy terminal repeat regions that non-covalently anchor them 
to the Pho of the cell wall. The important proteins included in this family are 
autolysin (LytA), pneumococcal surface protein A (PspA) and pneumococcal 
surface protein C (PspC) also known as Choline binding protein A (CbpA) 
(Mitchell, 2003). All these proteins have important roles in virulence and a brief 
summary of their specific functions are mentioned in Table 1.1. 
1.4.4.2 Lipoproteins 
This family of cell surface proteins are linked to the cell membrane through an 
enzyme called diacylglyceryl transferase (Lgt) (Chimalapati et al., 2012). These 
proteins have diverse functions and the majority of them form a component of 
the ATP-binding cassette-type (ABC) binding proteins responsible for uptake of 
Mn+2 , Zn+2 ions and other ions (Bergmann & Hammerschmidt, 2006, Lawrence et 
al., 1998). The members of this family of proteins include pneumococcal cell 
adhesin (PsaA), pneumococcal iron uptake protein A (PiuA) and pneumococcal 
iron acquisition protein A (PiaA) (Brown et al., 2001). 
1.4.4.3 LPXTG anchored proteins 
This family of proteins are anchored covalently to the cell wall via LPXTG motif 
(Leucine, proline, any amino acid, threonine and glycine) and is located at the 
carboxy-terminal end. This motif is recognised by the sortase enzyme that links 
the protein via a threonine residue to the peptidoglycan of the cell wall. Two 
important members of this family include hyaluronidase and neuraminidase 
(Mitchell, 2003, Tettelin et al., 2001). 
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Table 1-1 Summary of important virulence factors (VF) of S.pneumoniae and their functions 
Virulence Factor Location on 
bacterium 
Function 
Capsular 
Polysaccharide 
(CPS) 
Cell surface Resists complement activity and protects 
bacterium from being phagtocytosed (Anti-
phagocytic). 
Hides cell surface antigens from the host 
immune system and altering capsular 
expression during disease (Hammerschmidt et 
al., 2005). 
Cell Wall  
 
 
Beneath the 
capsule 
Surface proteins anchored to the cell wall. 
Cell wall components initiate inflammatory 
response (Tuomanen et al., 1985). 
Pho binds to PAF (Platlet activating factor). 
PAF is up regulated in viral infection which 
might explain the secondary pneumococcal 
infection (Mitchell, 2003). 
Pili Cell surface Mediates initial attachment of bacterium with 
the host. 
Second pilus discovered with its involvement in 
host cell adhesion (Bagnoli et al., 2008). 
Autolysin (LytA) 
 
 
 
 
LytB and LytC 
Cell wall; 
choline-
binding 
Degrades cell wall and hence release of other 
virulent factor e.g. PLY (Howard & Gooder, 
1974). 
Has an important role in the pathogenesis of 
pneumococcal meningitis (Hirst et al., 2008). 
LytA deficient mutants have decrease ability 
of replication in the lungs (Orihuela et al., 
2004). 
These autolysins have a role in nasopharyngeal 
colonisation (Gosink et al., 2000). 
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Pneumococcal 
surface protein 
(PspC) also 
called Choline 
Binding protein 
(CbpA)  
 
 
 
Cbp D,E,F,I,L 
and G 
 
Cell wall; 
choline-
binding 
Has a major role in adherence of bacterium to 
the nasophayrnx (Rosenow et al., 1997). 
Binds Factor H (Dave et al., 2001) which is the 
regulator of the complement activation and 
exploit it for bacterium survival (Herbert et 
al., 2012). 
Mutants show reduced virulence in both 
bacteremia and pneumonia models possibly  
due to less effective nasopharyngeal 
colonisation (Kerr et al., 2006, Rosenow et al., 
1997). 
CbpD,E and G have role in nasopharyngeal 
colonisation (Gosink et al., 2000). 
CbpF,I and L binds to elastin, a major 
component of blood and lung vessels (Frolet et 
al., 2010). 
Pneumococcal 
Surface Protein A 
(PspA)  
Cell wall; 
choline-
binding 
Highly variable protein expressed by all 
clinically important serotypes (Crain et al., 
1990). 
Inhibit deposition of the complement C3 and 
thus reducing complement mediated clearance 
(Mukerji et al., 2012). 
Binds to human lactoferrin, an iron binding 
protein thus involved in iron acquisition at the 
site of infection (Hakansson et al., 2001). 
Pneumococcal 
cell adhesion 
(PsaA) 
Cell surface; 
lipoprotein 
Part of ABC transport system for uptake of 
Mn+2 and Zn+2 into bacterial cytoplasm 
(Lawrence et al., 1998). 
Has a role in oxidative stress (Tseng et al., 
2002). 
Pneumococcal 
iron 
acquisition(Pia) 
Cell surface; 
lipoprotein 
Part of pneumococcal iron ABC transport 
system and was in mouse model required for 
full virulence (Brown et al., 2001). 
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and  
Pneumococcal 
iron uptake (Piu)  
Antibodies protection is via 
opsonophagocytosis rather than iron transport 
inhibition (Jomaa et al., 2005). 
Hyaluronidase 
(Hyl) 
Cell wall; 
LPXTG 
anchored. 
also secreted 
Breaks down hyaluronic-acid in the mammalian 
connective and extracellular matrix and 
enhances pneumolysin-mediated epithelial cell 
damage (Feldman et al., 2007, Humphrey, 
1948). 
Neuraminidase 
(NanA) 
 
 
 
 
 
Pneumococcal 
Histidine Triad 
(Pht) proteins  
 
Cell wall; 
LPXTG 
anchored. 
also secreted 
 
 
 
 
Cell surface  
Cleaves sialic acid from host glycolipids, 
oligosaccharide and lipoproteins revealing 
receptors for pneumococcal binding (King et 
al., 2006). 
Mediates entry of bacterium in the CNS 
(Uchiyama et al., 2009). 
Role in nasopharyngeal colonisation in 
chinchilla model (Tong et al., 2005). 
Desialylates competitor colonizing species 
(Shakhnovich et al., 2002). 
Inhibit complement deposition on 
pneumococcus through recruiting of human 
Factor H (Ogunniyi et al., 2009). 
Antibodies against PhtD and E prevent 
pneumococcal adherence to airway epithelial 
cells (Khan & Pichichero, 2012). 
Pneumococcal 
adhesion and 
virulence A 
(PavA) 
Cell surface Binds to fibronectin and inactivation of PavA 
gene resulted in markedly reduced virulence 
(Holmes et al., 2001). 
Hydrogen 
Peroxide (H2O2) 
Cell surface  Produced during aerobic growth and 
inhibits/kills other colonisers of the upper 
respiratory tract (Pericone et al., 2000). 
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PLY Cytoplasm Has two major activities; lysis of the cells and 
activation of the complement. The role of PLY 
is explained in detail as the toxin is the major 
focus of this study (Mitchell, 2003). 
  
1.5 Pneumococcal vaccines 
The history of pneumococcal vaccine dates back to early 1900, when for the first 
time whole killed pneumococci as vaccine was used with some efficacy against 
the bacterium (Chien et al., 2010).The discovery of antibiotics resulted in the 
loss of interest for vaccines but the focus shifted again on developing vaccines 
due to the emergence of antibiotic resistant strains (Tomasz, 1997). 
Currently used vaccines involve the use of CPS and are known as Pneumococcal 
Capsular Polysaccharide (PPV) and Pneumococcal Conjugate Vaccine (PCV). 
1.5.1 Pneumococcal polysaccharide vaccine (PPV) 
PPV contains capsular polysaccharide which acts as active immunogen and 
produce sero-type specific antibody protection promoting opsonisation and 
complement mediated phagocytosis (Malley & Anderson, 2012). A PPV vaccine 
with a mixture of 14 most prevalent capsular polysaccharide antigens were 
introduced in the United States in the year 1977 and the numbers increased to 
23 in 1983 (Robbins et al., 1983). The vaccine contain CP of the following 
serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 
19A, 20, 22F, 23F and 33F and covers 85 to 90% of IPDs in the developed world 
(Butler et al., 1999). 
Chapter 1  36 
PPV induces a T-cell independent response and the resulting response is short 
lived and lacks T-memory cells (Weintraub, 2003). Another major limitation in 
the use of PPV in young children (< 2 years of age) is its inability to generate an 
effective response against the vaccine due to immature immune system 
(Deficiency in maturation of distinct B lymphocyte sub populations) (Barrett, 
1985). Since this age group (<2 years) is highly affected by pneumococcal 
disease, an alternative vaccine for the protection of this group was required. 
1.5.2 Pneumococcal conjugate vaccines 
PCV was designed by conjugating the selected capsular polysaccharides to a 
protein carrier resulting in the T-cell dependent response. The response 
generated is long lived and has a memory T-cell response, unlike PPV which 
engages B cell and hence lacks memory response. PCV7 contains the purified 
capsules of the following serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F combined 
with detoxified diptheria toxin (CRM147). This vaccine is processed as a separate 
protein antigen rather than entering the polysaccharide pathway. 
In 2009-10 two more PCVs were introduced; a 13 valent PCV containing capsular 
polysaccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F 
and a 10 valent vaccine (Synflorix) using H.influenzae carrier protein containing 
CPS from serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Prymula & 
Schuerman, 2009). 
The introduction of PCVs has resulted in significant reduction of both non-
invasive and invasive pneumococcal diseases in children and infants (Principi & 
Esposito, 2012, Fitzwater et al., 2012). However, there are certain 
disadvantages with PCVs as limited serotypes can be included with this vaccine 
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and strain replacement/capsular switching (serotype replacement) by 
pneumococcus may result in long term vaccine failure (Coffey et al., 1998). The 
vaccine escape isolates of serotype 19A associated with PCV-7 has already 
emerged in the USA (Croucher et al., 2011). 
The other major concern with PCV is its high cost which is unaffordable in 
developing countries. There is a desperate need to develop cheaper, affordable 
and sero-type independent vaccines for use in the developing world. 
1.5.3 Other potential vaccine candidates 
Whole-cell killed vaccines have been tested in mice and have shown some 
promising results by inducing both the humoral and cell mediated immunity. This 
type of approach uses non-capsular antigens common to all serotypes (Malley & 
Anderson, 2012). 
Another approach to overcome the issue of serotype specificity is the use of 
conserved pneumococcal cell surface proteins as a vaccine. These recombinant 
protein based vaccines are easy to manufacture, cheap, robust and globally 
accessible. The interaction of these protein antigens with the immune system 
will result in the generation of antibodies resulting in host protection. However, 
since these proteins are surface exposed they are under constant selective 
pressure of the host immune response and exhibit some variability across 
serotypes. Cytoplasmic proteins will be under less selective pressure since they 
will be protected from such assault (PLY as vaccine candidate discussed in 
section 1.8.4 and 1.8.5). 
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Recently, a study conducted showed that mice immunised with PLY toxoids 
fused with PspA fragments provided protection against pneumococcal infection 
(Goulart et al., 2013).Other studies have also shown the protective effect of 
PspA and Ply toxoid ((PdB) discussed later)) in murine model of pneumonia and 
sepsis (Briles et al., 2003, Ogunniyi et al., 2007). Furthermore, a study showed 
that chemically detoxified PLY given in combination with PhtD confers 
protection against S. pneumoniae induced pneumonia in rhesus macques (Denoel 
et al., 2011). Immunisation with iron-uptake ABC transporter proteins piaA and 
piuA protected mice with I.N challenge with S.pneumoniae (Jomaa et al., 2005). 
1.6 Cholesterol dependent cytolysin (CDCs)  
CDCs also known in the past as thiol-activated toxins (TATs), are a family of β-
barrel pore-forming toxins, secreted mainly by more than 20 species of Gram 
positive bacteria. PLY belongs to this family and recently two CDC Desulfolysin 
(DLY) and Enterolysin (ELY) from Gram negative bacteria have also been 
identified and characterised (Alouf et al., 2006, Heuck et al., 2010, Hotze et 
al., 2013). The current known members of this family are  listed in the table 
below (Heuck et al., 2010). 
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Table 1-2 List of currently known Cholesterol dependent cytolysins (CDCs) 
 
Adapted mainly from (Heuck et al., 2010) with additional information taken from (Billington 
et al., 2000, Rampersaud et al., 2011, Jost et al., 2011, Hotze et al., 2013). *subsp. 
Equisimilis. 
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The toxins were historically named as TATs due to the observation that 
modification of an important cysteine residue renders it inactive. However, later 
studies showed the thiol group not to be contributing in toxin binding and or 
membrane insertion and hence TAT description for these toxins is a misnomer 
(Marriott et al., 2008, Saunders et al., 1989).The toxins are referred as CDCs 
because of the absolute requirement of cholesterol in the host target membrane 
for binding and pore formation (Heuck et al., 2010). 
1.7 PLY 
PLY belongs to the family of cholesterol dependent cytolysin (CDCs) family. PLY 
is regarded as one of the main virulence factors of S.pneumoniae. Despite the 
fact that the toxin was recognised more than 80 years back several fundamental 
mechanisms regarding its release and its localisation remain ill defined (Rubins & 
Janoff, 1998). 
1.7.1 Release of PLY 
All the members of the CDC family (except S.pneumoniae, S.mitis and 
S.pseudoneumoniae) have a cleavable signal sequence and are secreted 
extracellularly. PLY is different from other CDCs as it lack a N-terminal secretion 
signal and its released is dependent on autolysin (Jedrzejas, 2001). However, its 
release is still unclear with some studies showing PLY release independent of 
LytA (Balachandran et al., 2001) and others predicting its domain 2 dependent 
export (Price et al., 2012).The localisation of PLY is also debatable with some 
studies suggesting its localisation in cell wall compartment (Price & Camilli, 
2009). 
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1.7.2 Structure of PLY 
The crystal structure of PLY is yet to be elucidated but the crystal structures of 
PFO (Rossjohn et al., 1997), ILY (Polekhina et al., 2005), SLY and ALO (Bourdeau 
et al., 2009, Xu et al., 2011) have been determined. Figure 1.3 shows the crystal 
structure of PFO, a CDC produced by Clostridium perfringens. The crystal 
structure shows that the protein is rich in β sheets (Rossjohn et al., 1997). The 
structure and/or function studies of PLY are based on the model built on the 
basis of PFO. PFO has 48% sequence identity and 60% similarity with PLY (Gilbert 
et al., 1999)  
  
Figure 1-3 Crystal structure of PFO showing the 4 domains 
The black arrow indicates Trp-rich motif in undecapeptide region of domain 4 of the toxin. 
The red box indicates the three hydrophobic loops (L1-3). Adapted from (Rossjohn et al., 
1997). Domains 1, 2, 3 and 4 are represented by red, yellow, green and blue. 
 
Chapter 1  42 
PLY is a 53kDa protein with 471 amino acids (Walker et al., 1987) and like other 
CDCs it has 4 domains (Gilbert et al., 1999); Domain 1 (residues 6-21, 58-147, 
198-243, 319-342), domain 2 (residues 22-57, 343-359) and domain 3 (residues 
148-197, 244-318). Domains (1-3) form the N-terminal part while domain 4 (360-
469) forms the important C-terminal part of the protein (Rossjohn et al., 1998). 
Domains 1-3 are connected to domain 4 via domain 2 which is considered as the 
“neck” of the molecule (Rossjohn et al., 1997). 
Domain 4 is a compact β-sandwich shaped domain and has a Trp-rich motif 
(black arrow in figure 1.3) at its end. This motif resides in an important region of 
the toxin known as undecapeptide region (427-437) which is highly conserved 
among CDCs (Rossjohn et al., 1998). In addition to the undecapeptide region, 
domain 4 also houses three short hydrophobic loops (Loops1, 2 and 3; shown in a 
red square in figure 1.3) and their roles will be discussed in detail in the 
subsequent headings (Soltani et al., 2007). 
1.7.3 Biological effects of PLY 
PLY is a multifunctional toxin and is present virtually in all clinical isolates 
(Kanclerski & Mollby, 1987). The biological properties of the toxin have been 
thoroughly studied both in-vitro and in-vivo models. The toxin interaction with 
the host cells (host pathogen interaction) has also been studied in detail with 
both PLY deficient and PLY proficient strains. It has a range of functions and its 
importance can be determined from the fact that in a murine model of 
pneumonia, mutants lacking PLY genes are less virulent as compared to isogenic 
toxin-producing strains. PLY can induce many pro-inflammatory and physiological 
mediators and the biological effects of toxin on different cells and tissues are 
given in the table 1.3. PLY gene is highly conserved across all serotypes with 
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little variation (3.3%) over time and geographical location (Mitchell, 2006, 
Marriott et al., 2008). However, some sequence variations e.g. in (Serotypes 1, 
ST306) have some important consequences and are discussed later. The two 
main important functions of toxin is the ability to form pores and activating the 
complement pathway. The pore forming mechanism of the toxin is discussed in 
section 1.8. 
PLY pore forming ability makes it toxic to cells containing cholesterol and can 
damage eukaryotic pulmonary epithelial, endothelial cells (Steinfort et al., 
1989, Rubins et al., 1992) and neuronal cells (Reiss et al., 2011, Zysk et al., 
2001). PLY was found in the CSF from meningitis cases (Wall et al., 2012), in the 
lung tissue from mice pneumonia model (Witzenrath et al., 2006), in sputum 
from pneumonia patients (Wheeler et al., 1999) and in the middle ear cavity 
from otitis media (Palmu et al., 2004). 
The cytotoxic effect of PLY on the respiratory epithelial causes cytoplasmic 
blebbing, mitochondrial swelling and cell death (Steinfort et al., 1989). PLY 
helps pneumococcus to move from alveoli to interstitium and into the blood 
stream. This is achieved by breaking the epithelial tight junctions, increasing 
alveolar permeability, inflammation and thus aiding its spread into the blood 
(bacteremia) (Rubins et al., 1995, Orihuela et al., 2004, Kadioglu et al., 2002). 
In addition to this, PLY also impedes ciliary bronchial epithelial cell clearance 
and helps in propagation of organism in the lower respiratory tract. This effect is 
dependent on haemolytic activity as a mutant lacking haemolytic activity 
(W433F) showed reduced effect. Thus PLY perturbs host defences in respiratory 
tract which helps in proliferation and invasion of the bacterium (Feldman et al., 
1990, Steinfort et al., 1989, Rayner et al., 1995). 
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PLY causes neuronal cell death by increase in the calcium influx mediated 
through its pore forming ability and also induces mitochondrial damage (Braun et 
al., 2007, Stringaris et al., 2002). PLY also causes ependymal ciliary stasis, 
sloughing and cytoplasmic extrusion as it is toxic to ependymal cells (Mohammed 
et al., 1999). The toxin helps the organism in crossing the (BBB) by damaging 
brain’s microvasular endothelial cells (Zysk et al., 2001). The importance of PLY 
in pathogenesis of pneumococcal meningitis disease is evident from the fact that 
mutant lacking PLY had reduced virulence when compared with PLY proficient 
strains in a rat model of meningitis (Hirst et al., 2008). 
The role of PLY in AOM is not well known and pathogenesis of AOM might be due 
to cell wall components, cell surface proteins, inflammation in the middle ear 
and a minor contribution from the toxin (Sato et al., 1996, Stol et al., 2009). 
Anti-ply antibodies have been found from the middle ear fluid from the children 
with AOM and direct instillation of PLY induced damage on the cochlear hair 
cells of guinea pigs suggesting that PLY may contribute to deafness associated 
with adverse effects of AOM and meningitis (Rapola et al., 2000, Comis et al., 
1993). A study conducted by Franco-Vidal et al., 2008 on rat cochlear hair cells 
found that debilitating effects of toxin on cells can be minimised by zinc 
supplementation. Zinc supplementation possibly blocks the influx of calcium ions 
in the membrane by interfering with the toxin binding and subsequent pore 
forming ability (Franco-Vidal et al., 2008). 
PLY plays a role in eye infections and in a rabbit model the pathogenesis of 
endophthalmitis was directly related to the toxin’s pore forming lytic activity. 
The study carried by Green et al., 2008 showed that antibodies against PLY 
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confer protection against S.pneumoniae keratitis (Green et al., 2008, Sanders et 
al., 2008). 
Pore forming ability of the toxin was directly responsible for neuronal cell death 
(Stringaris et al., 2002), retinal layers damage (Sanders et al., 2008), damage to 
the phagocytes and immune cell response (Jedrzejas, 2001) and can induce 
apoptosis in dendritic cells (Littmann et al., 2009). PLY was thought to be lytic 
in all strains and its lytic property was assumed to be important for the 
pneumococcal disease progression until the identification of the non-haemolytic 
version of the toxin in serotype 1, ST306 causing invasive disease outbreak in 
Scotland. The protein alignment of ST306 with the D39 strain revealed 4 amino 
substitutions (Y150H, T172I, K224R and A265S) and 2 amino acid deletions 
(∆V270K271). This implies that lytic activity of the toxin is not required by some 
serotypes like ST306 to cause invasive disease. This also suggests that there is 
less selective pressure on these strains for conserving the nucleotide sequence 
encoding lytic activity and hence resulted in mutations described in this study 
(Kirkham et al., 2006b). 
Some serotypes (7F and 8) with reduced haemolytic than WT PLY were also 
identified and this reduction was attributed to the amino acid substitution at 
position 172 (Threonine-Isoleucine) (Lock et al., 1996). To date, there are 19 
distinct PLY alleles and recently a study done by Harvey et al., 2011 has shown 
that serotype 1 PLY variant (PLY04496) having reduced haemolytic activity have 
a higher bacterial count in the first 15 hours post challenge compared to WT 
strain. This implies that these alleles have a growth advantage in early stages of 
bacteremia which could be important for invasive serotypes. However, PLY 
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immunisation provided protection against all the strains irrespective of their 
haemolytic activity (Harvey et al., 2011, Jefferies et al., 2010). 
The functions of PLY extend beyond its lytic activity and complement activation 
is another major biological effect of the toxin. This immunomodulatory effect of 
toxin is independent of its pore forming ability. PLY has sequence homology to 
acute-phase protein C-reactive protein and can interact directly with C1q or 
indirectly through Fc portion of the immunoglobulin IgG, thereby activating the 
complement. The complement activation can however occur in the absence of 
anti-PLY antibody as well. The complement activation was shown to be mediated 
by the residue Aspartate 385 (D385), residing in domain 4 of the toxin and this 
region is shown to be homologous to the C-reactive protein. A mutation made in 
this region of the toxin (D385N) abolished complement binding (Berry et al., 
1995, Mitchell et al., 1991, Paton et al., 1984). PLY’s complement activation 
decreased C3 deposition and thereby reduces opsonophagocytosis. A study 
conducted showed that in-vitro PLY deficient strains have increased complement 
deposition compared to isogenic PLY proficient strains (Yuste et al., 2005). The 
importance of this pathway in pneumococcal infection was further strengthened 
by a study performed in mice with genetic deficiencies of different complement. 
Their results suggested that a loss of activation of the complement pathway 
resulted in severe septicaemia (Brown et al., 2002). The highly important role of 
complement in humans has also been established by many studies and it has 
been shown that patients having complement deficiencies (C2) have increased 
susceptibility to pneumococcal infections (Yuste et al., 2008, Skattum et al., 
2011). 
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The importance of complement inhibition in disease pathogenesis can be 
observed by the fact that complement-activation makes specific contribution in 
the pneumococcal pneumonia by a different mechanism and at separate stage of 
infection from the haemolytic activity of the toxin (Rubins et al., 1995, Rubins 
et al., 1996). In addition, it has been demonstrated in previous studies that both 
properties of the toxin are required for virulence of the organism in the model of 
bronchopneumonia and lobar pneumonia (Rubins et al., 1996, Alexander et al., 
1998). However, mutants lacking both the complement and lytic activity were 
still virulent compared to the PLY negative strains suggesting other important 
functions of the toxin contributing to its virulence (Benton et al., 1997). 
A study done has shown that in the host lung tissues T-cell recruitment response 
was influenced by the complement activating activity of the toxin and the 
neutrophil recruitment was mediated by the pore forming activity of the toxin 
(Jounblat et al., 2003). Neutrophils are first cells to respond during 
pneumococcal infection and are responsible for clearing bacteria from the lungs 
(Jones et al., 2005). The neutrophil recruitment from the vascular spaces to the 
nasophayrnx has also been observed during pneumococcal colonisation (van 
Rossum et al., 2005). Neutrophils play a key role in clearing infection as 
impaired recruitment resulted in severe pneumococcal pneumonia in mice (Sun 
et al., 2007, Nakasone et al., 2007). 
Resident alveolar macrophages are another group of phagocytic cells that 
provide immunity by engulfing the bacterium and releasing the inflammatory 
mediators. The loss of their function significantly alters the inflammatory 
response and release of cytokines (Jonsson et al., 1985, Marriott et al., 
2008).The effect of the toxin, on the host immune response, results in the 
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persistence or clearance of the bacterium hence implying that a fine balance 
must be maintained. This manipulation of neutrophilic response in pneumococcal 
pneumonia is extremely crucial since a subset of individuals die mainly due to 
dysregulated inflammatory response induced despite the clearance of the 
organism. This response results due to excessive secretion of pro inflammatory 
cytokines by neutrophils and hence switching off these pro inflammatory 
cytokines at appropriate time is beneficial for host survival (Dockrell et al., 
2012). 
Toll like receptors (TLRs) also known as pattern recognition receptors (PRRs), a 
component of innate immune system recognises microbial invasion and elicits a 
range of host defence mechanisms. There are other PRRs which include cytosolic 
NOD-like receptors (NLRs) and DNA sensors, e.g. DAI (DNA-dependent activator 
of interferon (IFN)-regulatory factors). TLR activation generates signal 
transduction pathways resulting in the formation of gene products which trigger 
inflammatory responses (recruitment of neutrophils and macrophages) and also 
leads to the activation of antigen specific adaptive immunity. The TLR signalling 
can also cause over activation of immune response and as a consequence fatal 
immune disorders can occur, so a negative feedback mechanism is required to 
prevent hyperactivation (Akira & Takeda, 2004, Takeda et al., 2003, Takeda & 
Akira, 2005, Koppe et al., 2012). 
Toll receptor was first discovered as transmembrane receptor for establishing 
dorso-ventral polarity in dorsophila during embryogenesis (Hashimoto et al., 
1988). It showed remarkable similarity with the mammalian Interlukin-1 (IL-1) 
pathway, which leads to the activation of transcription factor NF-κB, responsible 
for innate and inflammatory response (Belvin & Anderson, 1996). 
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So far, 12 mammalian TLRs (10 in humans and 12 in mice) have been discovered 
that are controlled by a family of regulator proteins adapters such as Myeloid 
differentiation factor (MyD88) that provide specificity to the response by each of 
these TLRs (Takeda & Akira, 2005, Koblansky et al., 2013). 
PLY has been shown to interact with TLR-4 and defined mutation in TLR-4 
renders mice more susceptible to colonisation and invasive disease when 
intranasally challenged with a PLY producing pneumococcus compared to the WT 
mice (Malley et al., 2003). An in-vitro study has shown TLR-4 dependent 
production of cytokines, chemokines (IL-1β, IL-6 and KC) and neutrophil influx 
after high dose of PLY (Dessing et al., 2009). 
The role of other TLRs ((TLR-2 (van Rossum et al., 2005) and TLR-9 (Albiger et 
al., 2007)) in pneumococcal infections have also been studied in-vivo and some 
conflicting results have been reported. Pneumococcal cell wall components e.g. 
lipoteichoic acids (LTA) have shown to activate TLR-2 and TLR-2 dependent 
neutrophil influx (Dessing et al., 2008). Neutrophil recruitment in a TLR-4 
dependent fashion has also been found in another study after PLY instillation. 
These differences might be in part due to the redundancies that exist between 
different TLRs (Dessing et al., 2009, Koppe et al., 2012). 
A study has shown that PLY interacts with other PPR; (Nod)-like receptor (NLR) 
P3 inflammasome independent of TLR-4. This interaction results in maturation of 
dendritic cells and production of IL-17A and IFN-γ by T cells. The study showed 
NLRP3-/- deficient mice were more susceptible to infection compared to the WT 
group. The study also identified the NLRP3 activation is dependent on the pore 
forming ability of the toxin and activation of lysosomal Cathepsin B for IL1-β 
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release. IL1-β has an important role in IL-17A activation and provides an 
important role against pneumococcal infection. IL-17 helps recruiting neutrophils 
and lymphocytes at the site of infection (Kafka et al., 2008, McNeela et al., 
2010). The pore forming ability required to activate NLRP3 inflammasome was 
also shown by a study which demonstrated impaired IL-1β production by strains 
with reduced haemolytic activity; for instance, ST 306 (Serotype 1). This might 
also explain that some strain (PLY004496) mentioned above have survival 
advantages in the blood within the first 15 hours of infection post infection since 
they do not engage the NLRP3 inflammasome thus facilitating the spread of 
bacterium in the blood. The full lytic activity of the toxin may hinder the early 
bacterial proliferation in blood and hence non-lytic strains show early growth 
advantage (Witzenrath et al., 2011, Harvey et al., 2011). 
PLY induces damage in a variety of host cells and exerts its pathogenic effect by 
another mechanism known as programme cell death or apoptosis. The apoptotic 
response is usually observed in CNS following pneumococcal meningitis 
(Bermpohl et al., 2005, Braun et al., 2002). This pathway involves the activation 
of p38-mitogen-activated protein kinase (MAPK) activation, calcium influx of 
calcium (Ca+2) mediated by pore forming ability of the toxin, reactive oxygen 
species (ROS) production and direct mitochondrial damage and release of 
apoptosis-inducing factor. PLY induced neuronal apoptosis is independent of 
caspases (1, 3 and 8) activation (Stringaris et al., 2002, Braun et al., 2007). In 
addition to neuronal cells, PLY can induce apoptosis in neutrophils, 
macrophages, dendritic and endothelial cells involving caspases activation 
(Dockrell et al., 2003, Littmann et al., 2009, Zhou et al., 2012, Colino & 
Snapper, 2003, Zysk et al., 2000). 
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Overall the toxin acts as a “double edge sword” during host-pathogen interaction 
whereby on one hand toxin stimulates excessive inflammatory response by 
releasing pro inflammatory mediators as described above and on the other hand 
toxin limits critical host immune responses ( e.g. complement activation, 
inhibition of lymphocyte proliferation and antibody response) and thus 
exacerbating injury to the host (Marriott et al., 2008). 
Table 1-3 Biological effects of PLY on cells and tissues 
Cells/Tissues 
Types 
Effects 
Alveolar and 
Bronchial epithelial 
cells 
Disrupts cells and slows ciliary beating which in turn 
facilitates spread of the organism and infection in the 
surroundings (Rubins et al., 1993, Steinfort et al., 1989, 
Feldman et al., 1990). 
Pulmonary 
endothelial cells 
Disrupts pulmonary endothelial barrier and thus possibly 
helps in disseminating bacterium from lung to blood 
stream (Bacteremia). Also activates phospholipase A 
contributing to inflammation and tissue damage (Rubins et 
al., 1994, Rubins et al., 1992). 
Neutrophils Inhibition of respiratory burst, chemotaxis and migration 
of neutrophils and thus facilitating the spread of the 
organism (Paton & Ferrante, 1983). 
Dysregulated release of IL-8 which is a neutrophil chemo 
attractant, resulting in excessive inflammation and 
damage to the respiratory epithelium. This favours 
microbial spread by subverting host immune response 
(Cockeran et al., 2002). 
Monocytes and  
Macrophages 
Release of IL-1β and TNF-α from monocytes resulting in 
inflammation and tissue damage (Houldsworth et al., 
1994). 
Stimulates Nitric oxide (NO), TNF-α and IL-6 production 
and resulting in excessive inflammation and injury (Malley 
et al., 2003, Braun et al., 1999). 
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Erythrocytes Cause the lysis of red blood cells hence lytic activity must 
be abolished before using as vaccine (Mitchell et al., 
1989). 
Lymphocytes and   
B cells 
Inhibits lymphocytes proliferation and antibody production 
thereby altering the adaptive immune response (Ferrante 
et al., 1984). 
Dendritic cells PLY inhibits DC maturation, release of pro inflammatory 
cytokines and induces caspase 1 dependent apoptosis. This 
helps pneumococcus to evade DC mediated host immune 
response (Littmann et al., 2009). 
Spleen  Induce IFN-γ production independent of its pore forming 
ability which in turns stimulates NO production (Baba et 
al., 2002). 
 
1.8 Pore formation 
The pore formation mechanism of CDCs still remains controversial. There are 
two proposed theories by which CDCs, including PLY, forms pores in the 
cholesterol containing membranes (Figure 1.4). One model suggests that 1-2 
toxins monomers bind to the membrane and forms a small pore and other 
monomers bind to the pre-existing pore followed by oligomerisation and this 
eventually results in the formation of a large pore. This model was based on 
studies done on Streptolysin O (SLO) (Palmer et al., 1998). The second model 
was based on studies done on PFO and suggests that toxin monomers binds to the 
membrane and forms a prepore first by oligomerising on the membrane and then 
the entire oligomer inserts in the phospholipid layer to form a large pore(Hotze 
et al., 2002, Shepard et al., 2000). However, a study done by Heuck et al., 2003 
has demonstrated that SLO can also form a prepore state (Heuck et al., 2003).  
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The prepore model is the most acceptable model based on studies done and in 
case of PLY, the cryo-EM study also confirms that it does not form pores as 
suggested by Palmer et al. 1998, rather a prepore is formed followed by a large 
oligomeric 260Å pore (Tilley et al., 2005, Heuck et al., 2010). 
 
Figure 1-4 Schematic presentation of proposed models of pore formation by CDCs 
A) Individual monomers bind to the membrane to form a prepore complex first which is 
followed by large transmembrane pore. B) Individual monomers insert and form a small 
pore followed by monomers joining the pre-existing oligomer, until the pore reached its 
desired size. The membrane is shown as light gray from above and the transmembrane pore 
is shown as white (Heuck et al., 2003). 
  
The 3 steps in pore formation include binding of the toxin, oligomerisation to 
form a prepore state and finally the formation of a large pore. 
1.8.1 Binding 
The initial step in pore formation is the binding to the toxin to the target 
membrane (Tweten, 2005, Flanagan et al., 2009). It has been long proposed that 
toxin uses cholesterol as direct receptors since pre incubating the toxin with 
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free cholesterol blocks binding probably due to the saturation of the receptors 
on the toxin (Nollmann et al., 2004). 
The observations drawn from studies that CDCs use cholesterol as receptors got 
confounded with the discovery of Intermedilysin (ILY) a human specific CDC 
which interact via non sterol receptor human (hu) CD59 (Giddings et al., 2004). 
However, in ILY initial binding does not require cholesterol but subsequent 
prepore and pore formation requires toxin interaction with cholesterol. This was 
shown by a study conducted by Giddings et al., 2003 whereby depleting 
membrane cholesterol resulted in the failure of toxins (PFO, ILY and SLO) to 
form pores in the membrane (Giddings et al., 2003). Thus cholesterol does not 
function only as receptor for binding but its functions extend beyond binding. 
Besides binding, cholesterol promotes oligomerisation step, triggers pore 
formation and stabilises pore (Rossjohn et al., 1997). 
D4 of the toxin initially interacts with the cholesterol containing membrane and 
CD59 in case of ILY (Giddings et al., 2004, Baba et al., 2001). A study has shown 
that recombinant D4 can bind to the cell membranes and immobilised 
cholesterol. Moreover, addition of purified D4 to cholesterol blocks the binding 
for the full length toxin and also the lytic activity. Hence D4 of the toxin was 
responsible for mediating initial contact of the toxin with the membranes and 
subsequent lytic activity (Baba et al., 2001). A study conducted has shown that 
in Listeriolysin (LLO), one of the members of the CDCs, domains (1-3) can also 
bind to the cell membranes along with D4. The purified domains LLO-d1-3 and 
LLO-d4 can also reassemble into a heamolytically active form and slight 
mutations made in this linker renders protein inactive (Dubail et al., 2001). 
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1.8.1.1 Undecapeptide and hydrophobic loops (L1-3) 
Domain 4 of all CDCs has 11 amino acid conserved Trp rich loop 
(ECTGLAWEWWR) known as undecapeptide region (residues 427-437 in PLY).This 
region is well conserved among all CDCs with slight variation in some members 
(Figure 1.5). A number of mutations have been made in the undecapeptide 
region of the toxin to evaluate its contribution in binding and subsequent lytic 
activity (SekinoSuzuki et al., 1996, Nakamura et al., 1998). The insertion and 
extension of the toxin into cholesterol containing membranes was thought to be 
mediated by Trp-rich region which forms a loop like structure acting as a 
“hydrophobic dagger” (Rossjohn et al., 1997). The importance of this region can 
be identified from the fact that the first tryptophan residue of the 
undecapeptide in PLY when substituted to phenylalanine (W433F) resulted in the 
significant reduction in the lytic activity of the toxin (Paton et al., 1991). 
Domain 4 also houses three short hydrophobic loops (L1-3) and these loops along 
with the tip of the undecapeptide region are in contact with the lipid bilayer 
while the rest of the domain 4 is surrounded by water (Ramachandran et al., 
2002). This led to the search for residues responsible for the initial interaction of 
D4 with membrane and a study showed that D4 loops (1-3) and not the 
undecapeptide are involved in the initial recognition of the toxin with the 
membrane (Soltani et al., 2007). Further research to track down the amino acids 
was carried by performing mutational analysis of all residues present in the 
three loops. The study found that two amino acids (threonine, leucine) in Loop 1 
PLY(T459G.L460G) was responsible for mediating this initial interaction with the 
cholesterol containing membranes and was present in all CDCs (Figure1.5). In 
ILY, the toxin initially interacts with CD59 but the cholesterol recognition motif 
is responsible for subsequent steps since substitution of this motif TL>GG in ILY 
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blocked pre-pore and pore formation. The study also suggested that the other 
residues in loop (1-3) may contribute to some insignificant binding by extending 
their side chains in the lipid bilayer (Farrand et al., 2009). 
 
Figure 1-5 Undecapeptide region and three hydrophobic loops in domain 4 of CDCs 
The protein sequence of all CDCs was obtained from NCBI and protein alignment was done 
using CLC Genomics Workbench3. Undecapetide region and Loop1 are shown in red box 
whereas Loop 2, 3 and TL region are shown within black box. 
 
1.8.2 Oligomerisation 
Five β strands present in domain 3 of the molecule are involved in the process of 
oligomerisation after binding. Oligomerisation occurs when β4 strand of one 
monomer binds to the β1 of the aligning monomer presumably by hydrogen 
bond. The β5 strand is a short strand present on the β4 strand and prevents 
monomer-monomer oligomerisation in the absence of membrane binding. The 
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toxin binds to the membrane resulting in the conformational change dissociating 
β5 subunit and exposing β4 which then interacts with β1 strand of the 
neighbouring monomer which is always exposed (Ramachandran et al., 2004, 
Tweten, 2005). 
1.8.3 Formation of β barrel pore 
The prepore oligomer upon reaching the size of complete ring structure is 
followed by the transition to pore complex. The 3α helices in D3 form 2 
amphipathic transmembrane β hair pin loops (TMH). The pore formation 
commences upon insertion of these TMH per monomer from 35 to 50 monomers 
in the lipid bilayer eventually forming a large transmembrane β barrel pore. The 
vertical collapse of D2 of about 40 Å brings these TMH within the striking 
distance of the lipid bilayer and the β-barrel pore has a diameter of about 250 to 
300 Å (Tweten, 2005, Czajkowsky et al., 2004). 
In summary, D4 first binds with the membrane via cholesterol recognition motif 
followed by insertion of the other loops and undecapeptide which strengthens 
the interaction (Farrand et al., 2009, Ramachandran et al., 2002). This is 
followed by oligomerisation where monomers bind and form a prepore complex. 
After oligomerisation, domain 2 begins to dissociate from domain 4 which brings 
the domain 3 closer to the membrane. Domain 3 unfolds and forms beta(β) 
hairpins loops which traverses into the membrane to form pores as shown in 
figure 1.6 below (Tilley et al., 2005). 
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Figure 1-6 Different stages of pore formation of PLY 
The domains are numbered (1-4) and the lipid bilayer is coloured grey. A) Monomer binding 
with the membrane. B) Prepore oligomer formed by 3 subnits. C) Dissociation of domain 2 
and insertion of TMH forming β- barrel pore(Tilley et al., 2005). 
 
1.8.4 PLY as a vaccine candidate 
PLY is one of the potential candidates to be used as vaccine since it is produced 
by nearly all serotypes with little variation over the time. PLY has been shown to 
provide protection when used alone (Kirkham et al., 2006a), as a protein carrier 
with current PCV (Kuo et al., 1995, Lee et al., 2001) and as a mucosal adjuvant 
(Douce et al., 2010). Anti-PLY antibodies given to mice also provide protection 
against the pneumococcal pneumonia (Garcia-Suarez et al., 2004, Salha et al., 
2012). However, PLY is toxic to be used as a vaccine ((forms large pores on host 
cell membranes) (Mitchell, 2006)) so a number of mutants were devised to 
reduce its toxicity yet maintaining its immunogenicity (Paton et al., 1984). 
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A number of mutants with reduced cytotoxic activity have been devised by site 
directed and random mutagenesis approach and tested as vaccines in animal 
models (Hill et al., 1994, Berry et al., 1995). One of the well characterised 
mutants is PdB with a single amino acid substitution of phenylalanine instead of 
tryptophan at position 433 in the undecapeptide region. PdB toxoid has shown to 
be protective in animal models when used alone and in combination with CbpA 
(Goulart et al., 2013, Paton et al., 1991, Neill et al., 2013). However, this 
mutant has unacceptable levels of toxicity (0.1 to 1% residual haemolytic 
activity compared to the WT) and therefore cannot be used as a vaccine (Paton, 
1996, Korchev et al., 1998). 
Recently, a toxoid version of the vaccine (PLYD1) has been made by making 
three substitutions (T65C, G293C and C428A) and has been shown to provide 
protection against pneumococcal lung injury and infection. This toxoid is 
designed based on the structure of the toxin and apart of its haemolytic activity, 
no other in-vitro experiments regarding its biological activity (binding assays, 
immune parameters) were mentioned in the study (Oloo et al., 2011). The result 
of this study and a previous study has shown that substituting C428A has no 
effect on the lytic activity of the toxin (Saunders et al., 1989). 
Another non-lytic PLY version (L460D) is constructed by mutating one of its 
cholesterol recognition motif and has shown to provide protection against 
pneumococcal colonisation in mice. However, the results of the excipient assays 
showed that toxoid was exhibiting aggregation phenotype without adding 
sugars(trehalose, sucrose and sorbotol; which exert stabilising effects) and was 
not conformationally stable when adsorbed on the surface of alhydrogel 
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(Alhydrogel is one of the currently licensed adjuvant to be used in human 
vaccines) (Hu et al., 2013). 
1.8.5 ∆6PLY a potential vaccine candidate 
∆6 PLY, a toxoid created by deleting the two amino acids at alanine and arginine 
positions 146 and 147 is one of the potential candidates to be used as a vaccine 
(Kirkham et al., 2006a). Protein alignment has also shown the presence of these 
residues in other CDCs (Figure1.7). 
The deletion of two amino acids resulted in the loss of oligomerisation and 
subsequent pore formation but the toxin still binds to the membranes. This 
mutant unlike PdB, was non-lytic even at concentrations >1mg/ml and was 
immunogenic and confer protection to mice challenged with S.pneumoniae 
(Kirkham et al., 2006a). 
 
Figure 1-7 Protein alignment of CDCs showing highlighted residues alanine and arginine 
rendering CDCs non-lytic 
The protein sequence of all CDCs was obtained from NCBI and protein alignment was done 
using CLC Genomics Workbench3.  
 
∆6PLY fused with a protein antigen given to mice has proven to be a strong 
mucosal adjuvant eliciting a strong antibody response to the antigen fused 
(Douce et al., 2010). This antigen response is independent to the fused antigen 
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and various other pneumococcal surface proteins (PspA, PspC and PhtD) fused 
with ∆6PLY have been tested for their adjuvanticity in the TJM group laboratory 
(T.J.Mitchell, personal communication, 2011). 
However, purified ∆6 PLY was shown to cause red blood cells to aggregate. The 
fluorescence microscopy images and FACS experiments also showed the red 
blood cells aggregation with ∆6PLY (This work and T. J. Mitchell, personal 
communication, 2009)  
This aggregation phenomenon makes the toxin unsuitable for using as a vaccine 
and therefore requires further investigation as to which residue/s are 
responsible for causing this aggregation behaviour. The identification of this 
residue/s will lead to the non-aggregation, non-lytic and immunogenic variant 
which can be used in vaccines alone, in combination with other pneumococcal 
protein antigens and/or conjugated to the capsular polysaccharide vaccines. 
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Aims of the study 
The aim of this study was to identify the toxin residue/s responsible for causing 
the aggregation/agglutination phenotype of the red blood cells.  
A number of molecular biology techniques (Site directed mutagenesis/Random 
mutagenesis/Alanine scanning mutagenesis) were used to track down the 
residue/s responsible for this phenotype. A number of mutants were designed 
and were tested in a 96 well round bottom plate. 
As the study progressed we were also able to identify the importance of residues 
in terms of maintaining the toxin’s structure and their contribution in the lytic 
activity. 
ASM (Alanine scanning mutagenesis) was done for each individual residue of 
D4PLY of the toxin and its lytic activity was measured. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Chemicals 
All chemicals used in this study were purchased from Sigma Aldrich, Fisher 
Scientific, Loughborough, UK, unless otherwise stated. 
2.1.2 Enzymes 
The oligonucleotides used in this study were purchased from Sigma Aldrich, UK. 
The restriction enzymes and GoTaq DNA used was purchased from Promega, UK. 
2.1.3 Proteins kits and supplies 
The Quick Change ® II XL site directed-mutagenesis kit used in this study, for 
constructing site directed mutants, was purchased from (Stratagene,UK).The 
random mutants constructed using Mutation Generation SystemTM Kit (MGSTM Kit) 
was purchased from (Finnzymes, UK). The prepacked HisTrap TM HP affinity 
columns for Immobilized Metal Ion Affinity Chromatography (IMAC), Hitrap TM 
Capto Q TM for anion exchange and PD10-Desalting columns for buffer exchange 
were obtained from GE Healthcare Buckinghamshire, UK. The Bio-scale TM Mini 
Profinity eXactTM 1ml cartridges for tagfree purification was purchased from Bio-
Rad,UK. 
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2.1.4 Antibiotics 
The antibiotics used routinely were ampicillin, kanamycin and choramphenicol. 
The stock solutions of these antibiotics were made in respective solvent i.e. 
(dH2O or ETOH), filter sterilised using 0.2µm filter and stored at -20
oC until 
required. The working concentration of antibiotic was calculated and added to 
the sterile broth media and agar after cooling them. 
2.2 Bacterial strains 
E.coli strains were grown overnight from a single colony with appropriate 
antibiotics in Luria Broth (L.B) at 37oC degree shaking at 180 rpm. 1 ml aliquots 
were made and were stored with 15% Glycerol at -80oC. The XL-1 blues 
(Stratagene,UK) were used for cloning and for storage of plasmids. The BL-21 
(DE3) (Stratagene,UK) chemical competent cells were used for protein 
expression. 
2.3 Vectors 
2.3.1 pET33b and pPAL7 
The plasmids used in this study are listed in table 2.6. Plasmid pET33b(+) 
(Novagen,UK) containing a kanamycin resistance gene along with pPAL7 
containing ampicillin resistance gene (patented vector from Biorad) were used in 
this study. The former was used for making site directed mutants and latter was 
also used for generating random mutations in PLY gene. 
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2.4 General molecular biology techniques 
2.4.1 PCR 
PCR was performed using 200µl PCR tubes from (Starlabs, Milton Keynes, UK) 
using Techgene thermal cycler (Bibbi Scientific, Staffordshire UK). The annealing 
temperature varied accordingly for different reactions depending on the melting 
temperature (Tm) of the primer used. A typical PCR reaction is outlined below. 
Table 2-1 Conditions used for PCR Reactions 
 
2.4.2 Agarose gel electrophoresis 
The agarose gels 0.8% w/v in tris-acetate-EDTA (TAE) buffer were used for 
analysis of plasmid DNA and PCR products and restriction digests. 100ml of the 
gel was prepared and for staining and visualization of products, 5µl of SyberSafe 
was added after cooling. 5µl of the products and 0.4µg of 1Kbp+ DNA standard 
ladder (Invitrogen, Paisley UK) were loaded and gel was run with 1 X TAE buffer 
at 100 Volts for 20 minutes. The UVpro-gel documentation system (UVtech) was 
used for gel visualisation and images. 
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2.4.3 dNTPs 
For PCR reaction mixes, a set of dNTPs (dATP,dCTP,dGTP,dTTP) from Invitrogen 
was used. 10µM final concentration was made in a ratio of 1:1:1:1 in 
DNase/RNase ultra pure H2O and store at -20
oC until required. 
2.4.4 Plasmid purification 
Plasmid DNA was purified using QIAspin Miniprep Kit (Qiagen) according to the 
manufacturer’s protocol. 
2.4.5 Bacterial transformation 
All plasmid DNA generated (listed in table 2.6) were transformed in chemical 
competent XL-1 Blues and BL-21(DE3).100ng of the expression vector was added 
to 50µl of E.coli (either XL-1 Blues or BL-21 (DE3)) in pre chilled 1.5ml 
ependorfs. After 20 minutes of incubation on ice, cells were heat-shocked for 
30sec at 42°C. The cells were kept again on ice for 2 minutes and 0.5ml of L.B 
broth was added and the reaction was incubated for 1 hour at 37oC. After 
incubation, 200µl of the culture was plated on L.B agar with appropriate 
antibiotics (kanamycin or ampicillin) at 50µg/ml. In random mutagenesis 
reactions, L.B agar was supplemented with 10µg/ml chloramphenicol (since 
transposon has chloramphenicol resistance gene) and 50µg/ml ampicillin (target 
plasmid). The next day colonies were picked and colony PCR reaction was done 
for successful transformation using primers flanking to the gene inserted. 
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2.4.6 Sequencing 
All plasmid DNA purified from the positive colonies (listed in table 2.6) were sent 
for sequencing to the Sequencing Service, University of Dundee using primers 7F 
and 7G listed in the list of oligonucleotides (Table 2.2). 
2.4.7 Oligonucleotides 
All oligonucleotides used in the study were reconstituted to 100mM 
concentration by addition of DNase/RNase free water. The 100mM was further 
diluted to 10mM working concentration by the addition of DNase/RNase free 
water. Both the stock and working concentration were kept at -20oC until 
required.
 Table 2-2 List of oligonucleotides used in the study 
      
 Primer Reference Primer Name Sequence (5' to 3') Primer Type 
(Sequencing/SDM/PCR)       
7F T7 old Fwd TAATACGACTCACTATAGGG Sequencing and PCR 
7G T7 old Rev GCTAGTTATTGCTCAGCGGTG Sequencing and PCR 
23B Delta6 forwards GGTCAATAATGTCCCAATGCAGTATGAAAAAATAACGGCTC SDM 
   23C Delta6 reverse GAGCCGTTATTTTTTCATACTGCATTGGGACATTATTGACC SDM 
   SDMD4 Forward(459,460) CCTCTACCTGAGGATAGCCGCCTGTTCCCCAAATAGAAATCGTCC SDM 
   SDMD4 Reverse(459,460) GGACGATTTCTATTTGGGGAACAGGCGGCTATCCTCAGGTAGAGG SDM 
   
NotI Forward 
 
GAATTCCTCGAGGCGCGGGCATAAGCCCGAAAGG SDM 
NotI Reverse 
 
CCTTTCGGGCTTATGCCCGCGCCTCGAGGAATTC SDM 
 
 
PCRTagfree Forward 
 
 
GTAGAAGAAGACAAGCTCTTCAAAGCTTTG PCR 
PCRTagfree Reverse 
 
CCGCGCCTCGAGGAATTC PCR 
 Delta6PLY363L>A Forward 
 
 
CAGCTTACAGAAACGGAGATGCACTGCTGGATCATAGTGG SDM 
Delta6PLY363L>A Reverse 
 
 
CCACTATGATCCAGCAGTGCATCTCCGTTTCTGTAAGCTG SDM 
 
 
Delta6PLYW>F Forward 
 
 
GTACCGGGCTTGCCTTTGAATGGTGGCGTACG SDM 
 
 
Delta6PLYW>F Reverse 
 
 
CGTACGCCACCATTCAAAGGCAAGCCCGGTAC SDM 
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2.5 Construction of plasmids by site directed 
mutagenesis (SDM) 
The Quick Change® II XL site directed-mutagenesis kit can successfully make 
point mutations, replacing amino acids and deleting or inserting single or 
multiple adjacent amino acids. The mutagenic oligonucleotide primers (25-45 
base pair length) are designed which complement each other and to the opposite 
strand except in the middle where the desired mutations (deletions or 
insertions) have to be made. The PCR was set up with 100ng of the plasmid 
according to the conditions in table 2.3. The high-fidelity pfuUltra II DNA 
plolymerase reads the entire plasmid on each cycle and plasmids with desired 
mutations are created. The resultant PCR product was incubated with 1µl of 
restriction enzyme DpnI at 37oC for 2 hours in order to digest the parental 
methylated plasmid. The nicked ummethylated plasmid was chemically 
transformed in E.coli (XL-1 blues) for nicked repair. 
Table 2-3 Reagent composition of SDM Reaction 
Reagent    Concentration and Volume µl 
Forward Primer    15pmol, 15µl 
Reverse Primer    15pmol, 15µl 
dNTP      10mM, 10µl 
Template DNA    100ng 
10X Reaction Buffer   5µl 
pfu Ultra II DNA polymerase  1µl 
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Table 2-4 Cycling parameters of a typical SDM reaction 
 
 
2.5.1 Construction of pET33bD4PLY(T459G.L460G) and 
pET33beGFPD4PLY(T459G.L460G) 
The plasmids pET33bD4PLY and pET33beGFPD4PLY was used to make the desired 
mutation at position 459 and 460 (TL>GG) using site directed mutagenesis 
protocol mentioned in section 2.5. The primers used in this reaction are given in 
the list of oligonucleotides. The plasmids from successful colonies were purified 
and were sent for sequencing. 
2.5.2 Construction of pPAL7∆6 PLY 
The pPAL7 containing PLY gene was taken and ∆6 PLY was made by deleting the 
two amino acids using mutagenic primers 23B and 23C using the site directed 
mutagenesis kit following the same protocol described in section 2.5. 
2.5.3 Construction of pET33beGFP∆6 PLY(L363A), pET33beGFP∆6 
PLY(T459G.L460G) and pET33beGFP∆6 PLY(L363A. T459G.L460G) 
The mutation 363 (lysine>alanine) was introduced in pET33beGFP∆6PLY using 
SDM Kit with SDM L363A primers and following the same protocol outlined in 
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section 2.5. The pET33beGFP∆6PLY was also used to make double mutation 
T459G, L460G using the same set of primers as used before for making this 
mutation in pET33bD4PLY. Finally, a triple mutant was made pET33beGFP∆6PLY 
(L363A, T459G, L460G) by using pET33beGFP∆6PLY L363A and introducing the 
double amino acid substitution (TL>GG) using the same set of primers and 
protocol as explained in section 2.5. 
2.6 Mutations made by random mutagenesis (RM) 
A panel of mutants was generated in pPAL7 WTPLY and pPAL7 ∆6PLY by random 
transposon-based insertion of five amino acids using Mutation Generation 
SystemTM Kit (MGSTM Kit) (Taira et al., 1999, Haapa et al., 1999). The system 
involves a bacteriophage Mu that inserts a transposon (Entranceposon) into any 
target plasmid at random sites. This in-vitro transposition reaction is catalysed 
by an enzyme MuA Transposase. 
The insertion clones generated as a result of this transposition reaction are 
digested by restriction enzyme NotI which removes the body of the 
Entranceposon. This results in the in-frame fifteen base pair insertion in the 
target DNA after the closure of NotI digestion clones by self ligation. Figures 2.1 
and 2.2 showing how random 5 amino acid insertions are made using this kit. 
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Figure 2-1 Different stages of in-vitro transposition reaction using mutation generation 
systemTM  
A and B) Target plasmid (Red), Target gene (Blue) and entraceposon (Green) (C and D) 
Entranceposon insertion in target DNA followed by NotI digestion (E and F) to remove the 
body of entranceposon and re-ligation with T4 DNA ligase resulting in 15 basepair insertion 
in target DNA. Figure made using Microsoft word 2007. 
 
 
 
Figure 2-2 Random15 basepair insertions in the target DNA. Figure modified from the online 
MGSTM instruction manual F-701 
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Table 2-5 Reaction protocol for the in-vitro transposition reaction 
Reagent    Volume µl 
Target DNA    size of target Plasmid(kb)x40ng (3µl) 
Reaction Buffer   4µl 
Entranceposon (M1-CamR)  100ng (1µl) 
MuA Transposase   1µl 
Deionized water   11µl 
The reaction outlined in table 2.5 was allowed to proceed for one hour at 30oC 
and then MuA Transposase was deactivated by incubating at 75oC for 10 minutes. 
This plasmid with transposon was then chemically transformed into the XL-1 
blues according to the protocol mentioned in section 2.4.5. The next day all the 
individual colonies were picked and colony PCR was performed with the PLY 
primers. The colonies with transposon were treated with NotI primer to remove 
the body of the transposon and were religated with T4 DNA Ligase (Figure 2.1). 
The plasmid was again chemically transformed again into the XL-1 blues and 
purified with Qiaspin Miniprep kit.  
The purified plasmid was then sent for sequencing and a PCR reaction was also 
set up with NotI miniprimers supplied with the kit to check the site of five amino 
acid addition. The sequencing results were analysed using Vector NTi software 
programme (Invitrogen, UK) and insertion of 5 amino acids were confirmed. The 
translation of 15 base pair insertions were done using figure 2.3. 
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Figure 2-3 Translation of 15 base pair insertions in the three reading frames 
Figure modified from the online MGSTM instruction manual F-701. 
 
2.6.1 Random mutagenesis in WT PLY and ∆6 PLY background  
The transposon based five amino acid random mutagenesis was made in both 
pPAL7 WT PLY and pPAL7 ∆6 PLY vector according to the protocol outlined in 
table 2.5. 
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Table 2-6 List of plasmids generated in the study 
Plasmid Description SDM/RM Origin 
pET33bD4PLY Contains domain4 PLY 
gene attached to N-
terminal His6 tag. 
 Dr Jiang 
Tao Ma 
pET33beGFPD4PLY Contains eGFP- D4PLY 
fusion attached to N-
terminal His6 tag. The 
GFP was amplified from 
plasmid pNF320 and 
mutated to F64L and 
S65T using primers 24W 
and 24X and generating 
enhanced (e)GFP. 
 Dr Graeme 
Cowan and 
Dr Jiang 
Tao Ma 
pET33bD4PLY(T459G.L460G) Contains D4PLY gene with 
mutations at sites 
T459G.L460G attached to 
N-terminal His6 tag. 
SDM This work 
pET33beGFPD4PLY(T459G.L460G) Contains eGFP-D4PLY 
fusion with same 
mutations in D4PLY  
SDM This work 
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pPAL7 PLY Contains the PLY gene 
without any tag 
attached. The gene 
encodes from residue M1 
to D471. 
 Dr Jiang 
Tao Ma 
pPAL7 ∆6 PLY Contains the PLY gene 
with two amino acids 
deletions at 146 and 
147(AR) made by using 
SDM primers 23B and 23C. 
SDM This work 
pPAL7 ∆6 PLY(W433F) Contains the PLY gene 
with two amino acids 
deletions at position 
(146,147) (AR) and one 
amino acid substitution 
at position W433F by 
using primers mentioned 
in the oligonucleotide list 
(Table 2.2). 
SDM This work 
pET33beGFP∆6PLY Contains eGFP-∆6 PLY 
fusion attached to N-
terminal His6 tag. The ∆6 
version is made by 
deleting 2 residues 
SDM Dr Jiang 
Tao Ma 
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(146,147) (AR) by using 
primers 23B and 23C. 
pET33beGFP∆6PLY (L363A) 
 
 
Contains eGFP-∆6 
PLY(L363A) fusion attached 
to N-terminal His6 tag. 
This mutant contains 
additional substitution at 
residue L363A using 
mutagenic primers. 
SDM This work 
pET33beGFP∆6PLY(T459G.L460G) 
 
Contains eGFP-∆6 
PLY(T459G.L460G) fusion 
attached to N-terminal 
His6 tag. This mutant 
contains additional 
substitutions at residues 
T459G.L460G using 
mutagenic primers. 
SDM This work 
pET33beGFP∆6PLY (L363A. 
T459G.L460G) 
Contains eGFP-∆6 
PLY(L363A. T459G.L460G) fusion 
attached to N-terminal 
His6 tag. This mutant 
contains additional 
substitutions at residues 
SDM This work 
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T459G.L460G and L363A 
using mutagenic primers. 
pPAL7 PLY-1 
 
Contains PLY gene with 5 
additional residues after 
residue T410. 
RM This work 
pPAL7 PLY-2 Contains PLY gene with 5 
additional residues after 
residue Q24. 
RM This work 
pPAL7 PLY-6 Contains PLY gene with 5 
additional residues after 
residue K389. 
RM This work 
pPAL7 PLY-9 Contains PLY gene with 5 
additional residues after 
residue D312. 
RM This work 
pPAL7 PLY-12 Contains PLY gene with 5 
additional residues after 
residue F112. 
RM This work 
pPAL7 PLY-13 Contains PLY gene with 5 
additional residues after 
residue G305. 
RM This work 
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pPAL7 PLY-19 Contains PLY gene with 5 
additional residues after 
residue E441. 
RM This work 
pPAL7 PLY-21 Contains PLY gene with 5 
additional residues after 
residue W433. 
RM This work 
pPAL7 ∆6 PLY-1 Contains ∆6 PLY gene 
with 5 additional residues 
after residue Q136. 
RM This work 
pPAL7 ∆6 PLY-5 Contains ∆6 PLY gene 
with 5 additional residues 
after residue G326. 
RM This work 
pPAL7 ∆6 PLY-13 Contains ∆6 PLY gene 
with 5 additional residues 
after residue S318. 
RM This work 
pPAL7 ∆6 PLY-27.10 Contains ∆6 PLY gene 
with 5 additional residues 
after residue R449. 
RM This work 
pPAL7 ∆6 PLY-29.4 Contains ∆6 PLY gene 
with 5 additional residues 
RM This work 
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after residue N7. 
pPAL7 ∆6 PLY-29.5 Contains ∆6 PLY gene 
with 5 additional residues 
after residue Q215. 
RM This work 
pPAL7 ∆6 PLY-35 Contains ∆6 PLY gene 
with 5 additional residues 
after residue L365. 
RM This work 
pPAL7 ∆6 PLY-44.1 Contains ∆6 PLY gene 
with 5 additional residues 
after residue N420. 
RM This work 
pPAL7 ∆6 PLY-44.2 Contains ∆6 PLY gene 
with 5 additional residues 
after residue T410. 
RM This work 
 
2.7 Library of mutants from DNA 2.0 
A library of mutants was designed and purchased commercially from DNA2.0 
(USA). The library was devised in such a way that every single residue in D4PLY 
was replaced by alanines and where alanines were present in the gene, they 
were replaced by glycines. The mutations were made both in WT PLY 
background and ∆6 PLY background. In total 112 mutants were made each in WT 
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PLY and ∆6 PLY background. The mutants were constructed in vector pJexpress 
401 with a six His tag attached on the N-terminal of the gene and an upstream 
T5 promoter which is IPTG inducible. 
The mutants were received from DNA 2.0 (CA, USA) stabbed in 96 well plates in 
L.B agar. Once the mutants were received, they were re grown in 5ml LB 
supplemented with 50µg/ml Kanamycin. All mutants were grown and glycerol 
stocks for all mutants were made in duplicates and were stored at -80o C. 
2.8 Expression and purification of the recombinant 
proteins 
This section elaborates the method deployed for the expression and the 
purification of the different proteins. Specific features of the proteins are 
discussed in the subsequent chapters. 
All proteins used in this project were purified by the author except for the 
purified eGFP only. eGFP was purified by one of the previous members of TJM 
group, Dr Jiang Tao Ma from expression vector pET33beGFP. This protein was 
used as control in fluorescent activated cell sorter experiments (FACS). 
2.8.1 Isopropyl β-D-thiogalactopyranoside (IPTG) 
IPTG used in this study for protein expression was purchased from (Melford, UK). 
1M stock was prepared in dH2O; filter sterilised with a 0.22µm filter syringe and 
stored at -20oC until required. 
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2.8.2 Protein expression 
The BL-21(DE3) cells containing expression vectors were grown in 2 X 1 Luria 
Broth (L.B) with 50µg/ml appropriate antibiotic. The flasks were incubated at 
37oC with shaking at 180rpm. Once the O.D of the culture reached to 0.8-1.0, 
1mM Isopropyl-β-D-thio-galactopyranoside (IPTG) at a final concentration was 
added into the culture to induce expression. After inducing with IPTG, cells were 
further grown for 6 hours in L.B at 30o C with shaking at 180rpm. After that the 
cells were centrifuged at 4000rpm at 4oC for 35 minutes using a Beckman J-6B 
large volume centrifuge. The pellet was saved and the supernatant was 
discarded. 
Each individual mutant of the library was grown in 10ml overnight culture with 
100µg/ml kanamycin. 1ml of this overnight culture was then grown in 250ml 
conical flask having 50ml Luria Broth (L.B) with 50 µg/ml Kanamycin. The 
expression was further carried in the same way as the described in 2.8.2. 
2.8.3 Cell lysis 
Cell pellet was thawed on ice and was re-suspended in pre-chilled 15ml/litre 
with phosphate saline buffer (PBS) (Oxoid,UK).300 units of DNAse I and 10mg of 
proteinase inhibitor benzamidine (Sigma-Aldrich Dorset,UK) was added per litre 
of cell culture. The cell suspension was sonicated 5 times for 30 seconds with a 
minute break between each cycle at 100 % by cell sonicator (Constant 
systems,Ltd, Warwick,UK). The cell lysate was then centrifuged at 14000g for 30 
min at 4oC in a 4K15 centrifuge (Sigma-Aldrich-UK). The supernatant were 
filtered by syringe using 0.22µm filter and the pellet discarded. 
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The cell lysis of the individual mutants of the library was done the same way as 
all other mutants except 1ml of pre-chilled phosphate saline buffer (PBS) was 
added and no proteinase inhibitors or DNAse were added. The individual cell 
suspension was sonicated 5 times for 10 seconds with a 30 seconds break 
between each cycle at 10 Amplitude microns by cell sonicator. (Soniprep 150 
MSE Ltd,UK). The cell lysate was then centrifuged at 13000g for 5 minutes in a 
table top centrifuge. The supernatant was saved and the pellet discarded. 
2.8.4 Protein purification 
The two methods were used for the purification of recombinant proteins during 
the study. The proteins with a His tag attached on the N-terminal were purified 
in a two step purification system. The proteins without a tag were purified in a 
single step purification following Profinity eXactTM protein purification system 
protocol as explained in section 2.8.7. 
2.8.5 Nickel affinity chromatography  
The pET33b vector allows addition of six histidines (His tag) attached to N-
terminal sequence of the required protein so all the recombinant proteins having 
His tag were purified by immobilized metal affinity chromatography first since 
His tag can bound tightly to the metal. The buffers used in the purification steps 
are outlined in the table 2.7. 1ml Histrap FF crude column (GE-Healthcare) was 
equilibrated 5X times with the wash buffer. The bacterial supernatant was 
passed through the column using a bench-top peristaltic pump (Master flex pump 
C/L) at a rate of 2ml/minute. The His tagged proteins bound to the column 
while other proteins and contaminants flowed through. The column was again 
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washed 5X with the wash buffer to remove any unbound proteins and then the 
column was attached to the ӒKTAPrimeTM Plus Purification system (GE Health 
Care) on which the Nickel Affinity Programme was run. The trapped proteins 
were eluted with a continous gradient of 0-500mM of imidazole in PBS. The 
purified protein fractions were run on a sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) gels as described in section 2.9.1. 
Table 2-7 Nickel affinity chromatography (NAC) buffers 
Name  Composition  
Nickel Affinity Wash Buffer 20mM imidazole in 1 X PBS. Filter sterilised 
with 0.22µM filter  
Nickel Affinity Elution Buffer 500mM imidazole in 1 X PBS. Filter sterilised 
with 0.22µM filter 
Phosphate Buffered Saline 
(PBS) 
NaCl 8g/L 
KCL 0.2g/L 
Na2HPO4 1.44g/L 
KH2PO4 0.24g/L 
pH adjusted to 7.4 and filter sterilised with 
0.22µM filter. 
 
2.8.6 Anion exchange chromatography 
The selected fractions from Nickel Affinity Chromatography were buffer 
exchanged into Anion Exchange Wash buffer to remove contaminating proteins, 
lipopolysaccharides (LPS) and DNA. 1ml Hi Trap Capto Q column (GE Health Care) 
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was washed 5X with anion exchange wash buffer at a rate of 2ml/minute. After 
washing the proteins were then loaded on the column at a rate of 1ml/minute to 
allow for maximum binding, washed again 5X times with the Anion exchange 
wash buffer before attaching to the AKTAPrimeTM Plus Purification system (GE 
Health Care) on which the anion exchange programme was run. The proteins 
were eluted using a linear continous gradient of anion exchange elution buffer. 
The collected fractions were run on SDS-PAGE gels. 
Table 2-8 Anion exchange buffers (AEC) 
Anion Exchange Wash Buffer 20mM tris-HCL pH 8.0. Filter sterilised with 
0.2µM filter 
Anion Exchange Elution Buffer 20mM tris-HCL and 500mM NaCl at pH 8.0. 
Filter sterilised with 0.2µM filter 
 
2.8.7 Profinity eXactTM protein purification system 
The pPAL7 uses the exact affinity cleavage technology by utilising an 
immobilized, extensively engineered protease, subtilisin S189 which binds to a 
small N-terminal co-expressed affinity tag in the protein fusion. The protease 
performs a specific, controlled cleavage after the addition of elution buffer; 
resulting in the removal of tag from the fusion protein directly on the column. 
During the elution step, the cleaved tag remain tightly bound to the column’s 
resin resulting in the release of highly purified recombinant protein without any 
tag attached to the N-terminus. 
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The buffers used in the tagfree purification are listed in the table 2.9. 1ml of 
Bio-Scale Mini Cartridge was washed with 10ml of wash buffer at a rate of 
3ml/minute using a using a bench-top peristaltic pump (Master flex pump C/L). 
The cell lysate was loaded on the column at a rate of 1ml/minute to allow 
maximum binding of the tag to the column resin. The elution buffer was then 
run through the cartridge at rate of 2ml/minute so as to saturate the cartridge 
with the elution buffer. The peristaltic pump was then stopped and the cartridge 
was incubated with elution buffer for 30 minutes at room temperature. The 
elution buffer was again run at a rate of 3ml/minute and the purified tagfree 
protein was eluted from the column leaving the tag attached to the resin. The 
protein was run on SDS-PAGE gel to confirm the presence of proteins. 
Table 2-9 Profinity exact buffers 
Name Composition 
Wash Buffer 100mM sodium phosphate in dH2O.pH 7.2 adjusted with acetic 
acid. Filter sterilised with 0.22µM filter. 
Elution Buffer 100mM sodium phosphate and 100mM sodium fluoride in 
dH2O.pH 7.2 adjusted with acetic acid. Filter sterilised. 
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Figure 2-4 Profinity eXact purification system 
The figure showing stages of Tagfree purification system. On column binding of protein 
followed by washing with wash buffer to remove contaminants and then cleavage of tagfree 
protein using elution buffer shown in A, B and C respectively. Figure drawn using Microsoft 
word 2007. 
 
2.8.8  Buffer exchange of protein samples 
The protein samples of 15ml or above were buffer exchanged in a dialysis tubing 
of 8kDa molecular weight cut off (Medicell international Ltd, London, UK). The 
proteins were dialysed against a greater than 50 fold volume of the buffer to be 
exchanged at 4o C for 30 hours. The proteins samples of less than 15ml were 
dialysed using PD-10 desalting columns (GE Healthcare) according to the 
manufacturer’s protocol. 
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2.8.9 Storage of protein samples 
All recombinant proteins were buffer exchanged to PBS using the protocol 
mentioned in 2.8.8. Before storage, purified proteins were concentrated by 
using Amicon Ultra Centrifugal Concentrators 50, 30 or 10kDa (Millipore, Watford 
UK) cut off depending on the size of the protein sample. The sample was 
centrifuged at 4000g, 4oC for 2 minutes in a 4K15 centrifuge (Sigma Aldrich). 
This step is repeated until desired concentration of protein is reached. This 
additional step further removes any contaminants from the purified protein. The 
proteins were aliquoted into 0.25ml volumes at -80oCfor long time storage and at 
-20oC and for short term storage. 
2.8.10 Concentration of the purified protein 
The concentration of the purified proteins was measured by using a derivation of 
Beer-Lambert law. 
Aλ =  ϵ c L 
Where A = Absorbance at 280nM (A280) 
ϵ = extinction co efficient of the protein sample 
L = Light path length in centimetres  
ϵ = Aλ / c L (Since L = 1cm) 
ϵ = Aλ / c 
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The absorbance reading at 280nm (A280) was measured using a NanoDrop ND-
1000 (Fisher Scientific, Loughborough UK). The Vector NTi software programme 
(Invitrogen,UK) was used to calculate extinction co efficient of the sample from  
amino acid sequence of the protein. 
2.9 Characteristics of the purified proteins 
2.9.1 SDS-PAGE 
The SDS-PAGE gels used in this study were pre-made NuPage 4-12% bistris gels 15 
wells from (Invitrogen UK). Additionally some gels were made following the TJM 
lab manual. The self-made gels (SDS 10% W/V) were poured using 10% resolving 
gel and 4% stacking gel and were run on Bio-Rad mini-protein apparatus. The 
protein marker SeeBlue® Plus 2 Pre-stained (Invitrogen UK) was used for 
indicating the size of the protein. 2-12µl of the protein was loaded with NuPage 
4X loading buffer supplemented with 10mM dithiothreitol (DTT) and denatured 
for 10 minutes at 70oC in a heat block. The proteins along with the 5µl protein 
marker were loaded on the gel and the gel was run at 180 volts for 40 minutes. 
The SDS-PAGE was then stained with Coomassie® R250 stain for several hours 
and then destained with several changes of destain and dH2O. 
2.9.2 Western blotting 
The proteins were further analysed by Western blotting. For Western blotting 
proteins were first run on the SDS-PAGE following the same protocol described in 
section 2.9.1. The proteins were then transferred to a HybondTM –P 
PolyVinylidene Fluoride (PVDF) membrane (Amersham Biosciences GE Health 
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Care) using a Xcell II blotting module (Invitrogen) for 90 minutes at 30 volts. The 
membrane was blocked overnight in 3% skimmed milk in tris NaCl (pH 7.4) at 
4oC. The membrane was blotted next day with anti-PLY primary antibody (1:1000 
dilutions in 3% skimmed milk) for 2 hours at 37oC in the shaking incubator. The 
membrane was then washed five times with tris-NaCl (pH 7.4) and then blotted 
with horseradish hydrogen peroxide-linked secondary antibody (1:2000 dilution 
in 3% skimmed milk) at 37oC for 1 hour in the shaking incubator. The membrane 
was again washed five times with tris-NaCl (pH 7.4) before developing in the 
dark using 4-Chloro-1- naphthol (Sigma Aldrich UK) as developer. The reaction 
was stopped by addition of dH2O. 
Table 2-10 SDS-PAGE and western blotting reagents 
1X Nu Page MES Running Proprietary formulation Diluted from 25X stock 
concentration with dH20 
10x tricine running 
Buffer 
30g tris, 144g glycine, 
10g SDS 
Diluted from 10x 
concentrated stock with 
dH2O 
Destain 50% dH2O, 40% methanol 
and 10% glacial acetic 
acid 
 
Stain  0.5g Coomassie R250 
stain in 0.5L Destain 
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Tris NaCl (pH 7.4) tris base 1.2g, NaCl 8.7g 
make up to 1L with dH2O. 
pH with HCL 
 
Developer 30mg 4chloro-1-naphthol, 
10ml methanol added to 
40ml tris NaCl(pH 7.4). 
30µl H2O2 added in the 
end. 
Make just before use 
 
2.9.3 Red blood cells assays 
The haemolytic assays were run to measure the haemolytic activity in WT PLY 
mutants and hemagglutination assays were run to observe the aggregation 
phenotype of ∆6 PLY mutants and D4 PLY mutants. 
2.9.3.1 Haemolytic assay 
The haemolytic assay was analysed by using 96 well round and flat bottomed 
wells (Costar, UK) by using a haemolytic assay described previously (Walker et 
al., 1987),with slight modifications. 1ml horse blood (E&O Laboratories, 
Scotland) was taken and washed 5 times with PBS to remove the lysed cells and 
antibodies. 2% horse blood was prepared by adding 200µl of washed horse blood 
in 10ml of PBS. 50µl of PBS was added in all wells of R-plate using multi-channel 
pipette. Purified WT PLY of known concentration was diluted (1:1000) and added 
in the first well of row 1 as positive control and 50µl of PBS only was added in 
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the first well of second row as negative control. The 50µl of purified protein of 
known concentration or 10µl cell lysate and 40µl of PBS (lysate in case of DNA 
2.0 library) were placed in duplicates in first wells of subsequent rows 3 to 8. 
Serial dilutions were made from of each row of by removing 50µl from previous 
well into the next well and repeating until 50µl is discarded from last well of all 
the row. 50µl of 10µM dithiothreitol (DTT) was placed in all the wells as reducing 
agent to oxidize any reduced CDC protein. 50µl of 2% of washed horse blood was 
added in all the wells and incubated for 15 minutes at 37oC. 50µl of PBS was 
added again in all wells and R-plate was centrifuged at 1000g for 1 minute in a 
4K15 centrifuge (Sigma Aldrich, UK) to pellet the intact cells. 100µl supernatant 
was transferred from each well into the flat bottomed plate and absorbance was 
measured at 540nM by FLUOstar Optima plate-reader (BMG Labtech, UK) to 
measure the levels of haemoglobin released in each well. 
From these results, the percentage (%) lysis in each well was calculated by using 
mean negative controls from PBS wells where 0% lysis has occurred, as 0% lysis 
value and the mean value from positive wells (Purified PLY) where 100% lysis has 
occurred, as 100% value. A curve of % lysis was generated against each well for 
each purified toxin. A typical sigmoid curve was then made by using GraphPad 
prism 5 software (GraphPad software, USA). 
For cell lysates from DNA 2.0 library in WT PLY background haemolytic activity 
was measured by measuring the endpoint. The reciprocal of the dilution at 
which the endpoint is reached gives the Haemolytic Units (HU) per ml of sample. 
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2.9.3.2 Hemagglutination assay 
The hemagglutination assay was carried out in the same way as the haemolytic 
assay described in section 2.9.3 with some modifications. The positive control in 
hemagglutination assays was ∆6PLY and ∆6PLY lysate as compared to WT PLY 
which was used in haemolytic assays. ∆6PLY form red blood cells aggregates 
which can easily be appreciated in R-Plate after centrifugation. The 
hemagglutination assay was therefore used to screen the ∆6 PLY mutants which 
were not forming the typical red cell aggregates as formed by ∆6PLY. 
The different phenotypes observed during the hemagglutination experiments are 
shown in figure 2.5.  
     
Figure 2-5 Phenotypes observed on a red cell assay 
Figure 2.5 showing different phenotypes on a 96 well plate. A) WTPLY used as positive 
control causes complete lysis of sheep red blood cells and a pinkish tinge in wells is 
observed due to the released haemoglobin. B) PBS used a negative control shows no lysis 
and red blood cells as pellets are seen after the final centrifugation step. C&D) Purified D4, 
∆6 PLY and their variants causing red blood cell aggregation and red cells appear to form 
clumps around the edges of the wells. This phenotype is marked in the first few wells and 
decreases as the concentration of protein drops in subsequent wells. E&F) ∆6 PLY mutant 
lysates of DNA 2.0 library also showing aggregation phenotype slightly different from 
purified proteins and G& H) aggregation negative mutants were not causing red blood cell 
aggregation and a red cell pellet was observed after the final step. The aggregation negative 
mutants showed a clearing effect (white background instead of pink as seen in PBS wells) 
in the first few wells, the cause of which is unknown. 
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Figure 2.5 showing different phenotypes on a 96 well plate. The WT and the 
mutant proteins displayed these phenotypes during the red cell assay 
experiments. The different phenotypes include complete lysis in the wells shown 
by WT PLY, no lysis by PBS, red cell aggregation phenotypes by D4, ∆6PLY and 
∆6PLY lysates of the DNA 2.0 mutant library and clearing well effect. The 
clearing effect means that the usual pinkish tinge in wells after the last 
centrifugation step is not observed as seen in PBS treated wells, rather a white 
background seen is in aggregation negative mutants. The reason for this clearing 
of wells is unknown and probable reasons are discussed in section 3.8. 
2.9.4 Fluorescence microscopy  
The fluorescent microscopy images were taken to show the mutant protein 
binding to horse erythrocytes. The horse red blood cells were prepared in water 
and PBS. 1ml of horse blood was taken in 2 eppendorfs and centrifuged at 13k 
rpm for 1 minute. The supernatant was removed and each pellet was 
resuspended in PBS and water. The cell suspension was centrifuged again and 
supernatant removed. The above procedure was repeated three times. 100µl of 
2% horse blood and 140nM of the purified proteins were added to eppendorfs. 
For controls 100µl of horse blood only and 100µl of 2% horse blood with 140nM of 
eGFP only was taken. The eppendorfs were incubated for 15 minutes at 37oC and 
then centrifuged at 1500g for 5 minutes. The supernatant was discarded and the 
pellet was again resuspended in PBS. 200µl of the sample with 200 µl of 4% 
paraformaldehyde (w/v) and incubated at room temperature for 20 minutes to 
fix cells. After incubation, the cells were again washed with PBS to remove any 
unbound proteins. 20µl of sample was put on glass slide and was air dried. A 
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drop of fluorescence mounting media (Dako UL Ltd, UK) was put directly on the 
spot and the cover slip placed directly over it. The slides were either kept on 
dark or observed under the microscope with ultraviolet (UV) light. The images 
were generated using the software velocity Image analysis software 
(PerkinElmer, USA). 
2.9.5 Cell binding assay by fluorescent activated cell sorter 
(FACS) 
The protein binding was assessed using fluorescent activated cell sorter (FACS). 
4% of horse blood was made after washing the horse blood with PBS as 
mentioned in 2.9.5. The proteins were diluted to 14nM/L, 140nM/L and 1400 
nM/L. Proteins samples were added to the washed horse blood in FACS tubes and 
incubated at 37o C for 15 minutes. For controls eGFP only at three 
concentrations (14, 140 and 1400nM) and RBCs only were taken. The numbers of 
events noted for each reading was 50,000 and each sample was run in 
quadruplet. The proteins were transferred to the FACS tubes and readings were 
noted using the Cell Sorter.  
The results were analysed using the Flowjo Software. Red blood cells suspended 
in PBS have a known amount of cell auto-fluorescence. To minimise the back 
ground cell auto-fluorescence gates FL1+ and FL1-ve gates were drawn based on 
the controls. 
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2.10 Statistical analysis 
The GraphPad® Instat (GraphPad® Instat Software Inc., San Diego, CA) was used 
for FACS data analysis. In the study unpaired t-test was used to compare the 
mean and the standard error mean (SEM) between two groups. For comparison 
between the three groups, one way analysis of variance (ANOVA) was conducted 
using Dunnet’s method to adjust the p-value for multiple comparisons. In all 
experiments, p<0.05 was considered significant.
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3 Construction, purification and characterisation 
of cholesterol binding PLY mutants 
3.1 Summary 
As described in section 1.8.1.1, the mutant version of PLY (T459G.L460G), 
mentioned by (Farrand et al., 2009), shows that residues threonine and leucine 
(TL) in D4 are responsible for initial binding of the toxin to the cholesterol 
containing membranes. D4 of the toxin is responsible for initial binding with the 
cholesterol containing membrane followed by the cell lysis (Baba et al., 2001). A 
study conducted recently has shown that D4PLY binds to human erythrocytes 
whereas D123 exhibited no binding and was required for the subsequent lytic 
process (Lim et al., 2013). Similar results were found in this study when purified 
D4 and purified D123 were compared in a haemolytic assay. Domains 123 was not  
binding to red blood cells (showing a similar phenotype as PBS treated wells) 
where as purified D4 was not causing lysis of the red cells, but rather binding 
and causing red cells to aggregate (Figure 2.5) ((This work and (Ma, 2011)). 
However, Listeriolysin (LLO) secreted by Listeria monocytogenes , both domain 
123 and domain 4 bind to the cell membranes and can reassemble into a 
haemolytically active form when secreted simultaneously, by the bacterium 
(Dubail et al., 2001). Recently binding of PLY (domains 1-3) with the bone 
marrow derived macrophages has also been reported by one of the members in 
the laboratory (Dr Catherine Dalziel, unpublished data).This binding may be due 
to different receptors on the surface of bone marrow derived macrophages not 
found on the surface of red blood cells. 
The phenomenon of red blood cell aggregation was also observed using ∆6 PLY 
and similar sort of aggregation was observed with purified D4PLY ((This study 
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and(Ma, 2011)). This suggests that residues responsible for this phenotype reside 
in the D4 of the toxin. 
The project was started by making the same mutations at residues 
(T459G.L460G) in the domain 4 of the toxin. For the ease of understanding and 
writing D4PLY(T459G.L460G) is referred at some places in this chapter and or figures 
in the thesis as TL mutant, since these two residues threonine and leucine were 
replaced by glycines. 
The eGFP version of the mutant toxin was also made so that the binding with red 
blood cells could be analysed on the fluorescent activated cell sorter and by 
fluorescence microscopy. The eGFP was fused to the D4PLY by ligation 
dependent cloning and the same construct was used as a template for mutation 
of residues (T459G.L460G) using SDM kit. 
Wild type D4, eGFP tagged WT domain 4 of the toxin and eGFP only proteins 
were purified for experimental controls. 
3.2 Construction of D4PLY and eGFPD4PLY (459,460 
TL>GG) by site directed mutagenesis 
The double amino acid substitutions were successfully made in the D4 and 
eGFPD4 of PLY using Quick Change ® II XL Site Directed-Mutagenesis kit following 
the protocol described in section 2.5. 
To analyse protein binding to the cholesterol containing membranes constructs 
encoding WT and the mutant versions; (pET33bD4PLY, pET33beGFPD4PLY, 
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pET33bD4PLY (T459G.L460G) and pET33b eGFPD4PLY(T459G.L460G)) were transformed in 
the BL21 (DE3) cells for protein expression. 
All four proteins were subjected to a two step purification process, first by 
immobilized metal affinity chromatography and then further purified by anion 
exchange chromatography (AEC). 
3.2.1 Purification of D4PLY(T459G.L460G) 
D4PLY(T459G.L460G) was purified first by loading the cell lysate onto a His Trap® 
column using a peristaltic pump. The column was then attached to the 
ӒKTAprime™ Plus (GE Healthcare) purification system on which the Nickel 
Affinity Chromatography programme was run. (Figure 3.1) 
 
Figure 3-1 His tag column output of D4PLY(T459G.L460G) AKTAprime™ 
Nickel Affinity Column (NAC) output of D4PLY(T459G.L460G) from AKTA showing protein elution 
and fractions numbers. Fractions 7-20 were run on an SDS-PAGE figure 3.2 below. The blue 
line (UV) is A280nm protein reading, which measures protein content. The green line 
represents imidazole concentration (0-0.5M). 
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The purified protein D4PLY (T459G.L460G) Histag6 has a predicted molecular 
weight of 18kDa.This was confirmed by running the eluted fractions on an SDS-
PAGE with a known molecular weight protein marker. 
 
Figure 3-2 SDS-PAGE of D4PLY(T459G.L460G) after NAC Purification 
Mol.wt of D4PLY(T459G.L460G) is 18kDa. 10µl of the recombinant protein was loaded on the gel. 
Lane M contains 5µl of the mol. wt.marker SeeBlue®Plus2, followed by Histag column 
purification fractions 7 to 20 from AKTA. The arrow showing the recombinant protein 
D4PLY(T459G.L460G)  corresponding to the right molecular weight compared with known 
molecular weight markers. There were other bands seen on the gel (contaminants) which 
were removed subsequently after the second AEC purification. 
The D4PLY(T459G.L460G) after NAC chromatography had some contaminants 
including LPS so it was further purified by using a 1ml CaptoQ Anion Exchange 
columns. The protein binds to the negatively charged column while the 
contaminating Lipopolysaccharides (LPS) being negatively charged will not bind 
to the column, this will be collected in the flow through. The protein was eluted 
from the column using a linear gradient of 0- 0.5M NaCl. The eluted fractions 
were then analysed by SDS-PAGE (Figure 3.3B). The selected AEC fractions were 
dialysed at 4oC with 2 litres pre-chilled PBS buffer. 
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Figure 3-3 Anion exchange chromatography output and SDS-PAGE of D4PLY(T459G.L460G) 
AKTA after AEC Purification 
A) AEC output of D4PLY(T459G.L460G) from AKTA showing protein elution and fraction 
numbers. B) SDS-PAGE of D4PLY(T459G.L460G) on which 10µl of the recombinant protein from 
fractions 8-21 were loaded. Lane M showing 5µl of the mol. wt. marker (SeeBlue®Plus2). 
Figure 3.3 shows that the second purification step yield a high quality protein 
which corresponds to the right size with the protein marker run on the gel. The 
fractions were pooled together and buffer exchanged into PBS before storing 
them at -80oC. 
3.2.2 Purification of eGFPD4PLY(T459G.L460G) 
The recombinant protein eGFPD4PLY(T459G.L460G) was purified in a similar manner 
to the D4PLY(T459G.L460G). 
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Figure 3-4 SDS-PAGE of eGFPD4PLY(T459G.L460G) after NAC Purification 
10µl of the recombinant protein was loaded. Mol.wt of eGFPD4PLY(T459G.L60G) is 44kDa. Lane 
M contains 5µl of the mol. wt. marker SeeBlue®Plus2 followed by His tag column 
purification fractions from 11-21. The fractions 12-21 show degradation, the reason for 
which is unknown. These fractions also showing many contaminants and therefore were 
discarded. Fractions 11 and 22-24 were saved as there was no degradation and have few 
contaminants as compared to other fractions. These fractions were saved for subsequent 
purification. 
The recombinant eGFPD4PLY(T459G.L460G) has a molecular weight of 44kDa. After 
the nickel purification a single peak was produced but some of the purified 
fractions (14 to 21) were degraded/cleaved when the fractions were analysed by 
SDS-PAGE. The two fragments appeared to be of 44kDa and 34kDa. This suggests 
that protein is not cleaved from the linker linking eGFP to the D4PLY as D4 is 
18kDa and eGFP is 26kDa. A similar sort of degradation was observed by previous 
laboratory member while purifying one of the protein (eGFP SLY) of cholesterol 
dependent cytolysin family (McInally, 2012). The reason of this degradation is 
unknown and could be due to errors in protein folding. There were some 
fractions (22-24) at the end of the gel without any degradation which 
corresponds to the right protein size to the molecular weight markers on the 
SDS-PAGE. These fractions were pooled together and run through the anion 
exchange purification step (Figure 3.5). 
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The rest of the fractions were collected and they were separately analysed 
through the anion exchange purification step. The purified protein fractions 
again were degraded/cleaved so were not saved and discarded (Lane 1 of Figure 
3.5 (A) SDS-PAGE gel). 
A) B)  
Figure 3-5 SDS-PAGE of eGFPD4PLY(T459G.L460G) and D4PLY(T459G.L460G) after AEC Purification 
A) 10µl of the recombinant protein was loaded. Lane M contains 5µl of the mol.wt. marker 
SeeBlue®Plus2. Fraction 1 is the pooled degraded fractions from NAC run separately on 
AEC and one of fraction was loaded on the gel. Fractions 11-21 are fractions eluted from 
AEC from previously saved non degraded NAC fractions. A few bands (contaminants) were 
also seen and were removed by the using Amicon Ultra Centrifugal concentrators as 
mentioned under heading 2.8.9. B) Lane M contains 5µl of the mol. wt. Marker, Lane 1 Blank, 
Lane 2 Pooled D4PLY(T459G.L460G) fractions in PBS after AEC and Lane 3&4 Pooled 
eGFPD4PLY(T459G.L460G) fractions in PBS after AEC. Two small bands were also seen around 
88kDa which might suggest dimer formation. 
 
The fractions obtained after AEC were analysed on an SDS-PAGE with a known 
molecular weight marker and the fractions corresponding to the right molecular 
weight were pooled together and buffer exchanged into PBS. The degraded 
fractions were also run separately on AEC and the one of the eluted fractions 
was run on the SDS-PAGE but that fraction was degraded as shown in lane 1 of 
figure 3.5A. The proteins with one single band, corresponding to the right 
molecular weight was further concentrated using Amicon Ultra-15 30kDa cut off 
centrifugal filters which further removed any contaminants less than 30kDa. The 
purified proteins D4PLY(T459G.L460G) and eGFPD4PLY(T459G.L460G) after AEC were 
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pooled together and were buffer exchanged to PBS and was again analysed on 
the SDS-PAGE (Figure 3.5 B) 
3.2.3 Purification of eGFPD4PLY and D4PLY. 
The two proteins (D4PLY eGFPD4PLY) were used as controls in the experiments 
including red cell assays, fluorescence microscopy and fluorescence activated 
cell sorter (FACS) along with the eGFP. The two proteins were purified in a 
similar manner to the TL mutants. 
A) B)  
Figure 3-6 SDS-PAGE of eGFPD4PLY and D4PLY 
10µl of the recombinant protein eGFPD4PLY was loaded. A) Lane M contains 5µl of the mol. 
wt. marker SeeBlue®Plus2. Fractions 11-24 are eGFPD4PLY fractions after AEC. There are 
some bands around 88kDa which might suggest dimer formation as seen in figure 3.5B B) 
Lane M is 5µl of the mol. wt. Marker, Lane 1 is 10µl of recombinant D4PLY after NAC and 
AEC and Lane 2 is pooled eGFPD4PLY fractions in PBS after the two step purification. 
There is one additional band (apart from D4PLY band) seen in lane 1 which might suggest 
overflow from lane 2 and the small band around 88kDa in lane 2 suggesting dimer 
formation. 
D4PLY and eGFPD4PLY have a predicted molecular weight of 18 and 44kDa 
respectively and SDS-PAGE confirmed its size compared to the protein marker. 
The dimer formation could be checked by running protein on size exclusion 
chromatography (gel filtration) and comparing the height of the eluted fraction 
with the controls. 
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3.3 Concentration, yield and LPS levels in the purified 
proteins 
The concentration of the purified proteins was measured as described in 
Materials and Methods section 2.8.10. The LPS Levels were measured to ensure 
that LPS are low (less than 5 International Unit (IU)/dose) and will not stimulate 
the immune system non-specifically if they were to be used in in-vivo 
experiments (Douce et al., 2010). The LPS levels was measured using Endosafe.-
PTS™ hand held spectrophotometer using the FDA-licensed disposable cartridges 
from Charles River following manufacturer’s instructions. 
Table 3-1 Concentration, yield and LPS levels in the purified proteins 
Name of the Protein Molecular weight     mg LPS Levels
      IU
WT D4PLY 18 2.74 0.266
WT eGFPD4 PLY 44 2.07 0.0402
D4 PLY (TL>GG) (459,460) 18 2.128 0.198
eGFPD4 PLY 
(TL>GG)(459,460)
44 1.182 0.102
 
3.4 Western blot of the purified proteins 
The purified recombinant proteins were further analysed by Western Blotting as 
outlined in section 2.9.2. Briefly, 1µg of the purified protein was loaded on the 
gel along with molecular weight protein marker SeeBlue®Plus2. The primary 
antibody used was rabbit anti PLY and the secondary antibody used in all of the 
samples was horseradish hydrogen peroxide-linked secondary antibody. The 
membrane was washed five times after adding both the antibodies and 
developed in the developer. 
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 B)  
Figure 3-7 Western blotting results of the purified proteins 
A) Lane M is the protein molecular weight marker followed by 1µg of the purified proteins. 
Lane 1 is WT D4PLY and Lane 2 is WT eGFPD4PLY. (B) Lane M is the protein molecular 
weight marker. Lane 1 is D4PLY(T459G.L460G) and Lane 2 is eGFPD4PLY(T459G.L460G).There was a 
band seen in figure 3.7 A&B around 88kDa in lane 2 of both gels possibly showing dimer 
formation. 
The western blot results (Figure 3.7A and B) further confirmed the size and 
identity of all the four purified proteins. 
3.5 Red cell assay of the purified proteins 
CDCs cause the lysis of red blood cells so to ensure that the purified 
recombinant proteins were still functionally active, red cell assay using sheep 
red blood cells were run for all of the purified proteins. The cell lysis was 
measured indirectly by the amount of haemoglobin released. As expected none 
of the purified D4 recombinant proteins were lytic. The full length toxin was 
lytic even at amounts as low as 1ng of the purified protein. The WT PLY used as 
positive control was diluted in (1:1000) in PBS and then 50 µl was added into the 
first well of 96 well round bottom plate and serial dilutions were made as 
explained in the section 2.9.3. In negative controls wells PBS was added. For all 
D4 and eGFP versions 1µg of the neat protein was added in the first well and 
serial dilutions were made thereafter. 
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 Figure 3-8 Red cell assay of the purified proteins 
1µg of D4PLY, eGFPD4PLY and D4PLY(T459G.L460G) was added in the first well of a 96 well plate 
and serial dilutions (1:2) were made thereafter. WT PLY (1:1000 dilution) and 50µl PBS was 
used as positive and negative controls. WTPLY causing red blood cell lysis and a pinkish 
tinge observed in WTPLY treated wells due to released haemoglobin. PBS only wells, 
causing no lysis and a red cell pellet is seen in centre after the last centrifugation step. 1µg 
of D4PLY, eGFPD4PLY cause no lysis but aggregation of red blood cells are seen in first 
few wells. D4PLY(T459G.L460G)  treated wells showing no visible aggregation and lysis but a 
clearing effect (white background as compared to pink in PBS wells) is seen in first 3 wells. 
These phenotypes are explained in figure 2.5.  
WTPLY in figure 3.8 used as positive control cause lysis of red blood cells (no 
intact pellet seen in first two wells) where as PBS used as negative control 
showing no lysis (all red cells pellet are intact). 1µg of WTD4PLY and WT 
eGFPD4PLY cause no lysis but rather aggregates red blood cells and this is 
consistent with finding of previous studies showing the same phenotype of these 
proteins on a 96 well plate (Ma, 2011). 
∆6PLY also form the same aggregation phenotype as D4PLY on a 96 well plate 
suggesting the site/s responsible for this behaviour resides in the D4 region of 
the toxin. Interestingly, this aggregation phenotype was not observed with TL 
mutants. There is a clearing effect in the wells treated with D4PLY mutant and a 
pinkish tinge in the wells (first three wells in both lanes of mutant protein) as 
seen with negative control (PBS) is not found. A similar effect was seen when 
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red blood cells were treated with purified D123 and eGFPD4PLY(T459G.L460G) 
(Figure 3.9). To further confirm this clearing effect other non-lytic streptococcal 
proteins PspC and PspA and non- pneumococcal protein e.g. BSA (Bovine Serum 
Albumin), were tested and the same clearing effect was seen suggesting non 
specific binding of the proteins. 
       
Figure 3-9 Red cell assay showing non-agglutinating and clearing well effect phenotypes. 
10 µl of the above proteins were added in the first well of the 96 well plate and serial 
dilutions were made. The non-lytic pneumococcal proteins (PspA and PspC) and non-
pneumococcal protein (BSA) are also showing the same clearing well effect phenotype as 
eGFPD4PLY(T459G.L460G) . D123 also showing the same background white colour in the first 4 
wells as the other proteins. All the above proteins are non-lytic as there is no lysis and the 
red cell pellet is intact after the last step. 
 
The specific haemolytic activity of the proteins (D4PLY, eGFPD4PLY, 
D4PLY(T459G.L460G) and eGFPD4PLY(T459G.L460G) ) were measured by calculating the 
percent lysis of the red blood cells at a known protein concentration. As 
expected D4PLY, eGFPD4PLY and the mutant versions were found to be non-
lytic. 
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Figure 3-10 Haemolytic activity of the recombinant proteins 
A sigmoid dose response curve of 50 % lysis was generated against each well for each 
purified toxin by using mean negative controls from PBS wells where 0% lysis has occurred 
and the mean value from positive wells (Purified PLY of known concentration) where 100% 
lysis has occurred. X-axis is log toxin concentration in mg/ml and Y-axis denotes % 
haemolysis. WT PLY (purple), D4PLY (red), D4PLY (T459G.L460G) (pink), eGFPD4PLY (dark 
green), eGFPD4PLY (T459G.L460G) (light green) were all tested under the same conditions in 
duplicates. 
The specific activity of the toxin was then calculated as Haemolytic units (HU). 1 
haemolytic unit is defined as the amount of toxin that causes 50% lysis of red 
blood cells. Thus the specific activity in HU/mg was then calculated and stated 
in the table 3.2. 
Table 3-2 Specific haemolytic activity of the purified proteins 
 
Figure 3.8 shows that D4PLY(T459G.L460G) was not giving the same appreciable 
aggregation phenotype on the 96 well plate as seen with WTD4 and eGFPD4PLY. 
To further evaluate the binding of these mutant versions of the toxin with the 
red blood cells fluorescence microscopy and flow cytometry experiments were 
done. 
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3.6 Fluorescence microscopy 
The fluorescence microscopy was done with eGFP tagged versions of the proteins 
to assess the protein binding with the red blood cells. The binding was seen both 
with intact cells and red cell membranes. 
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Figure 3-11 Fluorescence microscopy images showing eGFP tagged recombinant proteins 
binding 
The protein binding was observed using horse red blood cells. 140nM of the purified 
proteins were incubated with horse red blood cells at 37oC for 15minutes. (A, B &C) 
eGFPD4PLY showing binding and causing aggregation of horse red blood cells in DIC, GFP 
and overlay. (D, E & F) eGFPD4PLY showing binding and causing aggregation of horse red 
blood cells membranes in DIC, GFP and overlay. G&H) eGFPD4PLY(T459G.L460G) in DIC and 
GFP bound to the red blood cells and causing aggregation (small group of red cells shown 
in Figure 10G) which is comparatively less as compared to WTeGFPD4PLY (A,B and C). I) 
Red cells controls only in PBS showing single cells in DIC. Red blood cells binding with 
GFP (140nM) only used as one of the controls are shown in figure 5.13. 
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In Figure 3.11, the results of eGFPD4PLY binding with red cells are similar to 
ones observed in previous studies (Ma, 2011). D4PLY forms large clumps of red 
blood cells which are visible in the 96 well plate as well (3.11 A, B & C). To 
further confirm the binding, red cell membranes were made by lysing the cells 
with dH2O and washing the membranes thrice with PBS. The membranes were 
incubated with 140nM of eGFPD4PLY at 37oC and binding was observed under the 
microscope (Figure3.11 D, E & F). 
As expected at 140nM concentration of eGFPD4PLY(T459G.L460G), the binding of 
toxin was greatly reduced as compared to the eGFPD4PLY. Since threonine and 
leucine residues at position 459 and 460 of the PLY are the responsible for initial 
binding with the cholesterol containing membranes, it was expected that the 
toxin will not bind to the red blood cells at all. However, some binding of the 
toxin to the red cells was visible as judged by clumping of red blood cells in 
figure 3.11 G&H. This binding was also picked up by the GFP mode (black arrows 
in Figure 3.11 H). However, the signals were low and were not picked on the 
overlay. The red blood cells were also forming small aggregates of red blood 
cells with eGFPD4PLY(T459G.L460G) (Figure 3.11G).These small aggregates were not 
as profound as with the WT eGFPD4PLY. Red blood cells only in PBS observed 
under the microscope show no aggregation of the red blood cells (Figure 3.11I). 
The eGFP only protein used as one of the controls was neither binding nor 
causing the aggregation of the red blood cells and results were similar to red 
blood cells (Figure 5.13 A & B).  
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3.7 Cell binding by fluorescence activated cell sorting 
(FACS) 
The cell binding was further confirmed and quantitatively measured by FACS. 
The proteins were tagged with eGFP in order to assess the protein binding with 
red blood cell by the fluorescence channel (FL1) of the cytometer. The forward 
scatter channel (FSC) was also used to distinguish if there are single cells or 
more than single cells. The experiment was set up as explained in the section 
2.9.5. The FACS experiments were done on three different occasions to ensure 
consistency. 
In order to measure the intensity of protein binding with the red blood cells 
arbitrary units such as fluorescence Index (FI) was used. FI was calculated by 
multiplying the percentage of fluorescent cells with the mean geometrical 
fluorescence (GEM). This method has been used before to assess the bacterial 
binding with the complement (Hyams et al., 2010). 
 
Red blood cells only in PBS have a minimum amount of background 
auto-fluorescence. This back-ground cell auto-fluorescence was minimised by 
drawing gates FL1+ and FL1-ve based on the controls (Figure 3.12). 
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Figure 3-12 FL1-ve and FL1+ve gates drawn on negative control (Red cells with PBS) 
X-axis showing FL1+ve gate to measure background auto-fluorescence and Y axis showing 
number of events which in this case is 50,000. 
 
Figure 3.12 shows that the red blood cells with PBS only have negligible 
percentage of fluorescent cells (0.012%) and FL1-ve gates (no fluorescence) in 
all the samples were drawn keeping the FL1-ve gate at 101 on the X-axis (FL1-H 
channel). The cells which lie after 101 on the X axis were labelled as fluorescent 
cells and gated as FL1+ve. The percentage of FL1+ve cells for all controls was 
very small (less than 0.1%) as it is shown in the above figure. The samples with 
eGFPD4 at 1400nM concentrations had the highest number of fluorescent cells 
and the eGFP only controls had the minimum fluorescence (Figure 3.13). 
As expected with eGFPD4PLY (1400nM), binding was significantly higher as 
compared to the mutant version (Figure 3.13). Similar results were found on 
fluorescence microscope where large clumps of cells were seen at this protein 
concentration. Interestingly, the mutant version eGFPD4PLY(T459G.L460G) showed 
some residual binding (Figure 3.14). This binding was greatly reduced compared 
to the WT D4PLY. This suggests that there may be another binding site apart of 
this TL site which is contributing to this residual finding since TL substitution 
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does not completely remove the binding of the red blood cells. To exclude the 
fact that this is not because of eGFP only, controls were used at the same 
concentration as the proteins (eGFP only used at 14, 140 and 1400nM). 
              
Figure 3-13 FACS results showing proteins binding with the red blood cells 
X axis is FL1+ve channel which was set on log scale at 400 volts. Y axis is the number of 
events measured for every reading and in this case is 50,000.The protein binding with the 
red blood cells is seen by shifting of the graph to the right. Light green represents PBS with 
red blood cells , yellow shows eGFP at 1400nM, red shows eGFPD4PLY(T459G.L460G) at 1400nM 
and light blue represents eGFPD4PLY at 1400nM concentration. There were two peaks seen 
with eGFPD4PLY suggesting two or more cells. Figure was drawn using Flowjo software. 
In the case of eGFPD4PLY the graph has clearly shifted to the right suggesting 
more binding as compared to the mutant protein. Some binding of the TL mutant 
with the red blood cells was observed as compared to the controls. With 
eGFPD4PLY more than one prominent peak was seen as compared to other 
proteins. Similar peaks (more than one) were also observed previously with this 
protein at high concentrations with red blood cells (Ma, 2011). These double 
peaks may be the doublets, triplets or multiple cells giving different 
fluorescence signal with eGFPD4PLY. 
The binding of mutant protein with red blood cells was concentration dependent 
as it is increased with the increasing concentration of the protein. The three 
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concentrations of the TL mutant were noted for the binding along with the 
controls. The binding was minimal with the 14nM and was highest for the highest 
concentration 1400nM. 
  
Figure 3-14 FACS results showing eGFPD4PLY(T459G.L460G) binding with horse red blood cells 
Three different concentrations (14,140 and 1400nM) of eGFPD4PLY (T459G.L460G) were taken. X 
axis is FL1+ve channel which was set on log scale. Y axis is the number of events measured 
and is 50,000.The pink colour represents the control eGFP only (14nM), blue, yellow and 
green colour represents 14, 140 and 140nM of eGFPD4PLY(T459G.L460G). 
The results in figure 3.14 shows binding of protein with the red blood cells 
increased with the increase in the concentration suggesting that TL are not the 
only two residues responsible for binding to red blood cells and there might be 
some more residue/s contributing for this binding. 
The forward scatter channel (FSC) was used to observe any changes in the size of 
the cells that might have happened due to binding of the proteins. 
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Figure 3-15 FACS results showing the protein binding with the horse red blood cells in 
forward scatter channel (FSC) 
X axis is the forward scatter channel (FSC) which was set on linear scale at 350 volts. The Y 
axis shows the number of events captured during each reading and in this case is 50,000. 
The red graph is eGFPD4PLY (1400nM), yellow is eGFPD4PLY(T459G.L460G) (1400nM) and blue 
is eGFP only at (1400nM). The black arrow indicating the second peak observed with TL 
mutant. 
The eGFPD4PLY appears to be binding with more than one cell as more than two 
peaks are observed with it in Forward scatter channel (FSC). The first peak is the 
single cells and the second and the small third in eGFPD4PLY seems to be more 
than one cell. The two peaks were also seen with eGFPD4PLY in fluorescence 
channel (FL-1) which might explain that eGFPD4PLY form more than one clumps 
of cells and these may give different fluorescence signals and hence more peaks, 
when seen with FL-1 channel. The results show that with eGFP only control no 
second peak was observed where as with eGFPD4PLY(T459G.L460G) a small second 
peak was seen. The aggregation results of mutant proteins were evaluated as 
percentage (% of single and multiple cells) in section 5.7 (Figure 5.12).  
This data presented in here is in line with microscopy results which shows 
aggregation of two or three cells with the mutant protein where as the cell 
aggregation is more with eGFPD4PLY (more than 15-20), which might suggest 
that there is still some residual binding with TL (459,460) residues even after 
substituting them with glycines. 
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The FI (fluorescence index) of the different protein concentrations was 
calculated and their results were compared. The FI was calculated by 
multiplying the total number of fluorescence cells by mean geometrical 
fluorescence. The shifting of peak to far right in case of eGFPD4PLY in FL-1 
channel (Figure 3.13) also resulted in high FI (fluorescence index) of eGFPD4PLY 
in comparison to both the TL mutant and the eGFP only, where the readings 
were not as high. The FI readings of eGFPD4PLY at all concentrations (14,140 
and 1400nM) differ significantly when compared with both TL mutant and eGFP 
only (data not shown). 
The FI of TL mutant at three different concentrations (14,140 and 1400nM) was 
compared with the eGFP only at the same concentration. The different protein 
concentration of TL mutants and eGFP only were compared by using unpaired t-
test. 
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Figure 3-16 Graph showing unpaired t-tests between the control eGFP only and the 
eGFPD4PLY(T459G.L460G) 
The graph represents different concentrations of the TL mutant (14,140 and 1400nM) with 
corresponding eGFP only concentrations using unpaired t-tests. The P value <0.05 was 
considered to be significant. The * symbol shows that P value is significant (* = p<0.05). 
 
Figure 3.16 shows that there is no significant difference between 14nM of TL 
mutant and 14nM of eGFP only. However, significant differences were observed 
at higher concentrations 140M and 1400nM when compared with their 
corresponding controls (eGFP only 140nM and 1400nM). This result suggests a 
second site/s apart from this TL site responsible for binding with the red blood 
cells or there could be some residual binding with glycines in the mutant 
protein. 
The data for all three different concentrations of the TL mutant 14nM, 140nM 
and 1400nM was plotted and compared by using again One-way Anova to see if 
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they differ significantly. The values were compared with the 14nM of 
eGFPD4PLY(T459G.L460G). 
 
Figure 3-17 Graph showing the comparison of fluorescence index of three different 
concentrations of eGFPD4PLY(T459G.L469G) 
The graph shows the comparison of three different concentrations of the TL mutant (14,140 
and 1400nM) using analysis of variance Anova. The P value <0.05 was considered to be 
significant. The * symbol shows that P value is significant (* = p<0.05)  
Figure 3.17 shows that as the concentration of the TL mutant is increased from 
14nM to 1400nM, there is an increase in the F.I and this increase is significant (P 
value <0.05) when compared between concentration 14nM and 1400nM. This 
result confirms our previous finding of FACS results (figure 3.14) which is also 
showing the increase in binding of the toxin to red blood cells with the increased 
concentration. 
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3.8 Discussion 
The plasmid pET 33bD4PLY was constructed by ligation dependent cloning (LDC). 
The sequence encoding D4 of PLY was ligated in pET33b+. The plasmid pET33b 
eGFPD4PLY was also constructed by LDC by cloning D4 first in pET 33b+ and 
inserting eGFP gene later in the vector (Ma, 2011). These constructs were used 
by the author to construct TL versions of the mutant proteins by using the site 
directed mutagenesis kit. Since this traditional ligation dependent technique 
leaves some undesirable amino acids encoded by restriction sites ligating the 
two segments of DNA together (in this case eGFP with D4 of PLY) which might 
explain the degradation/cleaving of recombinant eGFPD4PLY. 
The red cell assays showed the aggregation of red blood cells with D4PLY and 
eGFPD4PLY. The same aggregation pattern was also observed when examined 
under the fluorescence microscope which might suggest that fusing eGFP to the 
N- terminal D4PLY does not interfere with this aggregation phenotype. This also 
suggests that there might be a site other than the TL site that is responsible for 
this aggregation. This site must be in the D4 of the toxin since the purified D123 
does not give this aggregation phenotype (Figure 3.9). 
The TL mutant showed no visible aggregation on the plate but clearing effect 
(results figure 3.8) of wells was observed on the red cell assay plate. A similar 
effect was also observed with D123 of PLY (Figure 3.9) and a non-haemolytic 
pneumolysin variant ST-306 (Data not shown) (Kirkham et al., 2006b). It is 
assumed that this clearing effect might be non-specific interaction of the 
protein with either DTT and/or PBS in the red cell assay plate since it was also 
seen with non-lytic Pneumococcal proteins like PspC and PspA and other non 
Chapter 3  123 
pneumococcal proteins like BSA (Figure 3.9). This clearing effect is not seen 
until the last centrifugation step of the red cell assay experiment. It was noted 
that if the plate was left on bench without this last centrifugation step, this 
clearing effect phenomenon is not observed suggesting the centrifugation step 
causes the protein to bind non-specifically with PBS and or DTT. 
The FACS results of D4PLY binding with horse red blood cells were consistent 
with the previous results (Ma, 2011). Interestingly, the TL mutant did not 
demonstrate the same aggregation phenotype as of D4PLY on the red cell assay 
plate but showed some residual binding, which increased as the concentration of 
the toxin was increased from 14 to 1400nM. This may suggest that binding of 
protein with the red cell membrane may be concentration dependent. This 
residual binding of TL mutant might suggest that TL is not only the site 
responsible for binding to the cholesterol membrane and other sites in D4 may 
contribute to this binding. This also suggests that substituting TL residues with 
glycines does not completely abolish binding and there is some binding with the 
glycines since the microscopy results show small cell aggregates (2-3) as 
compared to the WT protein (Figure 3.11). The Farrand et al., 2009 study 
showed in PFO when TL residues were individually substituted with either 
alanines or glycines, there was binding observed with red blood cells and when 
both the substitutions were made there was no binding and the %lytic activity 
was less than 0.2% (Farrand et al., 2009). 
However, contrary to Farrand et al., 2009, significant difference was found in 
fluorescence index (FI) value of the mutant protein when compared with 140nM 
and 1400nM of eGFP only. 
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Figure 3-18 Model showing PLY binding to red blood cells 
The above figure showing two sites, one is TL site and a possible second binding site. 
 
Based on the above results a model was hypothesised which might explain the 
binding of the toxin with the cholesterol membranes. PLY may have two binding 
sites; one is the TL site and there may be another binding site other than the TL 
site which is responsible for this residual binding with the red blood cells. 
Another possible explanation may that once the TL site and this new site binds 
to the cholesterol membrane there may be conformational change in the 
structure of the protein that exposes the D4 loops (L1, L2 and L3) residues and 
the undecapeptide which results in the insertion of the tryptophan residues and 
then coupled with the insertion of D3 transmembrane β-hair pin loops (Heuck et 
al., 2000). Another possibility might be that this second site is binding with 
other red blood cells which may explain the aggregation phenomenon observed 
if the lytic activity is abolished by making ∆6 version or using purified D4 only. 
TL residues initially bind to the cholesterol and then this interaction is 
strengthened by the other L1-3 residues. TL mutant does not perturb the 
structure of the protein so these changes are subtle and well tolerated (Farrand 
et al., 2009). The results of this study suggest that TL with the other binding site 
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interacts at the same time or TL binds first resulting in a conformational change 
which might result in the interaction of this new site with cholesterol and this 
phenomenon disappears when we block the TL site but we still get some residual 
binding with the new site. 
It will be interesting if the other binding site, as described in the model, is 
discovered (Figure 3.18) and binding phenomenon with the red blood cells is 
observed only by substituting this new site and leaving the TL site intact and also 
by substituting both the TL and new site. 
One potential problem might be that the recombinant proteins used in the above 
experiments were His-tagged protein and His-tag attached to the N-terminal of 
the protein might be responsible for this residual binding of the protein since the 
tag was also attached to eGFP version of the mutants. To overcome this issue a 
tagfree version of the proteins can be used in the experiments which will 
exclude any doubt of the His-tag binding with the red blood cells. This will be 
discussed in detail in the next chapter of the thesis.
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4 Purification and characterisation of mutants 
made by random mutagenesis 
4.1 Summary 
The results of previous chapter showed that mutant version of PLY(T459G.L460) was 
showing residual binding/aggregation with the red blood cells suggesting that 
there might be another site other than the TL site interacting with the red blood 
cells. The exact position of the site is not known but the red cell assay results 
demonstrate that the site is present in D4 of the toxin. Therefore random 
mutations were made in the D4 of the toxin using Mutation Generation system 
(MGSTM). 
The random mutants were initially made using the pET33bD4PLY vector but some 
issues in generation and purification of the mutants were observed. The reasons 
are described in detail in this chapter. As discussed in chapter 3, pET33bD4PLY 
has a His tag attached to its N-terminal which might be contributing to this 
residual binding. Due to these potential problems the tag free purification 
system was used. 
The tagfree WT PLY construct was made using Profinity eXact Purification 
System. The WT PLY is lytic even at very low concentrations and one of the aims 
of this study is to identify the sites which are responsible for causing the 
binding/aggregation of the red blood cells. It would be difficult to identify these 
sites in the WT PLY background because of its lytic activity so ∆6 version of the 
toxin was made (Kirkham et al., 2006b). This would not only abolish the lytic 
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activity the toxin but also at the same time will be useful in identifying the sites 
responsible for this residual binding/aggregation. 
The random transposon based insertion was made both in the WT PLY and the ∆6 
PLY background. The random mutations in the WT PLY background were made to 
identify any other residues in addition to the already identified 146 and 147 
residues (alanine and arginine) responsible for the lytic activity of the toxin 
(Kirkham et al., 2006a). The random mutants generated in the WT PLY 
background will also be useful to identify sites responsible for any other 
biological activity of the toxin. The random mutants made in the tagfree ∆6 PLY 
background will eventually solve the potential issue of His tag interference in 
binding with the red blood cells. 
A number of mutants were generated by using the method described in 2.8.7. 
These mutant proteins were then purified using Profinity eXact TM protein 
purification system. These purified mutant proteins were then screened for lytic 
activity in case of tag free WT PLY mutants, and for aggregation phenotype in 
case of ∆6 PLY mutants. Based on these results further SDM mutagenesis was also 
carried out in interesting mutants to see whether an addition of single amino 
acid addition/substitution results in phenotypic change. 
4.2 Random mutagenesis in pET33bD4PLY 
The residual binding site(s) was observed by making random mutations in the 
pET33bD4PLY. The 15 base pair random mutations were made by inserting 
transposon named as Entranceposon in the target DNA at any site. The body of 
the transposon can be removed later by using a NotI restriction enzyme that 
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specifically cleaves the body of the transposon leaving 15 additional base pairs in 
the target DNA at any site. For this specific reason the vector should not have 
any NotI recognition site. The pET33b vector has a NotI recognition site (Figure 
4.1) so it was removed before inserting the transposon. The two possible ways to 
remove this site were to either do a restriction digest with XhoI and SacI 
restriction enzyme and religating it or to do a site directed mutagenesis. 
 
Figure 4-1 Vector pET33bD4PLY showing different restriction sites 
The diagram was generated using Vector NTI software and showing D4PLY gene along with 
restriction sites NotI, SacI, XhoI and NdeI respectively. 
 
The pET33bD4PLY NotI restriction site was removed by doing a restriction 
enzyme digestion with XhoI and SacI. After digestion, plasmid was ligated with 
T4 DNA ligase overnight and was chemically transformed in XL-1 blues. To 
confirm that the NotI site has been removed the NotI digested pET33b and the 
parent pET33b was treated with NotI and NdeI. 
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Figure 4-2 Restriction enzyme digestion of pET33bD4PLY 
A) DNA Gel showing lane M= DNA marker followed by lane 1= Uncut vector and lane 2= 
vector cut sequentially first with XhoI and SacI enzyme.                
B) DNA gel showing lane M=DNA marker followed by lane 1= parent vector, lane 2 = vector 
with NotI site removed, lane 3= parent vector cut with NdeI and NotI and lane 4= Vector with 
NotI site removed cut with NotI and NdeI. The small arrow showing the D4 gene with the 
parent vector. 
Figure 4.2 shows that when the NotI site was removed and same plasmid treated 
with NotI and NdeI along with the parent plasmid, the parent plasmid yielded a 
small fragment of about 500 base pairs (small white arrow in figure 4.2B) 
whereas the vector from which the NotI site was removed did not give any 
fragment. The removal of NotI site from the vector was further confirmed by 
sequencing results. 
The next step was to treat the NotI cut plasmid with the MGS kit as explained in 
Materials and Methods section 2.5. The plasmid was treated with transposon for 
one hour. The plasmid has a kanamycin resistance gene and the transposon has a 
chloramphenicol resistance gene. 
The next day the plate was checked and colonies which had appropriate 
antibiotic selection were screened using a PCR reaction. All positive colonies 
were picked and colony PCR was performed using the primers (7F and 7G) 
flanking the PLY gene. The positive colonies where the transposon insertion has 
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occurred in PLY gene were 1254 base pairs bigger (size of Tn is 1254bp; 
mentioned in MGSTM protocol) than WT PLY. The plasmid DNA was purified from 
the positive colonies and was then treated with NotI enzyme to remove the body 
of the transposon, re-ligated with T4 DNA ligase and was chemically transformed 
in XL-1 blues.  
The plasmid DNA was purified from positive XL-1 blue colonies and was 
confirmed by sequencing. The 15 base pair insertions have a NotI site 
recognition site (GC GGCC GC) (Figure 4.10). The MGS kit also has a palindromic 
NotI mini primer supplied which can anneal to both the strands of the target 
DNA. 
In order to roughly evaluate the position of the transposon insertion a PCR 
reaction was set up using NotI mini primer with 7F and NotI mini primer with 7G. 
  
Figure 4-3 PCR reactions with NotI mini primers 
The figure showing primer annealing and amplification of D4PLY gene (green line), pET33b 
plasmid (red line) with primers 7F and NotI and 7G and NotI. The small black indicates 
transposon with NotI site. Two separate PCR reactions were set up; one with NotI 
miniprimer and 7F and the other with NotI and 7G. 
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Figure 4.3 shows the amplification with a combination of NotI mini primer and 
the vector-binding forward and vector-binding reverse primer. For each 
individual positive colony two reactions were set up, one with the vector-binding 
forward primer and  NotI mini primer and the second with the vector binding 
reverse primer and NotI mini primer.  
The PCR products were analysed on a gel and the size of the PCR product will 
roughly determine where the 15 base pair insertion has gone in relation to the 
two vector-binding forward and reverse primers. The exact location of the 15 
base pair insertions (5 amino acid residues) was determined by sequencing 
results. 
 
Figure 4-4 DNA gel pictures of transposon insertion and PCR with NotI mini primer 
4A) Showing the results of colony PCR with 7F and 7G primers. The white box indicates the 
two positive colonies (lanes 18 and 19) with transposon insertion. In all other lanes 
transposon was not inserted in D4PLY gene since all the bands are of the same size as 
positive control (D4PLY amplified with 7F and 7G primers) in lane 3. 4B) Lane M is the DNA 
marker followed by Lane 1 negative control (No plasmid with 7F and NotI mini primer), Lane 
2 Negative control again (colony where Tn has not inserted in the PLY gene) with 7F and 
NotI mini primer, Lane 3 (positive colony where Tn has inserted in the PLY gene) with 7F 
and NotI mini primer and Lane 4 same positive colony with 7G and NotI miniprimer. 
  
Figure 4.4 A shows the two plasmids highlighted with a white box in lanes 18 and 
19 appeared to have transposon inserted in them. They were treated with NotI 
to remove the body of the transposon, religated and plasmid DNA purified and 
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was sent for sequencing. A colony PCR was also done with NotI mini primer in 
figure 4.4 B. 
The result 4.4 B shows that with the positive colony (Tn insertion), a band of 
approximately 800 base pairs were present with 7F and NotI mini primer and a 
small band of approximately 200 base pairs present with 7G with NotI mini 
primer. There are few other bands present which might suggest non specific 
amplification because of the small size of the NotI mini primer (mentioned in 
the MGSTM protocol). 
The sequencing results for the three positive colonies were checked to see 
where exactly the five amino acids insertions have gone in the D4PLY. 
 
Figure 4-5 Transposon insertions in different regions of the pET33bD4PLY 
The above figure showing places of three positive transposon insertions (black stars) in 
D4PLY gene (green rectangular box), 7F and 7G primers annealing to the plasmid (red 
rectangular boxes). In Mutant 1 and 3, Tn has gone in the vector backbone and Mutant 2 
having Tn inserted in D4PLY gene.   
 
Figure 4.5 showing the two mutants (Mutant 1 and Mutant 3) were not actually in 
the D4PLY gene and therefore were discarded. The Mutant 2 was the only 
successful mutant where the transposon had actually gone into the D4PLY. 
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This plasmid containing the mutant DNA (five amino acid insertion) was then 
chemically transformed into BL-21 cells for expression. The protein was 
expressed according the same protocol as mentioned in section 2.8. This new 
mutant could not be purified due to formation of inclusion bodies. Several 
attempts were made to improve expression including change of induction 
temperature (37 oC to 20oC), concentration of IPTG (2mM to 0.5mM), use of auto 
induction media and time post induction (3 hours to 12 hours) but still the 
protein could not be expressed in the soluble form. 
One of the mutants generated in the WT PLY background (tag free system) 
discussed later in this chapter has the same 5 amino insertions (after residue 
389) and that mutant protein was soluble so further purification attempts of this 
mutant in pET33bD4PLY background were not carried out (Table 4.1). 
4.2.1 Problems in random mutagenesis with pET33bD4PLY 
There were several issues with transposon insertion in the pET33bD4PLY. Firstly 
there were not many positive colonies with transposon insertion in the actual 
D4PLY gene even after several attempts. The large number of colonies that grew 
on the plate after treating with the transposon showed that transposon insertion 
had occurred in the plasmid since the reaction was plated on the agar 
supplemented with both kanamycin and chloramphenicol. The colony PCR was 
done to pick the positive colonies in the D4 of the gene. The colony PCR results 
showed very few (only three) colonies with the transposon insertion. The 
possible explanation for not getting transposon insertion in the D4 gene itself 
could be that the D4PLY is relatively small and is roughly ¼ of the full length of 
the PLY gene and most of the transposon insertion was going in the vector back 
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bone rather than the actual gene. The transposon itself has no preference for 
any specific target sequence (MGSTM kit manual). 
Secondly, the primers (7F and 7G) used to amplify D4PLY gene were few hundred 
base pairs away from the gene and was amplifying some portion of the vector 
along with the D4PLY (figure 4.5). Two of the three positive colonies (black 
asterisk in figure 4.5) went in the vector instead of going in the actual gene. This 
was confirmed by the sequencing results of the three mutants. 
The next challenge was the purification of the mutant protein. As stated earlier 
several attempts were made to get the protein in the soluble fraction but were 
unsuccessful. The presence of the mutant protein was confirmed in the insoluble 
fraction by doing a western blot with anti-PLY antibody. The 5 amino acid 
insertion at the same place in full length PLY (WT PLY background) was soluble 
showing that 5 amino acid insertions are not tolerated by D4PLY alone (Table 
4.1). 
To address these issues, full length PLY in a tagfree system was used as a target 
so that a larger sequence region was provided for the transposon insertion; also 
any possible interference from His tag is removed to allow observation of 
residual binding/aggregation with the red blood cells. The new primers were 
also designed that were flanking PLY gene only (Figure 4.7). 
The tagfree vector (pPAL7) having the WT PLY gene was used. The WT PLY 
causes the lysis of the red blood cells and since the aim of the project is to 
identify sites that were responsible for causing the aggregation/binding of the 
red blood cells, so a pPAL-7 ∆6 PLY was constructed by deleting the two amino 
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acids at positions (146,147) using the SDM kit. The primers used were 23B and 
23C as mentioned in the list of oligonucleotides (table 2.2). The random mutants 
were made both in the WT and ∆6 PLY background. Previous experiments showed 
no differences in the lytic activity between the His tag purified PLY and the 
tagfree PLY (T.J.Mitchell, personal communication). ∆6 PLY tagfree protein was 
compared with the His tag purified ∆6 PLY on a hemagglutination assay to 
observe if there was still the same aggregation phenotype. 
4.3 Random mutagenesis in pPAL7 ∆6 PLY and WT PLY 
4.3.1 NotI site removal in pPAL7VECTOR 
The pPAL7 vector has a NotI site and the NotI site was removed by a SDM 
reaction using the SDM kit following the same protocol as described in the 
materials and methods section 2.5. The SDM reaction was transformed in XL-1 
blues and plasmid DNA purified and sent for sequencing. The sequencing 
reaction confirmed that the NotI site was successfully removed from the vector. 
4.3.2 Generation of pPAL7 ∆6 PLY 
The pPAL7 ∆6PLY was constructed from pPAL-7 WT PLY according to the same 
protocol as described above and in materials and methods section 2.5.  The 
resultant reaction was transformed in XL-1 blues and plasmid DNA was purified 
and sent for sequencing. The sequencing results confirmed that the two amino 
acids at position 146 and 147 (alanine and arginine) were successfully deleted. 
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 Figure 4-6 Sequencing results showing two amino acids deletion in WT PLY 
The above diagram shows the two amino acids (alanine and arginine) deletions at position 
146 and 147. The sequencing results (34 cut and 33 cut) were aligned with the parent 
(tagfree jiang, tag free with out NotI) and the new (Delta6 TagfreePLY) sequence using 
Vector NTI software. 
 
4.3.3 PLY amplification with TagfreePLY primers 
The 7F and 7G primers amplified the D4PLY gene along with few hundred bases 
on either side of vector. This led to transposon insertion in the vector region in 
two out of the three mutant generated in pET33bD4PLY (Figure 4.5). To 
overcome this issue, new primers were designed to amplify the PLY gene only. 
With the same PCR conditions the new primers were tried along with the 7F and 
7G and PLY was successfully amplified with both the primer pairs. 
 
Figure 4-7 DNA gel picture showing the PLY amplification with new set of primers 
Lane M showing DNA ladder followed by lane 1, negative control, Lane 2-4 PLY 
amplification with 7F and 7G primers and Lane5-7 PLY amplification with new primers. The 
two bands of 1650 and 2000 base pairs are indicated by the small white arrows. 
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Figure 4.7 showing PLY amplification with the new primers. The product 
amplified with the new primers was few hundred base pairs smaller since only 
the PLY gene was amplified.  
All positive colonies screened with these new primers will reduce any chance of 
false positive colonies (transposon insertion in the vector back bone) as seen 
with the 7F and 7G primers.  
4.3.4 Construction of random mutants in pPAL7 ∆6 PLY and WT 
PLY  
A number of mutants were generated in pPAL7 WT and ∆6 PLY background. The 
mutants were generated by using the protocol as described in the materials and 
methods section 2.6. 
 
Figure 4-8 DNA gel showing transposon insertion in PLY gene 
Lane M showing DNA ladder, Lane 1 is the negative control, Lane 2 is the positive control 
PLY gene. Lane (3-9) and 17 is the PLY gene with transposon insertion. Lane (10-16) and 
(18-25) showing colonies without transposon insertion.  
 
Figure 4.8 showing the initial screening of the positive colonies after the in-vitro 
transposition reaction. A colony PCR was set up with new primers and colonies 
with transposon insertion in ∆6 PLY gene are marked in boxes (White boxes in 
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above figure). The colonies with transposon insertion were bigger since 
transposon was 1254bp in size and PLY gene was 1408bp. The PCR was set up 
again with the PLY primers and transposon specific primers (M1 CamR) to see the 
presence of both the PLY gene and the transposon. 
 
Figure 4-9 DNA gel picture showing the amplification of ∆6 PLY and transposon with PLY 
and transposon specific primers 
The Lane M shows 1Kb+ Ladder followed by Lane 1 negative control, Lane 2 positive control 
WT PLY, Lane 3-13 colonies amplified with new PLY primers where transposon insertion 
have occurred in the PLY gene and Lane 14-24 are the same colonies amplified with 
transposon specific primers to confirm the presence of transposon. 
 
Figure 4.9 showing amplification of positive colonies (lanes 14-24) with 
transposon specific primers and a band of approximately 1200bp since the 
transposon was 1254bp in length. The same colonies (lanes 3-13) when amplified 
with PLY primers showed bands of around 2.8 kb since PLY was 1408bp and 
transposon was 1254bp. This reaction confirmed the presence of transposon in 
the PLY gene in these colonies. New PLY primers used were only amplifying the 
gene and not any portion of the plasmid. 
The plasmid DNA was purified for these positive ∆6 PLY colonies and was treated 
with NotI enzyme to remove the body of the transposon, religated with T4 DNA 
Ligase and was again transformed in XL-1 Blues cells. The plasmid DNA was 
purified from the XL-1 Blues cells and was sent for sequencing to identify the 
Chapter 4  139 
exact place of 5 amino acids additions. The same colonies were also treated 
with NotI mini primer as it was done with the one positive colony of 
pET33bD4PLY to identify the position of 5 amino acids insertion in the PLY gene 
(Figure 4.4b). 
 
 
Figure 4-10 Sequencing results showing addition of 15 base pairs (highlighted in yellow) in 
∆6 PLY background using Vector NTI software programme 
Figure showing sequencing reaction of 15 base pair additions (highlighted yellow) from of 
the positive colonies aligned to the parent sequence using Vector NTI software. 
 
Figure 4.10 shows the sequencing results of one of the mutants 29.5 (Table 4.1) 
generated in ∆6 PLY background. The results of the forward and reverse primers 
were aligned to the parent vectors ∆6 PLY without NotI site and Tag free PLY 
with NotI site. The results show the fifteen base pair addition (5 amino acids) in 
the plasmid. The 15 base pair addition is highlighted in yellow and is 
(TGCGGCCGCATTCAA). NotI sequence is GCGGCCGC which is present in the 15 
base pair addition (Figure 4.10) and NotI mini primer at this site along with 7F 
and 7G anneals and amplifies the gene in a PCR reaction and roughly identifies 
the 5 amino acid insertions as explained in figure 4.4. 
The mutants in WT PLY back ground were made exactly the same way as for the 
∆6 PLY back ground. A number of mutants were generated using the transposon 
mediated random mutagenesis in both WT PLY and ∆6 PLY back ground are listed 
in the table 4.1 below. The insertion place and translation of five amino acids 
residues are also mentioned in the table 4.1. 
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Table 4-1 List of mutants generated by transposon mediated random mutagenesis 
 
The table 4.1 explains the list of random mutants generated in WT PLY, ∆6 PLY 
and D4PLY background. It also shows exactly where the transposon has inserted, 
which new amino acid residues have been added to the protein and in which 
domains the insertions have gone.  
Table 4.1 also shows that the insertion place (after amino acid 389) of the only 
mutant generated in pET33bD4PLY. This mutant could not be purified due to 
problems mentioned in this chapter under the heading 4.2.1. 
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4.4 Protein expression and purification 
∆6 PLY was purified first by the Profinity eXact purification protocol. In total 8 
mutants were generated in WT PLY and 9 mutants were generated in ∆6 PLY 
background. All plasmids containing the mutant DNA were chemically 
transformed in BL-21 (DE3) for protein expression and were purified by Profinity 
eXact TM protein purification system as described in the materials and methods 
section 2.8.7. 
The purified proteins were analysed by SDS-PAGE gels. 
 
Figure 4-11 SDS-PAGE of ∆6 PLY, Mutant29.5∆6 PLY, Mutant1 WT PLY and Mutant2 WT PLY 
A) Mol.wt of ∆6 PLY and M29.5 is 53kDa. Lane M contains 5µl of the mol. wt.marker 
SeeBlue® Plus 2 followed by 5µl recombinant protein ∆6 PLY and M29.5∆6 PLY (Lane 1 and 
2). B) Mol.wt of M 1 WT PLY and M6 WT PLY is 53kDa. Lane M contains 5µl of the mol. wt 
.marker SeeBlue®Plus2, followed by 5µl purified protein M1 WT PLY and M6 WT PLY (Lane 1 
and 2). A few bands were seen (contaminants) in both the gels (A&B) and were removed by 
using Amicon Ultra Centrifugal concentrators as explained in section 2.8.9.   
Figure 4.11 showing purified proteins after one step purification and the protein 
size also correspond to the molecular weight markers. The purified proteins 
were passed through Amicon Ultra-15 50K centrifugal filter removing any 
contaminates less than 50kDa molecular weight. Unlike the TL mutants these 
random mutants were purified from 0.5 litre of the culture and screening was 
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done for aggregation negative mutants in case of ∆6 PLY and non-lytic in case of 
WT PLY background. All purified mutants were then run on as SDS-PAGE. 
All mutants in WT and ∆6 PLY back ground were purified in a similar way and 
purity was checked by running the SDS-PAGE (Figure 4.12). The proteins were 
then buffer exchanged into PBS and were stored at -80oC. 
 
Figure 4-12 SDS-PAGE showing purified WT PLY and ∆6 PLY mutants 
A) All purified ∆6 PLY mutants on a precast gel. Lane M is the 5µl mol.wt marker SeeBlue® 
Plus 2 followed by 5µl of M1, M35, M13, M27.10, M29.4, M5, M44.1 and M44.2 ∆6 PLY in 
Lanes1-8 respectively. All mutant proteins have expected size of 53kDa. B) All purified WT 
PLY mutants on a self poured gel. Lane M is the 5µl mol.wt marker SeeBlue® Plus 2 
followed by 5µl of M2, M9, M12, M13, M21 and M19 WT PLY in Lanes 1-6 respectively. The 
above proteins in gels A and B were purified by single step purification and hence some 
contaminants are present in the gels (small bands below and above 53kDa size). The 
proteins were passed through ultra centrifugal filters to remove contaminants before 
storage.   
 
All the purified proteins correspond to the expected size as the molecular weight 
marker. There were some contaminants and were removed using Ultra 
centrifugal filters before storage as explained in 2.8.9. 
The concentration of the all purified proteins were measured using Nano Drop 
and following the same method as explained in the materials and methods 
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section 2.8.10. The table 4.2 shows the concentration of the purified proteins 
from 0.5 litre of bacterial culture. 
Table 4-2 Concentration of the purified mutant proteins 
  
 
4.5 Western blot of the purified proteins 
All purified mutant proteins were further analysed by western blotting. The 
western blotting was done according to the same protocol as mentioned in the 
materials and methods section 2.9.2. 
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Figure 4-13 Western blot of the purified mutant proteins 
A) Western blots of ∆6 PLY mutants. 1µg each of the purified proteins was loaded on the gel. 
Lane M is the mol wt marker followed by M1, M5, M13, M27.10, M29.4, M29.5, M35, M44.1and 
M44.2 in Lanes 1-9 respectively. B) Western blots of WT PLY mutants. 1µg each of the 
purified proteins was loaded on the gel. Lane M is the mol wt marker followed by M1, M2, 
M6, M9, M12, M13, M12, and M21 in Lanes 1-8 respectively. There was a faint band above 
some of the purified proteins (Lanes 5-7 on both blots) which might be some non-specific 
antibody binding.  
 
4.6 Characterisation of the mutant proteins 
The lytic activity WT PLY mutants were analysed on the red cell assay plate. The 
∆6 PLY mutants were assessed for red blood cell aggregation on a 
hemagglutination assay. 
4.6.1 Lytic activity of the mutant proteins 
All 8 random mutants created in WT PLY background were assessed for their lytic 
activity. Lytic activity of each of individual mutant is plotted on the graphs 
(Figure 4.14). 
These experiments were set up to identify any other residues apart for the two 
residues (∆146A∆147R) identified by (Kirkham et al., 2006a) that may be 
responsible for the lytic activity. 
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In WT PLY background; four mutants (1, 6, 19 and 21), the 5 amino acid 
insertions had gone into the domain 4 whereas the other four mutants (2, 9, 12 
and 13), the insertions had gone into the domains 1-3 of the protein. All the 5 
amino insertion mutants in domain 4 were plotted in the same graph (Figure 
4.14A) and rest of the mutants were plotted in the other graph (Figure 4.14B). 
The lytic activity of these 5 amino acid random mutants for erythrocytes was 
assessed by indirect measurement of released haemoglobin. The specific 
haemolytic activities of the toxins were then calculated in HU/mg and are stated 
in table 4.3. 
 
Figure 4-14 Haemolytic activity of the mutant proteins 
% lytic activity of individual mutant (Y-axis) plotted on the graphs against log toxin 
concentration (X-axis) of each mutant. 
 
Figure 4.14A showing WT PLY mutants with 5 amino acid insertions in D4 of the 
toxin resulted in a decrease in lytic activity of the all of them apart from Mutant 
6, where the lytic activity is almost comparable to the WT PLY. The 5 amino acid 
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(a.a) insertions in Mutant 6 WT PLY were exactly at the same place (after 389 
amino acids) where the five a.a insertions in pET33bD4PLY had gone (Table 4-1). 
In case of D4PLY, this 5 amino acid random insertions made the mutant insoluble 
but in case of full length PLY it was soluble. The 5 amino acids residues inserted 
in case of Mutant 6 were (CGRRG) where as in D4 background it was (SAAAV) 
which may have made former soluble and the latter insoluble. 
The 5 amino acid insertions in three other mutants in D4PLY have all gone in 
important positions. In Mutant 21, the 5 amino acid insertion has gone in the 
undecapeptide region after first tryptophan residues and has made this mutant 
non-lytic. In Mutant 19, the 5 amino acid insertion has gone very near to the 
undecapeptide region exactly after 4 amino acids after the undecapeptide 
region and in Mutant 1; the 5 residues were inserted after the 3rd hydrophobic 
loop (L-3) of domain 4 PLY (Figure 4.16A). 
The results of this study were comparable with the findings of the previous 
studies (Korchev et al., 1998, Berry et al., 1995) which showed that 
undecapeptide region (residues 427-437) is an important region of the toxin and 
mutation made in this region at one of the first three tryptophan residue 433 
(W>F) drastically reduced the lytic activity of the toxin to 1%. Although in this 
study single amino acids were not substituted, but 5 amino acids were inserted 
at the same position. 
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Table 4-3 Specific haemolytic activity and some additional information of the mutant 
proteins 
 
The lytic activity of the other mutants where the 5 amino acid insertions were in 
the domains 1, 2 and 3 (Mutant 2, 9, 12 and 13) were similar to the WT PLY 
suggesting that addition of 5 amino acid residues in other domains does not have 
an effect on the lytic activity of the toxin. These random mutants had not gone 
in any well studied regions of the protein. None of these mutants had gone near 
the two residues (∆146A∆147R) which are responsible for abolishing the lytic 
activity of the toxin (Figure 4.16A). 
4.6.2 Hemagglutination activity of the mutant proteins 
The random mutants generated in the ∆6 PLY background were checked for their 
ability to aggregate/agglutinate red blood cells. In total 9 mutants were 
generated; four mutants (Mutant 27.10, 35, 44.1 and 44.2) had 5 amino acids 
residues inserted in domain 4 and five mutants (Mutant 1, 5, 13, 29.4 and 29.5) 
had insertions in domains 1, 2 and 3 of the toxin. The assay was done according 
to the same protocol as mentioned in the materials and methods section 2.9.3. 
The tagfree was also causing the same aggregation/ agglutination phenotype as 
His-tagged purified ∆6 PLY. ∆6 PLY is non-lytic so the specific lytic activity for 
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these mutants was not calculated and they were only screened for their 
aggregation activity. 
 
Figure 4-15 Hemagglutination assay of the mutant proteins 
1µg of mutant proteins was added in the first well the plate and serial dilutions were made 
(1:2) across the 96 well plate. The plates were observed for the agglutination of the red blood 
cells as seen with the ∆6 PLY. 1ng of WT PLY and 50µl PBS were used as positive and 
negative controls. The small arrows showing the Histagged and tagfree version of ∆6 PLY. 
 
Figure 4-15 showing the different phenotypes as explained in figure 2.5. PLY 
used as positive control was causing lysis and thus the pinkish tinge observed in 
the wells. PBS was not causing any effect and hence a red blood cell pellet was 
seen. The result shows that both the His-tagged and the tagfree PLY (black 
arrows) were showing aggregation phenotype. Therefore the His-tag seems not 
to be causing this aggregation phenotype. Mutants 1, 5, 13, 29.4, 29.5 was 
causing the same aggregation phenotype as cell lysates of the DNA 2.0 Library 
and Mutants 27.10, 35, 44.1 and 44.2 showing the same aggregation negative 
phenotype and clearing well effect as seen with TL mutants in figure 3.8. 
The results suggest that Mutants 27.10, 35, 44.1 and 44.2, where 5 residues were 
inserted in the domain 4 of the toxin were aggregation negative and Mutants 1, 
5, 13, 29.4 and 29.5 where amino acids were inserted in domains 1, 2 and 3 were 
agglutination/aggregation positive.  
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In these hemagglutination assays the same clearing effect of the wells was 
observed in Mutant 27.10, Mutant 44.2 and Mutant 35 as seen with the TL 
mutants. The clearing effect however, was less pronounced in Mutant 44.1. 
These mutations were mapped on the structure and figure 4.16B showing that all 
the aggregation negative phenotype mutants were near or in the well studied 
regions of the toxin whereas the aggregation positive phenotype mutants were in 
domains 1, 2 and 3 (all mutants highlighted in blue). 
Table 4.4 states the aggregation/agglutination type, domains of PLY where these 
5 amino acid insertions had gone and any important information of all the 
purified mutants generated in ∆6 PLY background. 
Table 4-4 Haemagglutination results of the mutant proteins 
 
4.7  Mapping of mutants  
The crystal structure of PLY is not solved and the structure prediction was made 
by using one of the computational tools for structure prediction, named the 
protein homology/analogy recognition engine (Phyre) (Kelley & Sternberg, 2009). 
PLY sequence was submitted to the website and the resulting PLY structure was 
then used to map the 5 amino acid mutations using PYMOL. 
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Figure 4-16 Structural model of PLY generated using computational software for structure 
prediction (Phyre2) and 5 amino acids mutation mapped using PYMOL 
PLY sequence was submitted to the website 
http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index, which predicts the structure of 
the protein based on the closely related solved protein structures. A) In WT PLY back 
ground, 5 amino acid insertions in mutants 1, 6, 19 and 21 are in D4 whereas in mutant 2, 9, 
12 & 13 insertions are in D1, 2 & 3 of PLY. B) In ∆6 PLY background 5 a.a insertion in 
mutants 27.10, 35, 44.1 and 44.2 are in D4 whereas Mutant 1, 5, 29.4 and 29.5 insertions are 
in D1, 2 & 3 of PLY. Undecapeptide, D4 loops 1, 2 and 3 are highlighted in magenta, blue, red 
and green. 
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In Figure 4.16A, insertions in M.1 and M.19 have gone in β- sheets of D4 and 
possibly interfering the subsequent pre-pore and pore formation after initial 
binding, thereby exhibiting decrease in lytic activity (table 4.3) where as in M.21 
the insertions are in the undecapeptide region and therefore this mutant may 
not have accomplished complete binding and thus showing no lytic activity at 
all. Mutant 6 lytic activity is similar compared to WT PLY since the mutation is 
neither in any loops (L1-3) nor the well conserved undecapeptide region and 
therefore might not be interfering with the binding and subsequent pore 
formation. 
In ∆6 PLY background (Figure 4.16B) 5 amino acid insertions in M27.10. 35, 44.1 
and 44.2 are in β-sheets of D4PLY near the undecapeptide region and near the 
loops (L1-3) and presumably hindering the perpendicular orientation of the 
domain 4 loops and undecapeptide thereby showing the agglutination negative 
phenotype. 
4.8   Issues with Random Mutagenesis using Tn insertion 
4.8.1 Purification of the mutant in pET33D4PLY   
The only mutant (Mutant 2) generated in pET33bD4PLY vector backbone was 
insoluble and due to time constraints, purification of this mutant from inclusion 
bodies was not performed. It was assumed that 5 amino acid insertions in this 
region of the protein might have made this mutant insoluble. However, mutation 
at the same position in full length WT PLY (Mutant 6) was soluble and almost 
2mg of the recombinant mutant protein was purified (Table4.1 and 4.2). This 
suggests that five amino acids insertion effect is different in D4PLY gene only 
compared to the full length toxin, which due to its larger structure may have 
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stabilised the mutant protein compared to the smaller domain 4 of the toxin, 
which renders it insoluble. The other reason might be the different amino acids 
insertions in these two mutants. In case of D4 PLY mutant, the 5 amino acids 
were SAAAV and in case of WTPLY, it was CGRRG. 
In both WT PLY and ∆6 PLY in pPAL-7 vector backbone, almost 50% (5 out of 9 in 
∆6PLY and 4 out 8 in WTPLY) of the transposon insertion went in D4 region of the 
gene. D4 is just a quarter (¼) the size of the full length toxin and the reason for 
this high percentage of Tn insertion in D4 is unclear as transposon has no 
specificity for any particular residues. In most instances the transposon inserted 
in the vector back bone as well. 
4.8.2  Purification of insoluble mutants in pPAL-7 vector 
Unlike D4PLY, mostly all the mutants in pPAL-7 vector were soluble although 3 
mutants were insoluble. In these three mutants (Mutant 27.3 in ∆6 PLY 
background and Mutant 25 and 42 in WT PLY background), the transposon was 
inserted between residues 190-198. In Mutant 27.3, the insertion was after 
residue 198, in Mutant 25 it was after 193 and in Mutant 42 after amino acid 
residue 190. Several things were tried (Induction time, amount of IPTG, 
temperature and auto induction media) but it was still not possible to purify 
these mutants. The most likely explanation could be that insertion at this site 
(190-198) might have made these mutants insoluble. These proteins were 
expressed in BL21 (DE3) and after induction both the pellet and supernatant was 
checked for protein expression. The pellet was again resuspended in the wash 
buffer and sonicated as explained in materials and methods section 2.8.3. The 
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supernatant and pellet was checked for presence of PLY by blotting with anti 
PLY antibody.  
 
Figure 4-17 Western blot showing PLY in insoluble fraction 
5 µl each of the sample (pellet and supernatant) was loaded on the gel.  Lane M is the mol wt 
marker followed by M 27.3 ∆6 PLY insoluble fraction (pellet) in lane 1 and soluble fraction 
(supernatant) in lane 2 followed by M 25 insoluble fraction (pellet) and soluble fraction 
(supernatant) in lanes 3 and 4 and M 42 WT PLY insoluble fraction (pellet) and soluble 
fraction (supernatant) in lanes 5 and 6 respectively. There were a band seen in lane 1 and 
lane 3 probably suggesting a dimer formation.  
  
Figure 4.17 shows that all these mutants were expressed but were not folding 
properly and hence were not included in further experiments. These three 
mutants could be co expressed with a protein chaperone (GroES / GroEL) that 
could minimise the chances of protein mis-folding. However due to time 
constraints this was not tried. 
Region (190-198) mapped on the structure showed that these residues were on 
one of the β sheet of toxin and insertions at this place might result in improper 
folding since this sheet is near to the 3 α helices ((α helices undergo transition to 
form β hair pin loops after prepore state(1.8.3)). 
 The random transposon mediated mutagenesis identified the regions where 
mutations can be made. The results of this study also suggest that up to 5 amino 
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acids insertions can be made in various regions of the gene. Previously all the 
studies were either deleting or substituting one to two amino acid residues. 
4.9 Single amino acid addition and substitution in PLY 
using SDM kit 
Mutant 27.10 in ∆6 PLY background has the 5 amino acid insertions between the 
actual cholesterol binding site (459,460) and the undecapeptide (residues 427-
437) and was showing aggregation negative phenotype on a hemagglutination 
assay plate (Table 4.4 & Figure 4.15B). In order to test the sensitivity of this 
region of the toxin to amino acid alterations, a single amino acid (Methionine) 
addition was made rather than five (MRPQR) using the site directed mutagenesis 
kit and its effect was compared with the 5 amino acid insertions (Figure 4.19). 
A single amino acid substitution was also made in ∆6 PLY background in at 
position W433F to observe its effect on the red blood aggregation. This is one of 
the three tryptophan residues in the undecapeptide region of the toxin. It is 
already known from the previous studies in WT PLY that mutation made in this 
residue results in the reduction of the lytic activity of the toxin but its 
aggregation phenotype was not checked (Paton et al., 1991). In a study done in 
PFO, all the tryptophan residues in the undecapeptide region were replaced with 
phenylalanines and resulted in decreased binding and hence reduced lytic 
activity and the same study also suggested Trp436 is responsible for maintaining 
the toxin structure (SekinoSuzuki et al., 1996). The results described here in this 
study also show that insertion of five amino acids at this place in the WT PLY 
back ground also resulted in reduction of the lytic activity of the toxin (Figure 
4.14A). 
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The above mentioned mutations were made successfully in pPAL-7 ∆6 PLY 
tagfree system using the site directed mutagenesis kit and following the same 
protocol as mentioned in section 2.5. 
4.9.1 Purification and characterization 
After the sequencing results were proved to be correct the mutants were 
chemically transformed into BL-21 (DE3) for expression. The proteins were 
expressed and purified following the same protocol as mentioned in section 
2.8.7. The proteins were successfully purified and after purification, proteins 
were analysed on an SDS-PAGE and a Western blot. The proteins were also run 
on a hemagglutination assay plate to observe the aggregation phenotype. 
 
Figure 4-18 SDS PAGE and the western blot of the purified mutant proteins 
A) 10µl of the purified proteins were loaded on the gel. Lane M contains the 5µl protein mol. 
wt marker followed by purified M.27.10 (methionine added after residue 449) followed by 
purified protein ∆6 PLY(W433F) in lanes 1 and 2 respectively. There was a band present in lane 
1 and 2 possible suggesting some contaminants which were removed using Amicon Ultra 
centrifugal filters. 
B) Western blots of mutant proteins. 1µg each of the purified proteins was loaded on the 
gel. Lane M is the mol wt marker followed by M.27.10 ∆6PLY (methionine added after residue 
449) and ∆6 PLY(W433F) in Lanes 1 and 2 respectively A faint band is seen which might 
suggest non-specific antibody binding. 
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The purified mutant proteins were pure and both were recognised by the anti-
PLY antibody. The protein concentration was also measured using nano drop and 
following the same protocol as stated in section 2.8.10. The concentrations of 
purified proteins were 1.38mg for ∆6 PLY (433 W>F) and 0.5mg for M.27.10 
(Methionine added after residue 449). 
The red cell assay for both of these mutant proteins was performed to check 
their agglutination phenotype. The assay was performed according to the same 
protocol mentioned in section 2.9.3. 
  
Figure 4-19 Red cell assay of the purified mutant proteins 
1µg of mutant proteins for ∆6 PLY (433 W>F) and M.27.10 (methionine added after residue 
449) was added in the first well the plate and serial dilutions were made (1:2) across the 96 
well plate. The plates were observed for the agglutination of the red blood cells as seen with the 
∆6 PLY. 1ng of WT PLY and 50µl PBS were used as positive and negative controls. 
 
Figure 4-19 shows that the single amino acid substitution W433F in the 
undecapeptide region results in the aggregation of the red blood cells as seen 
with the ∆6 PLY. This suggests substitution or addition at this place results in the 
reduction of the lytic activity but does not eliminate the aggregation phenotype 
from this mutant; if the amino acid is substituted at this place. This also predicts 
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that reduction of lytic activity does not eliminate the aggregation activity from 
the toxin and this is done by site other than the binding site of the toxin. 
On the other hand addition of 1 amino acid instead of 5 at the same place in 
Mutant 27.10 gives the same non-aggregation phenotype showing that addition 
of even a single amino acid in domain 4 is not tolerable for aggregation 
phenotype. As mentioned earlier, addition of 5 amino acid residues in Mutant 
27.10 were between the cholesterol binding site(s) and the undecapeptide 
region and even a single addition of amino acid residue may perturb the 
structure of the toxin, resulting in non-aggregation phenotype. One more 
possibility could be that presence of second binding site in this region of the 
toxin which may have resulted in this non-aggregation phenotype. It would be 
interesting to compare the results by substituting one single amino acid at this 
place. 
4.10 Discussion 
The five amino acid insertions were successfully added for the first time using 
this technique in D4, ∆6 and WT PLY. A total of 21 mutants were generated 
through this transposon based random mutagenesis. All of them were created in 
pPAL-7 vector with full length PLY except one (Mutant 2), which was made in 
pET33b D4PLY (Table 4.1). The aim of these experiments was to generate a large 
library of mutants to screen for the lytic activity and aggregation activity but 
this technique was unable to generate a large number of mutants mainly 
because a lot of transposon insertion went into the backbone of the plasmid 
rather than the gene. Transposon insertion is non-specific and it should insert at 
any site in target plasmid. 
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Previously, a study was carried out in which random single amino acid 
substitutions were made in the PLY gene and found an interesting region (H156) 
in the N-terminal region of toxin. This residue was shown to reduce the lytic 
activity of the toxin compared to the WTPLY (Hill et al., 1994). The results of 
this study are comparable with the previous studies (Korchev et al., 1998, Berry 
et al., 1995, SekinoSuzuki et al., 1996) and one of the mutants generated in WT 
PLY background (Mutant 21) has 5 amino acids (CGRTW) insertions in the well 
studied undecapeptide region. This mutant has reduced lytic activity as shown in 
figure 4.14. All the mutants listed in table 4.2 were successfully purified by 
using the Profinity eXact protein purification system using the 1 ml Bio-Scale 
Mini cartridge as described in 2.8.7. 
The lytic activity of mutants in WT PLY background (Figure 4.14 A and B) where 
5 amino acid insertions were in the domains 1, 2 and 3 of the toxin were 
comparable with the WT PLY toxin where as the insertions in D4 of the region 
resulted in a decrease in the lytic activity of the toxin apart from one mutant 
(Mutant 6). One probable reason for this might be that Mutant 6 is not inserted 
in any of important well studied region of D4, three small hydrophobic loops (L1, 
L2 and L3) and undecapeptide. 
Similar results were observed with mutants made in ∆6 PLY background where 
all mutants were found to be aggregation/agglutination negative with 5 amino 
acids insertion in D4 whereas all mutants were agglutination/aggregation 
positive with insertions in domains 1, 2 and 3 (Figure 4.15). This suggests that D4 
of the toxin is more sensitive to amino acid insertions compared to domains 1, 2 
and 3. 
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The random single base substitution described by (Hill et al., 1994) also found 
the lytic activity was not reduced much when mutations were made in domains 
1,2 and 3 apart from one mutant (H156Y) which resulted in a 98% reduction in 
lytic activity compared to WTPLY. This results of this study has shown no 
reduction in lytic activity in WT PLY mutants where 5 a.a insertions have gone in 
domains 1-3.  
The result of single amino acid substitution at (W433F) in ∆6 PLY background 
gives the same aggregation phenotype as ∆6 PLY where as single amino acid 
insertion in not tolerable in D4 and gives aggregation negative phenotype in 
Mutant 27.10. If time permitted, it would be very interesting to see how the 
toxin behaves by addition of one single amino acid at position 433 in ∆6 PLY 
background. The result of this will give a clue that whether toxin can tolerate 
single amino acid residue at important regions (Undecapeptide, Loops 1-3).  
The other experiments in future work would be doing the Circular dichroism (CD) 
spectroscopy of the mutant proteins and observing any significant structural 
changes by addition or substitution of the amino acids. Although it is already 
known from the previous work that substituting the cholesterol binding site with 
the glycines or alanines does not result in significant secondary structural 
changes when compared with the WT PFO (Farrand et al., 2009).CD experiments 
will reveal whether PLY mutants made by site directed mutagenesis and random 
mutagenesis result in the structural changes of the toxin. 
One of the mutants in ∆6 PLY with a non aggregation phenotype could also been 
tagged by eGFP and binding observed with the horse blood cells under the 
fluorescent microscope. Since tagging each individual mutant with gfp is labour 
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intensive, alternative approaches could be used including the use of secondary 
labelled fluorescent antibody which can bind to the toxin already bound with red 
cells. The proteins can also be directly labelled with Alexa Flour dye® and then 
treating them with cells and assessing binding by fluorescence microscopy. 
Similarly, FACS experiments could also be done with the eGFP tagged protein or 
secondary labelled fluorescent antibody, to observe the mutants’ binding with 
the red blood cells. The FACS experiments not only can determine the binding 
but can also calculate the extent of binding of different mutant versions of the 
toxins with the red blood cells. 
The toxins can also be used in-vivo experiments to determine their effectiveness 
in eliciting an immune response and compare the response of different versions 
of the toxins.
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5 Screening, characterisation and purification of 
PLY mutants 
5.1 Summary 
The random mutations made by addition of amino acids residues in of PLY did 
not give the clue as to which amino acid/s are responsible for the residual 
binding/aggregation of the red blood cells. However, a mutant with a single 
amino acid substitution made in one of the trypotophan residues in the 
undecapeptide region was still agglutinating red blood cells. This tryptophan 
residue was responsible for the lytic activity of the toxin as described in the 
results of the previous chapter. This result suggested that single amino acid 
substitution in D4PLY of the gene is tolerable as it gives the positive 
agglutination phenotype with W433F ∆6PLY mutant and every single amino acid 
substitution in D4PLY of the gene will eventually track the amino acid/s 
responsible for this residual binding/agglutination. 
In order to identify site/s responsible for this residual binding site, subtle 
changes were made in the D4 of the toxin. A library of mutants was designed and 
purchased commercially from DNA 2.0 (CA, USA). The details of the library are 
explained in this chapter under the heading 5.1.2. To date, no study has carried 
out scanning mutagenesis of every single residue across the whole length of 
D4PLY. 
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The library was screened for the lytic activity in WT PLY background and for the 
agglutination activity in the ∆6 PLY background. The lytic activities of the 
mutants were compared with the studies done previously. 
The screening activity for the aggregation negative mutants done in the ∆6 PLY 
background on a haemagglutination plate revealed an interesting mutant that 
was not causing the aggregation of the red blood cells. This mutant was purified 
and was tagged with eGFP and then again checked on a haemagglutination plate 
with different known protein concentrations. The aggregation/binding activity 
with the red blood cells was further confirmed by fluorescence microscopy and 
fluorescence activated cell sorting (FACS) experiments. 
The cholesterol binding region (TL) in full length toxin was mutated to glycines 
and was tagged with eGFP and an eGFP tagged triple mutant PLY (363,459,460 
LTL > AGG) was also constructed.  
This residue L363A was also checked in the other cholesterol dependent 
cytolysins (CDCs) by doing the protein aligning using the CLC Genomics software. 
5.2 Library from DNA 2.0 
As mentioned earlier, the addition of 5 amino acid transposon based random 
mutations did not reveal the site/s responsible for agglutination of red blood 
cells in ∆6 PLY background. Therefore, subtle mutations by substituting one 
single amino acid were made across the whole domain 4 of the toxin. The library 
was again made both in WT PLY and ∆6 PLY background. 
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In this library every single amino acid residue in D4 of the toxin was replaced by 
alanine and where alanines were present, they were changed to glycines. D4 of 
toxin extends from residues 360 to 471. All these individual residues (360-471) 
were replaced by alanines or glycines and then each individual mutant was 
either re-ligated in ∆6 or WT PLY background.  
 
 
Figure 5-1 Diagrammatic representation of DNA 2.0 library 
A&B) Mutants generated in both ∆6 PLY and WT PLY background. C&D) Mutant 1 of the 
library shown in both WT and ∆6 PLY background.  
  
In total 112 mutants were generated in WT PLY background and the same 
number of mutants were generated in ∆6 PLY background. WT PLY mutants were 
checked for the lytic activity and the ∆6 PLY were checked for the 
aggregation/agglutination activity since the background lysis were removed from 
them. Mutant 1 of the library both WT and ∆6 PLY represents the first amino 
acid residue of D4, asparagine which in the library is replaced by alanine, 
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mutant 2 of the library represents 2 amino acid residue of D4, glycine replaced 
by alanine until the last amino acid residue of D4 which is aspartic acid, 
replaced by alanine. 
The mutants were made in pJexpress 401 vector and a His tag attached to the N-
terminal of every mutant. The results of experiments described in previous 
chapters show that His tag has no effect on the residual binding/aggregation of 
the red blood cells. The promoter attached to the vector is T5 which is IPTG 
inducible and can work in any E.coli host strain. All mutants received were 
stabbed in a 96 well plates with cultures grown in E.coli strain (DH10β) with 15% 
glycerol.  
5.3 Screening of mutants for haemolytic activity 
All WT PLY mutants of library were screened for the haemolytic activity. The 
assay was set up according to the protocol as stated in materials and methods 
section 2.9.3. 
Due to time constraints 112 WT PLY mutants were not purified instead the lytic 
activities of the individual mutants were screened by using the cell lysate 
(standardised E.coli cell lysate with recombinant PLY). The concentration of PLY 
in all the cell lysates of the library was assumed to be equal as all the 
experiments were carried using same technique. If time permitted, 
concentration of recombinant proteins in cell lysate and hence specific lytic 
activity in mg/ml could be measured by setting up an ELISA and/or doing a 
western blot. However, the lytic activity (HU/ml) calculated in this study from 
the cell lysates were comparable with the results of the studies done previously 
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with purified recombinant mutant proteins. Cell lysate of WT PLY from library 
was used as a positive control and PBS only was used as a negative control. 
Unlike the purified proteins where specific haemolytic activity was calculated 
and expressed as percentage lysis, the lytic activity of the individual mutant was 
measured using the end point and every mutant of the library was compared to 
the end point from the lysate of the WT PLY. 
The detail of the every single mutant in the library and their haemolytic 
activities are given in the table below. There are five alanine residues at 
positions (337, 370, 396, 406 and 432) in domain 4 of the toxin so all of them 
were replaced by glycines. 
 
 
 Table 5-1 Library of mutants from DNA 2.0 
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5.3.1 Haemolytic assays titres measured as end points 
The end point is measured in Haemolytic units (HU) per ml (HU/ml) of the 
sample. The reciprocal of the dilution at which end point is reached is 
calculated as e.g. the first well has 10µl of the sample and 90µl of PBS which is a 
10 fold dilution, from this well 50µl is taken and added in the subsequent well 
and 50µl DTT is added to the first well resulting in a 20 fold dilution.  
50µl of red blood cells was again added and finally 50µl of PBS was added before 
centrifuging the plate which makes the final dilution in the first well to 80 fold. 
This dilution is only in a total volume of 200µl and since the dilution is to be 
calculated in HU/ml, so we multiplied it by 5 to make the dilution per ml, which 
is 1/400 for the first well. This means well 2 represents 1/800 dilution, well 3 
will be 1/1600 dilution and well 4 will be 1/3200 dilution and so on. Therefore if 
the end point was well 4 the haemolytic activity would be 3200 HU per ml of the 
sample as shown in the table below. 
 
Table 5-2 Haemolytic titre end points (HU/ml) of wells 
 
The end point calculated for WT PLY lysate was well no 9 and therefore the lytic 
activity was calculated to be 102400 (HU/ml) (Figure 1). All mutants in the 
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library are compared with this value. The haemolytic assay plates for screening 
the undecapeptide region of WT PLY library are shown below. 
  
Figure 5-2 Haemolytic assay of Cell lysate from DNA 2.0 library 
10µl of cell lysate of mutant proteins was added in the first well the plate and serial dilutions 
were made (1:2) across the 96 well plate. The plates were observed for the lysis of the red blood 
cells.  10µl cell lysate of WT PLY and 50µl PBS were used as positive and negative controls. 
WT PLY showing lysis of red blood cells and PBS showing no lysis.   
 
Figure 5.2 result showing end point (well 9) of WT PLY lysate in the haemolytic 
assay plate and hence the lytic activity calculated as 102400 HU/ml. In other 112 
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mutants of the library the lytic activity was either at end point 9 or less and 
none of the mutants had 0% lytic activity. All residues of the undecapeptide 
regions are represented by mutant numbers (68-78) of the library. Only three 
mutants in the library were found to have end points at well 2 on the haemolytic 
plate and these were the three tryptophan residues 433, 435 and 436 (Mutant 
74, 76 and 77 of DNA 2.0 library) of the undecapeptide region (Figure 5.2). None 
of cell lysates of the other mutants in the library had lytic activity equal to less 
than these mutants. Mutant 74, 76 and 77 are the three tryptophan residues in 
the undecapeptide region and have been known to reduce the lytic activity of 
the PLY in studies done previously (Korchev et al., 1998). 
All residues in the undecapeptide region are less lytic as compared to WT PLY 
lysate. The undecapeptide region in PLY starts from residue 427 and end at 
residue 437. The mutant 68 in the library represents the first residue Glutamine 
of undecapeptide region and mutant 78 of the library represents last residue 
Arginine of the undecapeptide region. 
The lytic activity measured as end points for all the mutants in the library are 
collectively shown in the figure 5.3 below. The % lytic activity of each individual 
mutant compared to the WT PLY of the library is shown in the figure 5.4. 
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Figure 5-3 The graph showing screening results of cell lysate from DNA 2.0 mutant Library 
The X axis on the graph showing the end points wells of the Haemolytic assay plate and Y 
axis showing the number of mutants for each end point.  
 
The screening results show that the end point was well 8 for 42 mutants (37.5%) 
out of 112 where as 26 mutants (23.2%) have same end point (Well No 9) as WT 
PLY. This means that more than 60% of the mutants in D4PLY have lytic activity 
similar to or 50% in comparison to WT PLY when single alanines substitutions are 
made. The total number of mutants having end points at well 5 or below was 14 
and represents less than 12.5% of the total number of mutants in the library. The 
total number of mutants having end point well 6 and 7 were 30 and represents 
26.6% of the total mutants. 
 
   
Figure 5-4 Lytic activity of WT PLY mutants form DNA 2.0 Library.X-axis on all the graphs showing mutant’s name and Y axis is% lytic activity compared to 
the WT PLY. All important regions are highlighted. Loop1, 2, 3 and undecapeptide region are highlighted as pink, blue, green and brown respectively. 
Residue 363 is highlighted as red.
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As expected figure 5.4 shows that all well studied important regions of the toxin 
have a significant drop of % lytic activity as compared to the WT PLY. These 
important regions are highlighted with different colours. The individual lytic 
activities of the highlighted important regions (Undecapeptide region and three 
hydrophobic loops L1, L2 and L3) of the toxin when replaced by alanines are 
represented in the figure 5.5 below.  
 
Figure 5-5 Haemolytic activity comparisons of mutant proteins with single alanines 
substitutions with WT PLY 
The X-axis showing the amino acid residues and Y axis represents the lytic activity in 
haemolytic unit per mg (HU/ml). A) The lytic activity of cell lysate of undecapeptide region 
(427-437) with WT PLY lysate. B) Comparison of lytic activity of cell lysate of loop 1, C) Loop 
2 and D) Loop 3 of D4PLY with WT PLY lysate. 
 
Figure 5.5 shows that the two amino acid residues (TL) or Cholesterol binding 
motif identified by Farrand et al., 2009 in loop 1, responsible for initial binding 
with the membrane cholesterol mentioned were represented by Mutant 100 and 
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101 of the DNA 2.0 library. The end point calculated was well No 5 and 3 and the 
haemolytic activity in (HU/ml) for these mutants were 6400 and 1600 
respectively. This activity is less than 7% and 2% when compared with WT PLY 
lysate. The lytic activity of cell lysate of the cholesterol binding motif 459(T>A) 
and 460(L>A) was more than the tryptophan residues of the undecapeptide. 
A study conducted has shown that substituting L460D removes toxin’s cytolytic 
activity whereas above results shows partial lytic activity when substituted with 
alanine (Hu et al., 2013). Farrand et al., 2009 substituted both these residues 
with glycines and found the lytic activity <0.02% compared to WT PLY. In this 
study every single amino acid in D4 of the toxin was substituted with alanines 
and lytic activity compared with WT PLY lysate. A study done recently has shown 
that PLY(L460E) and PLY(L460G) have different effects on oligomerisation activity of 
the toxin where the former renders toxin unable to oligomerise and latter has no 
effect. However, both the mutant versions have decreased lytic activity as 
compared to the WT PLY (PLY(L460E) is non-lytic even at 480nM where as PLY(L460G) 
is lytic at this concentration and non-lytic at concentrations below 8nM) (Taylor 
et al., 2013). The above results suggests that substituting different amino acid 
at same position gives different lytic and oligomerisation activity which might 
explain that difference in lytic activity in our results compared to previous 
studies (Farrand et al., 2009, Hu et al., 2013). It will be interesting to make 
double substitutions with alanine and/or any other amino acids in both the 
cholesterol recognition motifs and measuring the lytic activity of the toxin. 
The hydrophobic loop1 consists of residues GTTLYP from position 457-462 in PLY 
and in the library represented by mutants (98-103). All the residues in loop 1 
have shown a reduction in lytic activity up to 12.5 apart from proline where the 
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reduction is 25%. This is in line with a study done previously  which showed 
proline (462) substitution with serine resulted in 27% (Owen et al., 1994). 
Loop 2 consists of residues HSGAYVA from position (367-373) and represented by 
mutants (8-14) of the library. These results show a huge reduction in lytic 
activity in residues 367 and 371 (histidine and tyrosine). In a previous study 
carried by Berry et al.,1995 showed that histidine when substituted with 
arginine resulted in a 0.02% reduction in lytic activity and in this study when 
substituted with alanine resulted in 6.25% reduction in lytic activity (Berry et 
al., 1995). The lytic assay of residue PLY(A370G) in loop 2  showed no reduction in 
lytic activity as compared to WT PLY which is in line with a study done recently 
and showing recombinant PLY(A370G) has same lytic activity as compared to WT 
PLY (Taylor et al., 2013).  
Loop 3 consists of DLTAH at positions (403-407) and represented (Mutant 44-48) 
of DNA 2.0 library. These results show a decrease in lytic activity in the last 
three residues with the highest reduction observed in threonine at position 405. 
The lytic results in the undecapeptide region show that apart from cysteine 
residue at 428, all other mutants showed a decrease in lytic activity up to 85% or 
more when compared with the WT PLY lysate. The highest lytic activity observed 
was for cysteine which was 51200HU/ml and lowest was for all tryptophan 
residues of the undecapeptide at 800HU/ml.  
The results of the previous experiments also suggest that cysteine has no 
involvement in binding or insertion of the toxin into the membrane and when it 
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was substituted with alanine retained its haemolytic activity (Saunders et al., 
1989). 
The above results also show that some of the residues in loop 2 and 3 (370, 403 
and 404) when substituted to alanines seems to have no effect on the lytic 
activity of the toxin. The cell lysate of these residues have same lytic activity as 
the WT PLY lysate. None of the mutants with substitution in the undecapeptide 
or loop 1 have lytic activity equal to WT PLY.  
5.4 Screening of library for hemagglutination negative 
mutants 
The 112 mutants in ∆6 PLY background were screened for hemagglutination 
negative mutants. The 112 mutants were screened on a 96 well round bottom 
plate as described in the materials and methods section 2.9.3 and were observed 
for hemagglutination activity. 
Due to time constraints it was not possible to purify the 112 mutants of the 
library so the cell lysates (standardised E.coli cell lysate with recombinant PLY) 
were checked for hemagglutination activity. Purified ∆6 PLY and ∆6 PLY lysate 
was used as positive control whereas PBS only was used as negative controls.  
The results of hemagglutination assays were noted as positive or negative and 
were not quantitatively measured since the aim of these experiments were to 
identify agglutination negative mutants.  
50µl of the cell lysate of the mutants was used to measure agglutination activity 
in the plate. A typical hemagglutination assay plate is shown below in figure 5.6. 
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Figure 5-6 Screening of DNA 2.0 library lysates (∆6 PLY background) for hemagglutination 
activity 
50µl of cell lysate of mutant proteins form DNA 2.0 library was added in the first well of the 
96 well round bottom  plate and serial dilutions were made (1:2) across the 96 well plate. The 
plates were observed for the haemagglutination of the red blood cells. 1µg ∆6PLY, 50µl cell 
lysate of ∆6PLY was used as positive control and 50µl PBS was used as negative controls. 
All different phenotypes are explained in figure 2.5  
 
All mutants in the library apart from Mutant 4 caused the agglutination of the 
red blood cells. The same mutant L363A (Mutant 4) has a reduced lytic activity 
(12.5%) in WT PLY background (Figure 5.4). 
The cholesterol binding motif when replaced individually with alanines (T459A 
and L460A) was agglutination positive suggesting that these residues do not 
account for the agglutination property of the toxin but substituting both residues 
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with glycines do not result in appreciable agglutination on 96 well plate. 
However, some aggregation of red cells was seen with the fluorescence 
microscopy (Figure 3.11). It will be interesting to compare the agglutination 
behaviour on a hemagglutination plate by substituting both these TL residues 
with alanines. 
The only agglutination negative mutant, Lysine at position 363 when changed to 
alanine PLY (L363A) did not cause red blood cells to aggregate. This mutant was 
further purified and the purified protein was again checked for agglutination 
activity on a 96 well round bottom plate. This mutant (L363A) was giving the 
same clearing effect as observed with cholesterol binding motif in figure 3.8. 
In WT PLY background, the same amino acid substitution (L363A) resulted in 
87.5% reduction in lytic activity compared to WTPLY lysate (Figure 5.4 
highlighted in red) which may suggest its role in binding to red blood cells.  
5.5 Characterisation and purification of the agglutination 
negative mutant ∆6PLY(L363A) 
5.5.1 Purification of mutant by NAC and AEC 
The agglutination negative mutant PLY(L363A) was subjected to a two step 
purification process, first by immobilized affinity chromatography and then 
further purified by anion exchange chromatography (AEC). The collected 
fractions after AEC were analysed on an SDS-PAGE with a known protein 
molecular weight marker (Figure 5.7). 
Chapter 5  178 
The purified proteins concentration was measured as described in materials and 
methods section 2.8.10. The concentration of the purified protein was measured 
as explained in section 2.8.10 and is found to be 0.375mg. The purified protein 
after AEC was dialysed at 4oC with 2 litres pre-chilled PBS buffer and saved at -
80oC. 
 
 
Figure 5-7 SDS-PAGE of ∆6PLY(L363A) after AEC Purification 
Lane M contains 5µl of the mol. wt .marker SeeBlue® Plus2, followed by 10µl recombinant 
∆6 PLY (L363A) after AEC purification in lanes 1-3. 
 
The purified protein was further checked for its agglutination ability on a 96 well 
round bottom plate. 
5.5.2 Hemagglutination assay of the purified protein 
The purified protein mixed with red blood cells at concentration up to 5µg was 
analysed on a 96 well plate to observe whether it still agglutinates the red blood 
cells. 
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Figure 5-8 Hemagglutination assay of the purified mutant protein ∆6PLY(L363A) 
1, 2.5 and 5µg of the mutant protein was added into the first well of rows and serial dilutions 
were made (1:2) across the 96 well plate. The plates were observed for the haemagglutination of 
the red blood cells.  
 
Figure 5.8 showing hemagglutination was not observed at adding 1, 2 and 5µg of 
the purified protein directly into the first well of the corresponding rows. This 
result confirmed our previous results done with the cell lysate of the mutant 
which was agglutination negative. This suggests that this residue might be 
responsible for causing the agglutination when the lytic activity was toxin is 
abolished by deleting the residues at position 146 and 147 (alanine and 
arginine).  
The results with the purified protein suggests that cell lysate and purified 
protein have similar agglutination effects when run on a 96 well round bottom 
plate. The clearing effect of wells was also observed in the assay and increased 
with the increase in the concentration of the toxin. 
To further confirm the results by fluorescence microscopy and fluorescence 
activated cell sorting, eGFP version of the mutant protein was required so that 
the binding and the agglutination can be observed.  
The pET33beGFP ∆6PLY construct was used as template to make mutant versions 
by site directed mutagenesis using the SDM kit following the protocol mentioned 
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in section 2.5.3. For negative control eGFP only was used while purified eGFP ∆6 
PLY was used as positive control. 
5.6 Purification and characterisation of eGFP tagged 
mutants in pET33bvector 
The site directed mutagenesis was done using the SDM kit and the sequencing 
results of all the mutants were checked before expression and purification. All 
recombinant proteins have a six histidine tag attached to it and were subjected 
to a two step purification process, first by immobilized metal affinity 
chromatography then by anion exchange chromatography. 
5.6.1 Purification of eGFP-linked PLY mutants 
The fractions of the purified proteins from AKTA PrimeTM were run on an SDS-
PAGE gel (Figure 5.9) and their predicted molecular weights were confirmed 
with the known molecular weight protein marker on the gels. The predicted 
molecular weight of all the proteins is 83kDa. 
5.6.2  SDS-PAGE and western blot of the purified proteins 
The purified recombinant proteins were further analysed by Western Blotting. 
1µg of the purified protein was loaded on the gel against the known molecular 
weight protein marker SeeBlue® Plus2. 
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Figure 5-9 SDS PAGE and western blot of eGFP-PLY linked proteins 
A and B Lane M contains 5µl of the mol. wt .marker SeeBlue® Plus2, followed by 10µl 
recombinant proteins eGFP∆6PLY, eGFP∆6PLY(L363A), eGFP∆6PLY(T459G L460G) and 
eGFP∆6PLY(L363A T459G L460G) in lanes 1-4. There were some bands seen on western blot (5.9B) 
showing some background and were not appreciable on the SDS-PAGE. 
 
Figure 5.9 showing some background on the western blot which is not 
appreciated on the SDS-PAGE. 
5.6.3 Concentration of the purified proteins 
The concentrations of the purified proteins were measured and are stated in the 
table 5.3. 
Table 5-3 Concentration of the purified protein 
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5.7 Cell binding of mutant protein by FACS 
The cell binding of the mutant proteins with red blood cells were measured by 
using fluorescence activated cell sorter (FACS). The experiment was carried out 
following the same protocol as explained in the materials and methods section 
2.9.5. The gates FL1+ and FL-ve were drawn based on the controls (eGFP with 
red blood cells and red blood cells in PBS) to minimise the back ground auto 
fluorescence. 
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Figure 5-10 FACS showing binding of mutant proteins with horse red blood cells 
X-axis is the fluorescent channel (FL1) set on log scale and Y axis is the number of events 
measured which in this case is 50,000. 1400nM of the eGFP only (red) eGFP ∆6 
PLY(L363A.T459G.L460) (pink), eGFP ∆6 PLY(T459G.L460) (green),  eGFP ∆6 PLY(L363A) (blue) and eGFP 
∆6 PLY (black) were analysed for binding with red cells based on shifting of the graph to the 
right side, in case of positive binding. The figure was drawn using the flow jo software.  
 
As expected there is a clear shift in the graph on the right in case of eGFP ∆6 
PLY showing maximal binding. A second peak can also be seen with eGFP ∆6 PLY 
at 104 on the X-axis similar to eGFPD4PLY (Figure 3.13 first results chapter) but 
in this case it is off scale.  
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The cell binding has reduced considerably in all the mutant proteins when 
compared to eGFP ∆6 PLY. However, protein binding to red blood cells triple 
mutant eGFP ∆6 PLY(L363A.T459G.L460) is similar to the control eGFP only 1400nM 
whereas the there is slight shift on the right side for both the mutant proteins 
eGFP ∆6 PLY(L363A)  and eGFP ∆6 PLY(T459G.L460) suggesting some residual binding of 
cells with the mutant proteins. These results also suggest that residue 363, 
leucine when replaced with alanine can reduce the binding of PLY to red blood 
cells comparable to the TL mutant. This is evident from the results where the 
shifting of peak to the right side on the X-axis in case of L363A is similar to TL 
mutant. 
On a haemolytic assay plate the same mutant (L363A) resulted in a lytic activity 
reduction of more than 85% compared to WT PLY suggesting its role in binding 
along with the cholesterol binding mutant. 
The results were further confirmed by quantitatively measuring the binding of 
proteins with the red blood cells using the fluorescent Index (FI). The FI was 
measured as explained in the first results chapter under section 3.7. The FI of all 
the mutant proteins concentrations were compared with corresponding controls. 
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Figure 5-11 Fluorescent index (FI) of the mutant proteins 
The graph showing the comparison of 1400nM of the three mutant proteins compared with 
control. Statistical significance was determined by using One way anova using Dunnet’s 
post test to determine the significance between different groups compared with the control. 
The P value <0.05 was considered to be significant. The * symbol shows that P value is 
significant (* = p<0.05). FI is calculated multiplying the % of fluorescent cells with the mean 
geometrical fluorescence. 
 
Figure 5.11 illustrates that there is no significant difference between the eGFP 
only and eGFP ∆6 PLY(L363A.T459G.L460) at 1400nM of the protein concentration. The 
other two mutant ∆6 PLY(T459G.L460) and ∆6 PLY(L363A) differ significantly when 
compared with the controls. This suggests that the residue 363 was responsible 
for this residual binding seen with the TL mutant and mutating this residue 
resulted in the complete loss of binding of protein with the red blood cells. 
L363A mutation causes a significant decrease in the binding of protein with the 
red blood cells  compared to eGFP ∆6 PLY (not shown in figure 5.11) which might 
explain the reduced lytic activity of the mutant L363A (12.5%) in the WT PLY 
background compared to the WT PLY. 
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The t-test was used to compare the other two concentrations (14 and 140nM) of 
the mutant proteins with the corresponding controls. There was no significant 
difference at 14nM of all mutant proteins when compared with 14nM of eGFP 
only whereas significant differences were observed at 140nM of the protein 
concentration except the triple mutant eGFP ∆6 PLY(L363A.T459G.L460) where no 
significant difference was observed when compared with the controls (data not 
shown). These results are in line with the previous results where no significant 
difference was observed between TL mutant at 14nM where as at 140 and 
1400nM the binding differ significantly when compared with the controls at the 
same concentration. 
The mutants were further analysed for their agglutination activity on forward 
scatter (FS Linear) and forward scatter area (FS Area). Unlike the previous 
results chapter where the cell population was identified on the peaks this time a 
more quantitative approach was taken by drawing a gate (black line) around the 
control eGFP only 1400nM. The same gate was applied on all the observations 
and cell population within and outside the gates recorded. The cell population 
lying within the gate was marked as single cell and in case of negative control 
was 98.3%. 
As already shown in figure 5.10 that the increase in binding resulted in the 
shifting of the graph towards the right and two peaks indicating more than single 
cells where as in case of forward channel (linear vs. Area), the cells well spread 
out on Y axis (FS-area) were labelled as more than single cells. The single cells 
were present in drawn polygonal gate or area surrounding it. 
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Figure 5-12 FACS results showing red blood cell population (single/multiples) on forward 
scatter channel 
X axis the forward scatter channel (Linear) set on the linear scale and Y axis is the Forward 
scatter channel (area) also set on linear scale. 1400nM of the protein concentration was 
used. eGFP only and eGFP ∆6 PLY were used as negative and positive controls. Black line 
represents polygonal gate drawn around the single cells. The percentage of single cells are 
given for each individual proteins. 
 
 Figure 5.12 showing that in negative control (eGFP only) more than 98% of the 
cell population are in the gate (single cells) where as in the positive control 
eGFP ∆6 PLY than 36.6% of the population are more than single cells. The cells 
have well spread around the Y axis (FS area) in case of positive control. The 
results of eGFP ∆6 PLY(L363A) and eGFP ∆6 PLY(L363A.T459G.L460) (A&B) were similar to 
the control eGFP 1400nM (C)  and the same cell population 98% was seen inside 
the drawn gate. In case of eGFP ∆6 PLY(T459G.L460), there was more population of 
cells (blue dots) outside the drawn gate compared to the A & B. The single cell 
population inside the gate was 96% which is 2% less as compared to the controls 
and the other two mutants. 
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5.8 Fluorescence microscopy 
The fluorescence microscopy was done to assess the binding of proteins with the 
red blood cells.  
  
Figure 5-13 Fluorescence microscopy images showing eGFP tagged recombinant proteins 
binding 
The binding of different proteins versions with red blood cells was analysed. (A,B) eGFP 
only with red blood cells in PBS in DIC and GFP.(C) eGFP∆6PLY(T459G.L460G) binding with red 
blood cells in DIC. (D&E) eGFP∆6PLY binds and forming clumps with red blood cells as 
seen DIC and GFP. (F) eGFP ∆6 PLY(L363A) binding in DIC. GFP mode of mutant proteins are 
not shown as the binding was not picked up by this channel. GFP only and eGFP∆6PLY 
were used as negative and positive controls. 
These results are in line with the previous findings with eGFP ∆6 PLY forming 
large clumps of red blood cells and aggregation pattern is similar to the pattern 
observed in purified eGFPD4PLY as seen in the chapter 3 (Figure 3.11).  
From the above and previous results (Figure 3.11) it is observed that binding of 
mutant proteins with red blood cells is not readily picked up the green 
fluorescence (gfp) channel of the microscope. The result of mutant proteins 
under gfp channel of the microscope is similar to eGFP only. It might be that 
binding is significantly reduced and not picked up by the gfp channel. The FACS 
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analysis also predicts a small difference (2%) between eGFP and TL mutant as 
shown in figure 5.12.  
5.9  Other Cholesterol dependent cytolysins (CDCs) 
The above results show that residue 363 (leucine) in domain 4 is an important 
residue in PLY responsible for significant residual binding of the proteins with 
the red blood cells. The presence of this residue was checked by doing a protein 
alignment across other members of CDCs using CLC GenomicWorkbench3 
software. 
 
Figure 5-14 Sequence alignment of member of CDCs using CLC genomic software 
The sequences were downloaded from the NCBI website were aligned by using the CLC 
genomics workbench 3.7.1  
 
The above alignment shows the residue leucine highlighted with black line, 
responsible for residual binding and or/aggregation of red blood cells is present 
in almost all members of CDCs aligned, apart from Perfringolysin (PFO) and 
Streptolysin O (SLO) which have isoleucine at this same position. 
Chapter 5  190 
∆6 Suilysin (SLY) has leucine at the same position and gives the same aggregation 
phenotype as ∆6 PLY (Dr Carol McInally, Personal communication, 2012). PFO 
and SLO naturally have isoleucine instead of leucine but PFO is lytic so this 
aggregation pattern cannot be observed in WT PFO. However, the effect could 
be observed in these two toxins by abolishing their lytic activity. 
The L363A mutation was also mapped using PYMOL software and is shown in the 
figure 5.15. 
 
Figure 5-15 Structural model of PLY generated using Phyre2 and highlighting residue 
responsible for aggregation along with loops and undecapeptide region 
PLY structure is predicted based on the solved crystal structures of the proteins already 
present in the protein data bank using computational software programme Phyre2. Residue 
363 (leucine) causing agglutination is highlighted as red along with the 3 loops and 
undecapeptide region. The above diagrams were drawn using PYMOL software The region 
having mutation L363A was zoomed again with the three loops (L1, L2, L3) and the 
undecapeptide region which are highlighted with blue, red, green and magenta. The TL 
residues in loop1 (zoomed picture) are highlighted in yellow. 
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Figure 5.15 shows that L363A mutation is on the first β sheet of D4 and close to 
the hydrophobic loop 2 of D4PLY. Mutating L363A might interfere with the 
subsequent binding after the initial attachment of the cholesterol recognition 
motif (TL) with the membrane. 
The undecapeptide and loops (1-3) are assumed to anchor the toxin in the 
perpendicular orientation after binding so mutation in this residue close to loop 
2 might have been affected and resulted in either the abolishment of prepore 
oligomerisation and/or pore formation (Ramachandran et al., 2002). One 
possible explanation is that L363A mutation might be interfering with the 
cholesterol docking after the initial binding and hence reduction in lytic activity. 
5.10 Discussion: 
A total of 112 mutants were screened for the lytic activity in WT PLY background 
through this alanine scanning mutagenesis approach. To our knowledge, no 
previous study has scanned the whole D4 of PLY but instead has substituted 
important residues in D4PLY (L1-3 loops and undecapeptide). In this study cell 
lysates were assessed for lytic activity and although this technique is not optimal 
but still gives us some clues as to which mutants might be important for lytic 
activity of the toxin. This alanine scanning mutagenesis has been done in a study 
done recently in LLO showing in-vivo effect of single substitution on the 
virulence of the organism. Their study was able to identify a number of 39 novel 
residues in LLO previously uncharacterised (Melton-Witt et al., 2012). The 
results of this study has also identified some mutants (4, 6, 80, 83, 84, 86, 91 
and 97) and (81, 92 and 94) not residing in L1-L3 and undecapeptide region and 
reducing the lytic activity by 87% and more than 90%. However, further 
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experiments needs to be conducted with these mutants and lytic activity 
measured using purified recombinant proteins. 
The haemolytic assay results in the study are comparable with the studies done 
previously. The haemolytic activity of tryptophan residues in the undecapeptide 
region in our study is less than 1% of the WT PLY and the reduction in lytic 
activity has also been reported in the studies done previously (Korchev et al., 
1998, SekinoSuzuki et al., 1996). In the same study, residue 428 cysteine when 
replaced with glycine and serine resulted in the reduction of haemolytic activity 
to 3 and 25% of the WT PLY. However, in this study the activity was reduced to 
50% and this is supported by studies done by Soltani et al., 2007 which suggests 
that modification at this residue does not affect the binding in PFO but rather 
blocks the subsequent tryptophan residues insertion (Soltani et al., 2007). 
Cysteine 428 replaced with alanine had no effects on the lytic activity and 
binding with the red blood cells was also shown by a study carried by Saunders 
et al., 1989 which showed similar effects as WT PLY (Saunders et al., 1989). The 
same mutation C428A made by another study also found no difference in lytic 
activity compared to the WT PLY (Oloo et al., 2011). 
The residue 385 (aspartic acid) known to be involved in activating the 
complement without affecting the haemolytic activity was shown by study done 
by Alexander et al., 1998 and the results of this study also showed no difference 
in the lytic activity when this residue is replaced with alanine (Alexander et al., 
1998). 
The % binding activities in D4PLY loops 1, 2 and 3 in PFO when replaced with 
alanines were assessed by Farrand et al.,2009 and found that in PFO, residues 
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(T489A, Y492A) in loop 1, (S399A, V403A) in loop 2 and (D434A) in loop 3 have 
50% or more binding when compared with WT PFO and the results of this study 
also suggests the same residues have haemolytic activities ranging from 12.5 to 
100% (Farrand et al., 2009). Their study also reported 100% or more binding with 
residue A401G in loop 2 and this study also found the lytic activity of the same 
residue to be 100%. 
The histidine substitution with arginine in loop 2 resulted in reduction of lytic 
activity by 0.02% in a study done by Berry et al., 1995 whereas this study has 
shown reduction by 6.25% when replaced with alanine which might be due to the 
different nature of residues; arginine being polar basic and alanine non-polar 
hydrophobic (Berry et al., 1995). 
The role of the C-terminus in binding was also observed which showed that 
truncated versions with 6 and 11 amino acid deletions in the C-terminal resulted 
in the loss of more than 99% of the haemolytic activity and a reduction in 98% 
binding compared to the WT PLY. The results of this study also shows a reduction 
of 12.5 to 50% in the lytic activity when these 11 residues were individually 
substituted with alanines (Owen et al., 1994). 
Recently, a study conducted to evaluate cholesterol-depended binding of 
different mutants of PFO (L491C, A401C, V403C and A437C). PFO(L491A) (one of 
the cholesterol binding motifs in PFO) and PFO(V403) (in loop 2) requires more 
cholesterol concentration to trigger binding. Their results depicts that D4 
residues located around the conserved cysteine in the undecapeptide region 
modulates the cholesterol threshold content required for toxin membrane 
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interaction. They also suggested that residues other than TL residues might also 
be involved in binding and requires further investigation. (Johnson et al., 2012). 
The hemagglutination assays of the 112 mutants in the library revealed residue 
363 responsible for the residual binding/agglutination of the red blood cells and 
this residue lies in close proximity of loop 2 of the D4 of the toxin. This 
substitution might have several consequences including structural perturbation 
of the loop-1 resulting in loss of binding. Another possible explanation could be 
that this mutation is affecting the conformational change required after the 
initial binding of the TL residues since mutation at this residue only resulted in 
the reduction of the lytic activity of the toxin by 87.5%. The involvement of 
residues (in and/or near loop 2) in binding with the membranes has also been 
suggested by a recent study done in LLO (Melton-Witt et al., 2012). 
Further evaluation of this residue for binding can be done by running cholesterol 
binding assays and substituting residue 363 with any other charged residue 
and/or glycine and by comparing the aggregation and lytic effect of the toxin 
with alanine substitution. 
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6 Concluding remarks and future perspectives: 
The primary aim of the project was to locate site/s in ∆6 PLY responsible for 
aggregating/agglutinating red blood cells in order to further improve ∆6 PLY as a 
vaccine candidate. 
The flow chart below explains how the above explained aims were achieved 
during the progress of this study. 
Mutant generated in D4PLY by substituting cholesterol binding motifs (Farrand et 
al., 2009) TL>GG by SDM (pET33bD4PLY(TL>GG)) (Chapter No 3).  
 
Mutants made in full length toxin (WT & ∆6 PLY) backgrounds by RM. The 
mutants generated in WT PLY were checked for their lytic activity and ∆6 PLY 
were analysed for their aggregation/agglutination behaviour (Chapter 4). 
 
ASM approach was taken and mutants were devised again by mutating every 
single residue in D4PLY by alanines and/or glycines in both the (WT & ∆6 PLY) 
backgrounds (Chapter 5). 
Mutants generated in ∆6 PLY background were tested and eventually the amino 
acid (L363A) responsible for this activity was located. L363A substitution 
completely abolished the aggregation activity associated with ∆6 PLY at 
concentrations up to 5µg. 
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The crystal structure of PLY has not yet been solved and identification of the 
residue was done by screening the library of all individual residues present in the 
D4 of the molecule. The 363 residue in PLY responsible for agglutination of red 
blood cells was mapped on PYMOL software and its position, orientation of side 
chain and distance (363 and TL) was measured. 
 
Figure 6-1 Showing orientation and distance of residues L363 and L460 (one of the 
cholesterol binding motifs) in PLY 
PLY model was made using computational software for protein prediction PHYRE2. The 
side chain distances between residues 363 and leucine 460 on loop 1 is measured. L363 and 
L460 are highlighted as red and green The figure was generated by PYMOL software. 
 
Figure 6.1 show that 363 residue lies near the C-terminal on one of the first β 
strands (near loop 2,) of domain 4 PLY. 363 and TL residues are not right next to 
each other and distance of side chains between residues ((363L and 460L, (one 
of the cholesterol binding motif)) measured was found to be 23.1 Å. The 
distance between the residues and the position of side chain suggest that it may 
not be interacting with the red blood cells at the same time. Although, the side 
chain of L363 is pointing inwards, it could be that this residue is not directly 
accessible and thus not involved in initial binding but conformational change of 
molecule after initial binding with TL residues could result in the subsequent 
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binding with other red blood cells hence causing agglutination by this second site 
as hypothesised in the model (Figure 3.18). In WT PLY background, L363A 
substitution resulted in 87.5% reduction of lytic activity compared to the WT 
PLY. Another explanation might be that this residue is second binding site as 
suggested in the model (Figure 3-18) and is interacting with mannose rather than 
cholesterol since a study done recently have shown that isolated D4 binds to 
mannose (Lim et al., 2013). However, this requires further investigation. 
A study conducted in LLO suggests residues flanking loop2 may have some 
underappreciated role in binding with the membranes (Melton-Witt et al., 2012). 
Circular dichroism (CD) experiments can be done to evaluate any difference in 
secondary and tertiary structure of the mutant compared to the WT PLY. Studies 
done previously have shown that up to double amino acid substitutions in PLY 
gene is well-tolerated and does not result in any perturbation of the toxin 
molecule (Farrand et al., 2009). 
In this study for the first time in PLY gene, 5 amino acid insertions were made by 
RM and it was well-tolerated. These mutations gave a clue as to which regions 
are important in terms of structure and biological activity of the toxin. The 
haemolytic activity of the purified proteins was similar when amino acids were 
substituted/added and is comparable to the previous studies. However, a single 
amino acid addition in C-terminal region of D4 region of PLY is intolerable 
probably suggesting that this region is not suitable for conjugating with other 
proteins and/or polysaccharides. Another region (190-198) of the toxin in 
domains (1-3) was also identified which renders it insoluble. 
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In terms of ∆6 PLY as a vaccine molecule, unlike W433F, it is non-toxic at high 
protein concentrations (mg/ml) and addition of L363A substitution seems to 
make it ideal to be used as a vaccine molecule alone. ∆6 PLY has also been 
shown to act as strong adjuvant and its adjuvant activity is independent of the 
carried antigen fused (Douce et al., 2010).The mechanism of ∆6 PLY(L363A) 
interacting with cells is interesting and the experiment conducted in this study 
shows that substituting L363A blocks agglutination activity of the molecule. The 
comparison of this new toxin with ∆6 PLY warrants further investigation by 
setting up experiments to check the adjuvant activity of this new mutant .The 
reasons of ∆PLY adjuvant activity are still unclear. It could be that the 
aggregation of red blood cells is responsible for ∆6 PLY’s adjuvanticity. 
∆6 PLY(L363A) presumably has some biological activities which appears to be “non-
toxic” to the host and can be retained? One of them is TLR-4 activation which in 
turns results in the activation of the host immune response and thus suggesting 
its immunogenic potential. A few preliminary in-vitro experiments were run as 
an off-shoot of this project and suggest that the TLR-4 binding sites are located 
in regions around residues 138-142 (YGQVN>AAAAA). The results of experiment 
show that a PLY mutant with 5 amino acid substitution at this place has no 
effect on the lytic activity compared to the WT PLY but IL-1β production is 
significantly reduced. This implies that ideal vaccine should be interacting with 
immune cells and therefore isolated domains (D1-3 and D4) fused with eGFP 
were unable to mount an appropriate immune response when given in mice (Ma, 
2011). 
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The study succeeded in making a toxoid which is non-toxic, binds to cells and 
does not aggregate but whether it is beneficial in terms of immunity requires 
further follow up experiments. The next stage probably is set up some in-vivo 
experiments with or with-out any added adjuvants (Alum, Aluminium hydroxide) 
and to check this version (∆6 PLY L363A) with a version that does not bind to the 
cells at all (PLY L363A, T459G, L460G), a toxoid that binds to cells and cause 
aggregation of cells (∆6 PLY), W433F, PLYD1 and comparing immune parameters 
(antibody production, Th-17 response, effect on colonisation) of these tested 
toxoids. 
The search of an ideal PLY vaccine candidate has been going on for the last few 
decades. The protein is toxic so designing a molecule which is non-toxic, 
immunogenic, safe, cheap, and efficacious and provides broad serotype-
independent protection is the ultimate goal. So far, only one toxoid PLYD1 has 
reached phase 1 clinical trials and results published recently results show it has 
fewer side effects in adults yet the safety has not been checked in the main 
target population (infants and kids) (Kamtchoua et al., 2012). The success of 
∆6PLY as adjuvant described by the study done by Douce et al., 2010 is 
promising since it provides a generic platform and different pneumococcal 
protein/s can be fused and higher concentration of toxin can be given to achieve 
maximal response. However, the study also showed that membrane binding of 
protein was essential for adjuvant activity. 
The success of Synflorix and PCV-13 is promising and instead of conjugating 
H.Influenza carrier protein and detoxified Diptheria toxin, to capsular 
polysaccharides, ∆6 PLY and or ∆6 PLY (L363A) can be used which can provide non-
serotype specific protection. The studies for the search of next generation 
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pneumococcal vaccines are ongoing and it is likely that a combination of 
pneumococcal proteins as vaccines can also be used in future. The present study 
has identified the residue responsible for agglutination of the red blood cells and 
hence enhanced the safety potential of ∆6 PLY to be used in the next generation 
of pneumococcal vaccines 
6.1 Future work 
Data generated from this project identified the residue (L363) in PLY responsible 
for causing agglutination of red blood cells. However, the exact mechanism how 
it stops agglutination is unclear. It will be interesting to observe the behaviour 
of this residue among other CDCs. Future experiments supporting the proposed 
model and leading to the eventual goal of suitable PLY toxoid to be used in 
future pneumococcal vaccine should include: 
• Cholesterol binding assays, whereby pre incubating ∆6PLY with water 
soluble cholesterol might result in no agglutination activity on the 
hemagglutination assay plate due to saturation of TL site which fits in the 
hypothesised model (Figure 3-18).The second binding site could be 
binding to mannose (Lim et al., 2013). This binding of toxin to mannose 
can also be calculated by setting up experiments and comparing the % 
mannose binding with ∆6 PLY, ∆PLY(L363A) and ∆6 PLY(T459G.L460G). 
• The residue should be checked in other CDCs and mutating the 
corresponding 363 residue of PLY in other CDC members to check if it 
blocks the agglutination activity. ∆6 SLY causes agglutination of red blood 
cells and has same residue leucine as PLY, therefore changing ∆6 SLY 
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corresponding residue to alanine and or other residue to check it stops 
agglutinating red cells. PFO has isoleucine at the same place and ∆6PFO 
was made but the agglutination could not be observed since ∆6PFO was 
lytic (Section 7.1 and 7.2). The residue 363 in PLY could also be change to 
other residues e.g. to isoleucine to check if agglutination activity is due 
to iso-group. The residue can also be substituted with other basic (e.g. 
lysine), acidic (aspartic acid) or residue with no side chain (glycine) and 
observing the effect. As mentioned earlier CD experiments should be done 
with these mutants to observe any change in secondary or tertiary 
structure. 
• Mutant 363 had reduce lytic activity compared to WT PLY so purification 
of recombinant PLY(L363A) in WT background and observe binding and pore 
formation of this toxin with cells by electron microscopy (EM) and 
comparing results with WT and ∆6 PLY. The % haemolytic activity in 
HU/mg of purified recombinant protein can also be calculated and 
compared with WT PLY. 
• In-vivo experiments and measuring antibody response in mice and 
checking its adjuvant activity as explained in the above paragraph. 
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7 Purification and characterisation of ∆6 PFO 
7.1 Protein purification  
The recombinant protein ∆6 PFO was purified in the same way as the other 
mutant proteins except it was not passed through the AEC column. After the 
initial purification through the nickel affinity chromatography the protein was 
further purified by size exclusion chromatography (SEC) column following the 
protocol as explained below. 
∆6 PFO after NAC was further purified using Hi Load 16/60 Superdex 200 pg 
column from GE Health Care. The column was washed overnight with PBS at 
0.5ml/minute. ∆6PFO was first buffer exchanged into PBS and then loaded onto 
the column at 0.1ml/minute. The column was attached to the AKTAPrimeTM plus 
purification system (GE Health Care) and the SEC Programme was run. 
 
Figure 7-1 Purified fraction of recombinant ∆6 PFO on a pre cast gel after size exclusion 
chromatography (SEC) 
Lane M contains 5µl of the mol. wt.marker SeeBlue® Plus 2 followed by 5µl recombinant 
protein ∆6 PFO fractions after SEC in lanes 24 to 33. There were few bands (contaminants) 
which were removed before storing proteins at -80oC. 
 
Appendices  203 
Purified ∆6 PFO has a predicted molecular weight of 54kDa. The purified ∆6 PFO 
fractions loaded on the SDS-PAGE correspond to the same molecular weight 
when compared to molecular weight markers. The purified fractions were 
aliquoted and stored at -80o C. 
 
7.2 Hemagglutination assay of the purified protein 
∆6 PFO was run on a 96 well hemagglutination assay plate according to the same 
protocol as followed for the other hemagglutination assays. 
 
Figure 7-2 Hemagglutination of the purified ∆6 PFO 
1, 2 and 5 µg of purified ∆6 PFO was placed in the first well of the corresponding rows and 
then serially diluted across the whole plate. PBS only and ∆6 PLY were used as negative 
and positive controls.  
 
The toxin was checked with 3 different concentrations of 1, 2.5 and 5µg. The 
toxin has naturally isoleucine instead of leucine at position 363 so it was 
suspected that the ∆6 PFO will be agglutination negative but results showed that 
even after deleting the two residues alanine and arginine the toxin is still lytic 
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even at 1µg. Therefore we were unable to ascertain the aggregation 
phenomenon with ∆6 PFO. 
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Publication, conference participation and presentations  
 
Activation of memory Th17 cells by domain 4 pneumolysin in human 
nasopharynx-associated lymphoid tissue and its association with pneumococcal 
carriage. 
Gray C, Ahmed MS, Mubarak A, Kasbekar AV, Derbyshire S, McCormick MS, 
Mughal MK, McNamara PS, Mitchell T, Zhang Q. 
Pdf version of the paper attached after the list of references. 
Poster presentations (Presenting author underlined) 
M.K.Mughal and T.J.Mitchell. (September 2012) “Development of Pneumolysin as 
a vaccine candidate.” Society of General Microbiology (SGM), Birmingham, UK. 
M.K.Mughal and T.J.Mitchell. (November 2010) “Development of Pneumolysin as 
a vaccine candidate.” World Pneumonia Day: perspectives on pneumonia and 
pneumococcal disease. Glasgow, UK. 
M.K.Mughal and T.J.Mitchell. (June 2010 and 2011) “Structure and function 
studies of Pneumolysin.” Internal poster presentations at the University of 
Glasgow, UK. 
Oral presentation 
M.K.Mughal and T.J.Mitchell. (May 2012) “Development of Pneumolysin as a 
vaccine candidate.” Internal seminar at the Institute of Infection, Immunity and 
Inflammation, Glasgow, UK. 
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